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ABSTRACT 
The primary prevention of food allergy in childhood is an important public health goal. 
Estimates suggest six to eight percent of children worldwide are affected by food allergy 
(1) and the majority of children affected are of preschool age or younger (2). In 2011 it 
was reported that over 10% of one year old infants living in Melbourne, Australia have 
challenge-proven IgE-mediated food allergy (3). This is the highest reported prevalence 
of challenge-proven food allergy in the world. Food related anaphylaxis, a life 
threatening condition, has become prominent with a three-fold increase in food 
anaphylaxis related hospital admissions in Australia between 1994 and 2005 (4). The 
upward trend in food anaphylaxis admission rates worldwide has continued in recent 
years (5-8). The majority of this increase has been among children less than five years 
old (4). The causes of increased food allergy prevalence among children remain 
uncertain and there is a clear need to identify modifiable factors in the modern 
environment that may be driving this phenomenon. 
The modern environment has been associated with a rapid rise in a range of immune 
related non-communicable diseases including childhood food allergy (9). Exposures in 
the modern environment that may be relevant to the increase in food allergy include 
maternal folate status during pregnancy, low vitamin D status during infancy and a 
paucity of maternal and infant microbial experience (10-14). This PhD project 
investigated potential relationships between each of these putative risk factors and IgE-
mediated food allergy at one year of age.  
The Studies described in this thesis were conducted within the context of the Barwon 
Infant Study (BIS), a population derived birth cohort (n=1074) designed to investigate 
the early life origins of a range of non-communicable diseases in the modern 
environment (15). Of specific relevance to food allergy, BIS incorporated a longitudinal 
assembly of detailed epidemiological data and biospecimens during gestation and early 
postnatal life, in combination with an assessment of food allergy status by formal clinical 
assessment and in-hospital food challenge as required at one year of age.  
Food allergy prevalence at one year of age in BIS was 7.7% (95% confidence intervals (CI) 
6.0-9.8) with raw egg allergy the most common at 6.5% (95% CI 5.0-8.4). The prevalence 
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of peanut and egg allergy was then compared between BIS and the HealthNuts cohort - 
a study conducted in Melbourne, Australia, that used the same determination of food 
allergy status at one year of age as BIS. The lower rates of peanut and egg allergy in BIS 
relative to HealthNuts (for peanut, 1.5% [95% CI 0.6-2.3] versus 3.1% [95% CI 2.5-3.5], 
p=0.011), (for egg, 6.5% [95% CI 5.0-8.4] versus 9.4% [95% CI 8.6-10.2], p=0.009) 
appeared to be largely statistically accounted for by higher rates of dog ownership in 
infancy, later onset of eczema, earlier introduction of allergenic solids and less parental 
migration from Asia among the BIS cohort. 
The level of maternal red blood cell (RBC) folate associated with a decreased risk of 
neural tube defects (NTDS) in the offspring is greater than 906 nmol/L. The great 
majority of women in BIS had levels well above this threshold. Reassuringly though, 
there was no convincing evidence of a positive association between elevated maternal 
folate status in the third trimester of pregnancy and food allergy among the offspring 
(adjusted Risk Ratio (aRR) 2.89, 95% CI 0.90-9.35). Consistent with this, there was no 
evidence of a positive association between maternal folic acid supplementation in early 
to middle pregnancy and food allergy among the offspring (aRR 0.43, 95% CI 0.16-1.15). 
Among the infants in BIS, a vitamin D level less than 50 nmol/L was present in 45% of 
babies at birth and 24% at six months of age. There was however no evidence that 
vitamin D insufficiency (VDI) during the first six months of infancy associated with 
subsequent food allergy at one year of age (VDI at birth, aRR 1.25, 95% CI 0.70-2.22; VDI 
at six months, aRR 0.93, 95% CI 0.41-2.14). There was only very weak evidence of a cross 
sectional association between VDI and food allergy at one year (aRR 1.89, 95% CI 0.86-
4.13). 
Pet ownership in pregnancy was associated with a reduced risk of food allergy at one 
year of age (adjusted Odds Ratio (aOR) 0.44, 95% CI 0.25-0.77). Similarly, pet ownership 
in infancy was associated with a reduced risk of food allergy at one year of age (aOR 
0.32, 95% CI 0.18-0.56). Pet or livestock exposure was associated with a reduced risk of 
food allergy at one year of age (aOR 0.31, 95% CI 0.17-0.54). There was no evidence of 
an association between Caesarean section delivery and a reduced risk of food allergy 
among offspring (aOR 1.05, 95% CI 0.59-1.87). Maternal Group B Streptococcus 
colonisation during pregnancy was associated with a substantially decreased risk of food 
allergy among offspring at one year of age (aOR 0.33, 95% CI 0.13-0.87). It was not 
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possible however, to ascertain whether the relationship between maternal Group B 
Streptococcus colonisation and decreased food allergy among the offspring related to 
the pre or postnatal period.  
The findings in this thesis have a number of important implications. Food allergy in 
infancy remains a common and important disease in Australia. Comparison of the rates 
and determinants of food allergy prevalence’s between the BIS and HealthNuts cohorts 
reinforces the likely importance of earlier introduction of allergenic solids and diverse 
microbial experience during early life as preventive strategies. Periconceptional folic 
acid supplementation, which is an important public health initiative for the prevention 
of foetal NTDS, does not appear to increase the risk of food allergy in infancy. However, 
re-assessment of current supplementation practices and recommendations are required 
as many women have unnecessarily elevated folate levels. There continues to be 
insufficient evidence to recommend routine vitamin D supplementation for the 
prevention of food allergy in infancy and larger studies and/or clinical trials are required. 
The composition of the maternal vaginal-enteric microbiome associates with the risk of 
food allergy among the offspring. Further work is needed to evaluate underlying 
mechanisms and to determine whether these operate during pregnancy, birth or 
infancy. 
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CHAPTER 1 INTRODUCTION 
Childhood food allergy is a modern world epidemic, associated with a significant economic 
burden on families and the healthcare system (16). The increased demand for food allergy 
related services and the lack of a cure have directed research into modifiable early life factors 
that may refine primary food allergy prevention strategies. The majority of previous food 
allergy focused studies have been cross-sectional, retrospective with outcomes of variable 
quality. To comprehensively examine potential early life factors for childhood food allergy 
development and overcome the previous limitations, antenatal and postnatal exposures within 
the same study including epidemiological data and biological samples are required. To date, 
there has never been a large, population derived birth cohort study combining antenatal 
recruitment, detailed biological sampling and determination of food allergy status by formal 
oral challenge. 
This thesis explores the potential early life origins of the increased prevalence of 
Immunoglobulin E (IgE)-mediated food allergy among infants in Australia, utilising a regional 
prospective birth cohort, the Barwon Infant Study (BIS) in South-east Australia. To identify the 
outcome, this PhD project determined the prevalence of clinically-proven IgE-mediated food 
allergy among one year old infants in BIS. This project then examined the contribution of 
putative early life risk factors to food allergy prevalence differences between the Barwon 
region and the proximal urban centre, Melbourne, using two harmonised cohorts, BIS and the 
“HealthNuts” study. Within BIS, the project investigated the relationships between (a) maternal 
antenatal folate status, (b) infant vitamin D status (VDS) at birth and six months of age and (c) 
antenatal and early life microbial exposures and subsequent clinically-proven IgE-mediated 
food allergy at one year of age. The thesis has provided a foundation for future microbiome 
analysis within BIS. 
 
1.1 Food allergy prevalence and putative risk factors 
Food allergy prevalence estimates are dominated by retrospective observational data, derived 
from self or parental report and/or review of medical records. Such data lacks objectivity and 
reliability in the measurement of food allergy status, which may contribute to the diverse 
estimates of food allergy prevalence worldwide. Estimates suggest six to eight percent of 
children worldwide are affected by food allergy (1). It is clear, however, that over the last 
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twenty years rates of potentially fatal reactions to food (anaphylaxis) have steadily risen in the 
developed world. Such increases have been documented in the United Kingdom (UK) (6, 17), 
the United States of America (USA) (7, 18), Australia (5) and developed areas of Asia (19). The 
HealthNuts study, which wed a community recruited population based cohort in urban 
Melbourne, Australia and the robust outcome of challenge-proven food allergy, has provided 
the most rigorous infant food allergy prevalence estimate to date (3). HealthNuts also identified 
several environmental and early life risk factors associated with the development of infant food 
allergy (20, 21). However the study design was cross–sectional with retrospective surveys of 
early life factors that can be subject to recall bias. What are now required are longitudinal 
studies with biospecimen repositories and regular collection of epidemiological data to 
establish whether putative risk factors are associated with the robust outcome of clinically-
proven IgE-mediated food allergy. The access to biospecimen repositories then enables 
investigation of mechanistic pathways underlying such associations. 
1.2 Eczema and food allergy 
Eczema is a chronic inflammatory skin disorder of childhood with a relapsing remitting course 
(22). Similar to food allergy, prevalence estimates for eczema in infancy vary internationally 
from approximately 14% in Europe (23) up to 28% in Australia (24). Eczema in infancy is 
strongly associated with the later development of IgE-mediated food allergy (25, 26), and 
precedes the development of other atopic conditions as part of the “atopic march”(27). The 
dual allergen hypothesis suggests early onset eczema may play a causal role in food allergy 
development through allergic sensitisation developing to food allergens that are absorbed 
through a disrupted skin barrier (28). Consequently, though not a principal outcome in this 
study, eczema is included in the project analysis as it may have a genetic or environmental 
cause in common with food allergy. Eczema may also act as a confounder or mediator for other 
environmental exposures associated with food allergy. 
1.3 Maternal folate levels during pregnancy and IgE-mediated food allergy 
among offspring 
The recommendation of antenatal folic acid supplementation to prevent foetal neural tube 
defects (NTDS) (29) is coincident with the rise in infant food allergy prevalence in developed 
countries. There is evidence that folate increases deoxyribonucleic acid (DNA) 
hypermethylation in-utero (30), an epigenetic process that can alter expression of genes, 
including those that affect immune development during foetal life (31, 32). Such effects of 
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folate have been demonstrated in mouse models (33). It has been proposed that elevated 
maternal folate status in pregnancy via DNA hypermethylation, may influence early life infant 
allergy development. In humans, however, there is limited and conflicting evidence regarding 
the relationship between maternal folate status in pregnancy and food allergy (34, 35) among 
offspring. Previous studies of maternal folate status in pregnancy and food allergy among 
offspring lack robust objective outcomes and are variable with respect to the quality of 
exposure and covariate data. There is also ongoing uncertainty regarding the definition of an 
excessively elevated maternal folate status in relation to several health outcomes. 
1.4 Vitamin D levels in early infancy and IgE-mediated food allergy 
A variety of evidence suggests that low VDS in early life may be a risk factor for the 
development of infant food allergy (21, 36, 37). Biologically, Vitamin D promotes induction of 
regulatory T cells (38) and bowel epithelial integrity (39), which may reduce the risk of allergic 
sensitisation and subsequent food allergy development. Modern lifestyle choices however, 
such as increased time spent indoors due to technological advances, skin cancer concerns and 
expansion of the built environment have contributed to a population-wide low VDS in the 
developed world (40). These factors and ecological evidence in both hemispheres that 
anaphylaxis and food allergy rates are higher in areas further from the equator (36, 41) have led 
to multiple studies examining maternal and infant VDS (directly measured or other proxy 
measures) and allergy outcomes (21, 42-52). However, overall evidence remains inconsistent. 
Positive studies have demonstrated associations between low (21, 44, 48) and high VDS (42), 
respectively, and increased risk of food sensitisation, food allergy or eczema. These findings, 
however, have not been replicated in several negative studies (43, 49, 51, 52). Disentangling 
the relationship between VDS and food allergy is a complex task as vitamin D has been 
independently associated with many of the established and emerging risk factors for food 
allergy (53). What is required is a longitudinal evaluation of the relationship between VDS and 
subsequent clinically-proven food allergy that incorporate detailed measurement of the full 
range of potentially relevant covariates.  
1.5 Microbial factors and IgE-mediated food allergy in infancy 
Evidence suggests early life microbial exposures influence infant immune development (54, 55) 
and modifies the risk of food allergy in childhood (20, 56). The original ‘Hygiene Hypothesis’ by 
Strachan proposed that increased exposure to infections in early life through larger family sizes 
was protective against childhood allergic disease (57). Subsequently, a range of evidence has 
Chapter 1 
 4 
supported an association between early life non-pathogenic microbial experience, such as 
larger family size (20, 58, 59), domestic pets (20, 60), farming environments (58, 61-63) and 
reduced risk of allergic disease (20, 58-60, 62, 63). Various mechanisms have been proposed to 
explain the association between early life microbial experience and decreased allergic disease; 
including increased bacterial endotoxin exposure (63, 64), host gene environment interactions 
(65, 66), and favourable composition of the maternal and infant gut microbiome (67). 
The hypothesis that the relationship between non-pathogenic microbial experience and allergic 
disease is mediated by changes in the early life gut microbiome has been described as ‘The 
Hygiene Hypothesis revised’ (67). The early life gut microbiome composition is influenced by 
factors including larger family size (68, 69), obstetric interventions in pregnancy (70), 
intrapartum antibiotic use (71), exposure to domestic pets (69, 72, 73) and “westernised 
lifestyle” choices such as infant formula feeding and diet (74, 75). Thus, it is possible the above 
factors are proxy markers for the early life microbial experience (both antenatal and postnatal) 
that modifies maternal and infant gut microbiome composition, which in turn influences infant 
immune development and risk of food allergy.  
In this context, there is a clear need for longitudinal studies of sufficient size with extensive 
epidemiological data and biospecimens to explore the underlying pathways between modern 
environmental factors, gut microbiota composition, immune development and risk of food 
allergy. The determination of clinically-proven IgE-mediated food allergy provides a superior 
study outcome as opposed to allergic sensitisation, which is of uncertain clinical significance or 
parent reported food allergy. 
1.6 Thesis overview 
The work for this thesis was conducted within BIS, a regional prospective birth cohort with a 
longitudinal collection of biospecimens at critical early life developmental stages. The thesis 
summarises the work and research undertaken during the period of my PhD candidature and 
comprises: 
Chapter 1 – brief introduction 
Chapter 2 – a comprehensive background literature review of the research questions 
investigated in this thesis. 
Chapter 3 – detailed materials and methods used to determine the exposures, (maternal 
antenatal folate status, maternal and infant VDS and environmental microbial factors) and the 
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outcomes in the thesis (IgE-mediated food allergy and eczema in infancy). 
Chapter 4 – Study 1, the aim of which was a), to determine the prevalence of IgE-mediated food 
allergy in a regional setting (BIS) and b), compare with food allergy prevalence in a proximal 
urban cohort (the HealthNuts study, Melbourne, Australia). The comparison was utilised to 
investigate the contribution of various environmental and early life risk factors to the disparity 
in food allergy prevalence’s between the two cohorts.  
Chapter 5 – Study 2, the aim of which was to examine the association between maternal red 
blood cell folate levels during the third trimester of pregnancy and food allergy among the 
offspring at one year of age (BIS). 
Chapter 6 – Study 3, the aim of which was to examine the association between VDS during the 
first six months of infancy and subsequent food allergy at one year of age (BIS). 
Chapter 7 – Study 4, the aim of which was to examine the association between early life 
microbial factors and subsequent food allergy at one year of age (BIS). 
Chapter 8 – a conclusion to the thesis and discussion of potential directions for future clinical 
practice and research.  
Chapter 1 
 6 
Table 1.1 : Summary of the hypotheses examined in this thesis. 
Study Hypothesis Chapter 
(1a) The prevalence of IgE-
mediated food allergy among 
one year old infants in the 
Barwon region of Australia. 
That the prevalence of IgE-mediated food allergy 
among one year old infants in the Barwon region is 
the same as the prevalence previously reported for 
Melbourne. 
4 
(1b) The contribution of 
environmental and early life 
risk factors to differences in 
food allergy prevalence 
between two proximal 
harmonised cohorts 
Putative environmental and early life risk factors 
contribute to food allergy prevalence differences 
between urban and mixed regions. 
4 
(2) Maternal antenatal folate 
levels and offspring risk of IgE-
mediated food allergy and 
eczema. 
That elevated maternal folate status is associated 
with an increased risk of IgE-mediated food allergy 
and/or eczema among the offspring. 
5 
(3) Vitamin D status in the first 
six months of infancy and 
subsequent clinically-proven 
IgE-mediated food allergy. 
That low VDS in the first six months of infancy is 
associated with increased risk of IgE-mediated food 
allergy and/or eczema in the first year of life. 
6 
(4) Early life microbial exposure 
and risk of subsequent IgE-
mediated food allergy. 
That early life microbial exposures are associated 
with a reduced risk of IgE-mediated food allergy in 
the first year of life. 
7 
  
Chapter 2 
 7 
 
CHAPTER 2 LITERATURE REVIEW 
2.1 Introductory statement 
This chapter describes the background literature underlying the research questions examined in 
the thesis. Broadly, the review describes (i) the mechanisms and background of IgE-mediated 
food allergy, (ii) the evidence regarding the potential relationship between maternal folate 
status in pregnancy and food allergy among the offspring, (iii) the evidence regarding the 
potential relationship between maternal and infant VDS and childhood food allergy and (iv) the 
evidence regarding the potential relationship between the early life human gut microbiome 
and childhood food allergy. 
2.2 What Is IgE-mediated food allergy? 
Food allergy is defined as an adverse health effect arising from a specific immune response that 
occurs reproducibly on exposure to a given food (76). IgE-mediated food allergy is characterised 
by preceding allergic sensitisation and subsequent clinical allergic reaction following allergen 
re-exposure through the gut including the oral cavity (Figure 2.1) or more rarely through 
inhalational exposure (77). By definition the clinical allergic reaction is acute (usually within 1-2 
hours) and may involve one or more physical signs including urticaria, angioedema, vomiting 
and diarrhoea (76). Food induced anaphylaxis is a severe IgE-mediated reaction involving 
cardiovascular and respiratory compromise which may cause death (78). 
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Figure 2.1: Diagram showing mechanism of allergic sensitisation. Antigens are presented to the 
immune system via the gut epithelium resulting in production of IgE antibodies. In a clinical reaction 
IgE antibodies bind to mast cells resulting in release of inflammatory mediators. Figure take from Otsu 
(79). 
 
2.2.1 The development of allergic sensitisation 
Allergic sensitisation is the process where allergen-specific T and B cells recognise and respond 
to an allergen leading to production of allergen-specific IgE antibodies (76). Antigen presenting 
cells or dendritic cells take up the antigen in the gut, process the antigen and present peptides   
via major histocompatibility complex II to CD4+ naïve T cells, which are then directed to 
differentiate into either T-helper (Th) 1, Th2, Th9 or Th17 effector cells (Figure 2.2) (80). 
  
Chapter 2 
 9 
 
 
Figure 2.2: Effector T-cell subsets. After antigen presentation by DCs, naive T cells differentiate into 
TH1, TH2, TH9, and TH17 effector subsets. Cytokines promote the differentiation of the naive T cell, IL-4 
in particular promoting the Th2 pathway which is involved in the allergic response. Figure taken from 
Akdis (80). 
 
Effector T cells can release cytokines that potentiate the allergic response. Allergic disease is 
thought in part to be related to enhanced Th2 responses (81). T regulatory cells (Treg) are cells 
derived from naïve CD4+ T cells. T regulatory cells are developed either in the thymus as natural 
T regulatory (nTreg) cells, or peripherally as induced T regulatory (iTreg) cells (Figure 2.3) (82). 
Once generated, Treg cells express Foxp3 which enables mature Treg cells to suppress 
proliferation of other T cells (83). It is thought that CD4+CD25+Foxp3+ cells regulate and 
suppress Th2 related allergic inflammation (82). Th2 cell cytokines stimulate B cells to switch 
class and produce IgE. Recent work suggests that IgG expressing B cells provide the majority of 
the source isotypes that are subsequently switched to IgE producing cells (84). In allergic 
subjects, allergen-specific IgE is bound to the surface of mast cells via high affinity Fce 
receptors. On re-exposure, allergen binding to allergen-specific IgE results in crosslinking of 
surface bound IgE, which in turn stimulates mast cells to release preformed mediators and 
produce additional pro inflammatory mediators, which together lead to an allergic response.  
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Figure 2.3: Foxp3+ Tregs regulate Th2-mediated inflammation and allergy. Natural Tregs (nTregs) 
inhibit priming and effector function of allergen-specific Th2 cells. Induced Tregs (iTregs), which 
develop via conversion of naïve CD4 T cells into Foxp3+ Tregs during therapeutic exposure to 
allergens, can also function in this manner. Figure taken from Venuprasad et al (82). 
 
The state of sensitisation may or may not be associated with clinical allergic reaction upon 
allergen re-exposure. The factors that lead to sensitisation are poorly understood. One possible 
mechanism is resistance to, or escape from gastric acid or enzymatic digestion. In concert with 
an intact gut epithelial barrier, these factors normally result in ingested dietary proteins not 
being presented to the Gut Associated Lymphoid Tissue (GALT). Previous experiments on mice 
have shown that antigens which have bypassed gastric acid digestion through intra-ileal 
delivery are immunogenic once absorbed, whereas antigens that have undergone gastric acid 
digestion and are subsequently absorbed induce tolerance (85). Another experiment revealed 
that oral tolerance could be disrupted by feeding mice encapsulated antigens that avoided 
gastric acid and enzyme digestion (86). Concordantly, many food allergens, such as egg and 
peanut, have been shown to be resistant to breakdown by gastric acid (87). It has also been 
demonstrated that defects in gut barrier function are associated with an increased risk of 
allergic sensitisation (88). 
However, the presence of sensitisation does not always result in clinical allergy, with only 30-
55% of people who are sensitised to food allergens such as egg, milk or peanut being truly 
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allergic and reacting upon re-exposure (3). The factors that determine whether or not an 
individual who is sensitised, also manifests clinical allergy remain unknown.  
2.2.2 Allergic sensitisation and the dual allergen hypothesis 
Another possible mechanism for allergic food sensitisation is presentation of antigen 
cutaneously through a disrupted skin barrier in early life (28). In murine models, exposure to 
ovalbumin and peanut through abraded skin led to particular IgE-mediated responses (89) and 
allergic sensitisation (90). In subsequent human studies, proxy markers of a disrupted skin 
barrier, including filaggrin gene null mutations (91), increased transepidermal water loss in the 
neonatal period (92) and early onset eczema (three months of age or less) (25), have each been 
associated with subsequent food allergy development. Based on this evidence, the “dual 
allergen hypothesis” has been developed. The hypothesis states, allergic sensitisation can 
develop through food allergen exposure via a disrupted skin barrier and food tolerance 
develops through early oral exposure to food protein. The timing of oral or skin exposure to 
food protein determines the likelihood of allergic food sensitisation developing (28) (Figure 
2.4).
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Figure 2.4: Dual-allergen exposure hypothesis for the pathogenesis of food allergy. Figure from Lack 
(28). 
2.3 Food allergy in childhood 
Food allergy is becoming an increasingly common diagnosis in children. Estimates suggest six to 
eight percent of children worldwide are affected by food allergy (1). It has been demonstrated 
in recent years that over ten percent of one year old infants living in Melbourne, Australia have 
challenge-proven IgE-mediated food allergy (3). Over the last twenty years rates of potentially 
life threatening reactions to food (anaphylaxis) have steadily risen in the developed world (93). 
Such increases have been documented in the UK, the USA and developed areas of Asia (6-8, 17, 
19, 94). Concordantly, in Australia between 1994 and 2005 admission rates for food induced 
anaphylaxis through the Emergency Departments increased threefold, primarily in children less 
than five years old (Figure 2.5) (4), and the trend of increased food induced anaphylaxis rates 
has continued since 2005 (Figure 2.6) (5).  
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Figure 2.5: Time trends in food-induced anaphylaxis admissions.  Categorised by age group (1994-
2005; A) and causative allergen (1994-1998; B). Figure taken from Liew et al (4). 
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Figure 2.6: Age-specific admission rates to Australian hospitals (per 105 per population year) for food–
related anaphylaxis. Figure taken from Mullins et al (5). 
 
A number of hypotheses have been proposed to explain the rise in food allergy in childhood, 
the dual allergen hypothesis described previously (28), avoidance of early allergenic solid 
exposure (95), infant diet/feeding (95), early life VDS (12, 36), early life microbial exposure (67) 
and population migration (95). To date no single hypothesis has fully explained the rise in 
childhood food allergy and the cause remains elusive. However, the modern environment and 
associated lifestyle factors have contributed to the development of all these hypotheses. The 
modern environment encompasses factors such as maternal folate status, infant VDS and 
changes in the microbial exposures of the mother and infant (10, 11, 13, 14). This thesis seeks 
to examine these putative risk factors in relation to the development of IgE-mediated food 
allergy in infancy. 
  
Chapter 2 
 15 
 
2.4 The relationship between high maternal folate status during pregnancy 
and IgE-mediated food allergy among the offspring 
A recent successful example of the public health campaign to optimise maternal health to 
prevent foetal morbidity, has been maternal periconceptional folic acid supplementation to 
reduce the risk of foetal NTDS (29). There is emerging evidence that promotion of 
micronutrient supplementation in pregnancy, particularly in the developed world, may be 
leading to a supraphysiologic maternal folate status becoming commonplace among pregnant 
women (96-98). This phenomenon has paralleled the marked increase in allergic disease (3, 17, 
18, 93). In this context, it has been suggested that the combination of folic acid fortification of 
the food chain plus exogenous folic acid supplementation throughout pregnancy, may have 
unintended adverse effects on other offspring health outcomes, including allergic disease (34, 
99, 100). Folate is a methyl donor that may affect DNA methylation (101) which in turn may 
modify the activity of genes involved in immune development and function (102, 103). The 
definition of excessive folate status in pregnancy remains uncertain and there is limited human 
data regarding the relationship between maternal folate status in pregnancy and IgE-mediated 
food allergy among the offspring. The aims of this section are to review: (a) the history of folic 
acid supplementation, (b) evidence regarding the potential definition of high maternal folate 
status, and (c) the mechanistic and epidemiological evidence of a relationship between high 
maternal folate status and food allergy among the offspring. 
2.4.1 Folate and folic acid history 
Folate is the umbrella term to describe the group of compounds that possess similar biological 
effects, including natural folates and synthesised folic acid (104). Folate was discovered through 
work investigating the causes of macrocytic anemia in the 1930’s (104). Studies conducted in 
the 1960’s and 1970’s among lower socioeconomic groups living in the north west of the UK 
were the first to demonstrate an association between folate deficiency and complications of 
pregnancy including foetal NTDS (105, 106). Periconceptional maternal folic acid 
supplementation of 400 mcg/day to reduce foetal NTDS risk was first recommended in the early 
1990’s (29). Subsequent work published in 1995 estimated that the optimal maternal Red Blood 
Cell (RBC) folate status to minimise foetal NTDS risk was greater than 906 nmol/L (107).  
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2.4.2 Folate metabolism 
Folates are part of the B-vitamin group. They play a role in nucleic acid synthesis and mediate 
the transfer of one carbon unit in biochemical reactions. Folate plays an important role in the 
synthesis of methyl donor groups involved in DNA methylation, which is a key epigenetic 
determinant of gene function (101) (Figure 2.7). 
 
 
Figure 2.7: Folic acid and folate metabolism for DNA methylation. Gene names for enzymes are in 
italics and cofactors are in parentheses. DHF, dihydrofolate; DHFR, dihydrofolate reductase; DNMT, 
DNA methyltransferase; dTMP, thymidylate; dUMP, deoxyuridine monophosphate; MS, methionine 
synthase; MTHFR, methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; SHMT, serine hydroxymethyltransferase; THF, tetrahydrofolate; TS, thymidylate 
synthase, taken from Crider et al (101). 
 
2.4.3 What is high folate status? 
To date, research regarding maternal folate status in pregnancy has primarily focused on the 
identification of folate deficiency. There is minimal evidence and no consensus regarding the 
definition of normal or high folate status either in the periconceptional period or during 
pregnancy. 
Folate status in humans can be measured in two forms: serum/plasma folate or RBC folate. 
Serum folate is more susceptible to errors than RBC folate (108), as a high intake of folic acid 
supplementation (≥1000 mcg) prior to blood sampling can cause a falsely elevated serum 
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folate. Accordingly, a fasting serum folate may be a better reflection of actual folate status than 
a random serum measure (108, 109). RBC folate compared to serum folate, is a better measure 
of long term folate status as it tends to reflect body stores of folate for the previous three to 
four months. This is because erythrocytes accumulate folate during erythropoiesis (110) and 
RBC folate levels are not affected by recent dietary intake (111). 
The World Health Organisation defines RBC folate deficiency as <340 nmol/L (112). This 
threshold was based on previous cross sectional data, demonstrating increases in 
homocysteine as folate concentration decreases (113). The published reference ranges of RBC 
folate in pregnancy based on older studies vary according to trimester (Table 2.1) (114-117). 
 
Table 2.1: Published RBC folate reference ranges in pregnancy (nmol/L). 
Trimester 1 Trimester 2 Trimester 3 
310 - 1334 213 - 1875 247 - 1502 
 
A maternal RBC folate level greater than 906 nmol/L has been recommended since the mid 
1990’s in an strategy to reduce the risk of foetal NTDS (107). More recent analysis using a 
bayesian model on two cohorts in China taking 400 mcg/day folic acid supplementation 
suggested that a RBC folate range of 1000-1300 nmol/L is associated with near maximal 
reduction in foetal NTDS risk, with negligible additional benefit for levels greater than 1300 
nmol/L (118) (Figure 2.8).  
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Figure 2.8: Bayesian model of RBC folate concentration and risk of NTDS. Figure taken from Crider et 
al (118). 
 
Since the published recommendation of folic acid supplementation and implementation of 
mandatory fortification of grains and cereals in the food chain (119-122), an increased 
prevalence of an elevated maternal folate status has been reported in several countries (98, 
123). To attempt a clarification of an elevated maternal folate status, recent studies that 
examined RBC folate status as an exposure have defined elevated thresholds by dividing the 
folate distribution into quartiles (124) or quintiles (125) and adopting the top quartile/quintile. 
By contrast, other studies (96) have defined elevated maternal RBC folate as greater than 1360 
nmol/L (reflecting the 97th percentile and above from the American post fortification National 
Health And Nutrition Examination Survey (NHANES, 1999-2004) (97). The biological implications 
of these various thresholds are uncertain.  
2.5 Folate and food allergy - possible mechanisms 
The theoretical basis for maternal folate status affecting offspring food allergy risk is via DNA 
methylation, one of many epigenetic mechanisms that can control gene expression (126). 
Epigenetics is classically defined as “the branch of biology which studies the causal interactions 
between genes and their products, which bring the phenotype into being” (127). Folate status 
can affect DNA methylation (101), and in turn alter the activity of genes related to immune 
development and function (102, 103). 
Evidence from both animal and human studies indicates that DNA methylation changes may 
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affect risk of allergy. In particular, findings from mouse studies suggest DNA methylation may 
have epigenetic effects on the Th1/Th2 skew in asthma (128). Work published by Hollingsworth 
et al in 2008 has stimulated much of the recent research on maternal folate and allergic 
outcomes. The authors suggested a diet high in methyl donors in maternal mice could enhance 
allergic airway disease in immediate offspring and partially in subsequent generations (129). 
However, this article was later retracted in 2016 due to concerns regarding a lack of 
reproducibility of respiratory measurements on the subjects in the experiments (130). 
In human studies, disruption of DNA methylation profiles is associated with asthma morbidity 
in older children (131). Differences in DNA methylation profiles have been demonstrated in 
children with allergic rhinitis compared to healthy children (132) and DNA methylation profile 
changes may also play a role in atopic dermatitis (133). Altered DNA methylation has been 
proposed to have effects on T-cell lymphocyte development (134) that may influence food 
allergy risk postnatally (134, 135). The BIS group has also demonstrated differences in 
methylation of genes related to Treg cell differentiation and stability at birth in association with 
subsequent food allergy (136). DNA methylation driven alterations in the Th1/Th2 immune 
balance have also been associated with development of cow’s milk allergy in children (135). 
2.5.1 Epidemiological evidence for an association between proxy measures of maternal 
folate status and offspring allergy 
There are seven human studies that have investigated the relationship between maternal 
report of folic acid supplementation and/or diet and offspring allergic disease (Table 2.2). Five 
of these studies examine offspring respiratory outcomes in prospective birth cohorts, and the 
evidence is conflicting. There are no studies to date relating proxy measures of maternal folate 
status in pregnancy to the robust outcome of challenge-proven food allergy. 
In the Dutch ‘KOALA’ birth cohort study (n=837), folic acid supplement use before or during 
pregnancy was not associated with any offspring allergic outcome (137). They did not however, 
consider dietary intake of folate in their study. Another Dutch birth cohort study (n=3786) 
examined use of folic acid containing supplements in pregnancy in relation to offspring 
respiratory and eczema outcomes up to eight years of age (138). There was no association 
between use of supplements containing folic acid in pregnancy and atopy outcomes. More than 
50% of women in the study stated they had taken a “folic acid” supplement. Limitations of this 
study included failure to record either the weeks of pregnancy during which the supplement 
was used or the total duration of supplement use. 
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A Japanese birth cohort (n=1002) examined intake of the B group of vitamins including folate 
during pregnancy and offspring wheeze and eczema outcomes at 16-24 months (139). There 
were no associations between maternal folate intake in pregnancy and offspring wheeze or 
eczema outcomes. Of note however, the mean daily folate intake recorded was 284 mcg/day 
(standard deviation (SD) 82.2), which is well below the internationally recommended daily 
folate intake for pregnancy (at least 400 mcg/day) (140), in a country without mandatory food 
fortification with folic acid. Furthermore the participants were mostly from higher 
socioeconomic groups, which may limit the applicability of the results to the general 
population. 
A Western Australian study (n=484) estimated maternal folate intake from diet and the amount 
of folic acid ingested through oral supplementation daily in relation to offspring allergic 
outcomes (34). Seventy-six percent of mothers were taking folic acid supplements in the study. 
Higher levels of folate supplementation (>500 mcg/day) intake were associated with the 
development of eczema by one year of age (adjusted Odds Ratio (aOR) 1.30, 95% Confidence 
Intervals (CI) 1.01-1.67). The study cohort had a predominance of allergic mothers, potentially 
limiting the generalisability of the findings. A Norwegian study (n=32,077) by Haberg et al 
investigated folic acid supplementation in the first thirty weeks of pregnancy (99). Forty three 
percent of women in the study reported taking folic acid supplements in both the first and 
second trimester of pregnancy. Folic acid supplementation was associated with an increased 
relative risk of wheezing at 6-18 months of age (adjusted Relative Risk Ratio (aRR) 1.06, 95% CI 
1.03-1.10). Limitations of the study included the lack of data on dietary folate intake and failure 
to record the amount of folic acid ingested. It is also unclear whether wheeze at this age should 
be considered an allergic disorder.  
An Australian prospective birth cohort study (n=557) investigated the relationship between 
reported maternal folate intake both from diet and supplements in the first and third trimester 
in relation to physician diagnosed asthma up to five and a half years of age (100). Of note 25% 
of mothers reported not taking a folic acid supplement at any stage of pregnancy. Folic acid 
supplementation in the third trimester of pregnancy was associated with offspring asthma 
diagnosed at three and a half years (aRR 1.26, 95% CI 1.09-1.47) and asthma persisting at five 
and a half years (aRR 1.32, 95% CI 1.03-1.69). Dietary folate alone was not associated with 
asthma in offspring at any stage. Combined dietary folate and folic acid supplementation 
provided the same associations with asthma as folic acid supplementation alone (100). The 
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study results were limited by having only 76% follow up on the outcome at five and a half years. 
A Finnish birth cohort (n=6288) examined folic acid supplementation and dietary folate intake 
in the eighth month of pregnancy and cow’s milk allergy in the offspring at 3 years (35). There 
was weak evidence of an association between total folate intake (dietary and folic acid 
supplementation) and increased risk of cow’s milk allergy at 3 years (aOR 1.15, 95% CI 1.00-
1.32). Limitations of the study included the use of a questionnaire to estimate folate intake. The 
authors also acknowledged that motivated more educated families with healthier lifestyles 
were retained in the study leading to possible confounding issues (35). 
In the UK “ALSPAC” birth cohort, Granell et al investigated the MTHFR C677T polymorphisms in 
mothers and children and atopic outcomes at eight years in children (141). Humans with this 
polymorphism and the TT genotype are more susceptible to the epigenetic changes associated 
with low folate status. The study also gathered questionnaire data on the mother’s folate 
intake in the second and third trimester of pregnancy and use of folic acid supplements. There 
was no evidence of an association between the TT genotype of the MTHFR C677T 
polymorphism and allergic outcomes among offspring. There was also no association between 
maternal dietary folate intake and childhood atopy (aOR 0.98, 95% CI 0.88-1.10), nor was there 
an association between reported maternal folate supplementation at 18 weeks (aOR 0.99, 95% 
CI 0.78 -1.25) or 32 weeks (aOR 1.15, 95% CI 0.98-1.35) of pregnancy and childhood atopy. The 
reported maternal dietary folate intake in the study was relatively low at 256 mcg/day, with 
only 12% of mothers reporting taking folic acid supplements in early pregnancy. The period of 
pregnancy for mothers in this study (1991-1992) however, coincided with the publication of the 
recommendation of periconceptional folic acid supplementation to prevent NTDS (29). As the 
dietary folate intake in this study was in the pre-fortification era, its comparative value to more 
recent maternal practices is low. The study results are also limited by a lack of data regarding 
the amount of folic acid ingested through supplementation, particularly in the third trimester.  
2.5.2 Epidemiological evidence for an association between directly measured maternal 
folate status and offspring allergy 
Several studies have examined directly measured serum folate status in relation to offspring 
allergic outcomes, but to date no study has investigated serum folate measures in relation to 
challenge-proven food allergy. The only study to examine RBC folate measures in relation to 
allergic outcomes was the Dutch KOALA birth cohort (n=837). RBC folate was measured late in 
the third trimester (week 35) (137). There was weak evidence that higher levels of RBC folate 
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were associated with a small decreased risk of asthma at six to seven years in a dose dependent 
manner (p=0.05), but no association was observed for any other allergic outcome. In the 
Western Australia study, serum folate was measured in the third trimester and at delivery, and 
was related to eczema, allergic sensitisation and food allergy (defined by positive skin prick test 
(SPT) and history of reaction) among offspring at one year of age (34). There was no association 
between maternal serum folate levels and food allergy or eczema. Of note, both higher (>75 
nmol/L) and lower (<50 nmol/L) levels of cord blood serum folate were associated with allergic 
sensitisation at one year in the study, (aOR 3.59, 95% CI 1.40–9.20), (aOR 3.02, 95% CI 1.16–
7.87) respectively, compared to levels between 50 nmol/L and 75 nmol/L.  
In a Dutch birth cohort study (n=8742) plasma folate was measured in the first trimester of 
pregnancy (n=5965) and related to atopic dermatitis outcomes at four years of age. Higher 
levels of plasma folate (≥16.2 nmol/L) were associated with increased prevalence of atopic 
dermatitis up to four years of age (aOR 1.16, 95% CI 1.03–1.32) (142). The same study also 
examined the MTHFR C677T polymorphism, which was not associated with any allergic 
outcome, nor did it modify the relationship between maternal folate status and allergic 
outcomes among offspring. Of note, 69% of mothers took folic acid in early pregnancy and at 
the time of the study food fortification with folic acid was not mandatory (142). The mean 
serum folate in non-supplemented mothers was 9.6 nmol/L (SD 4.3) and in supplemented 
mothers was 20.8 nmol/L (SD 8.6). The serum folate mean is higher than the Norwegian study 
described below (143) where the median in non-supplemented mothers was 5.8 nmol/L and in 
supplemented mothers the median was 10.9 nmol/L, but it is difficult to make a direct 
comparison between the two studies as the Norwegian study measured serum folate in the 
second trimester with a skewed distribution of folate which means they could only describe a 
median level. 
In a case-control study within a birth cohort conducted in Norway (n=1962) Haberg et al 
measured second trimester plasma folate levels in relation to maternally reported offspring 
asthma symptoms and medication use in the first three years of life. The highest quintile of 
maternal plasma folate (>17.84 nmol/L) was associated with an increased risk of asthma (aOR 
1.66, 95% CI 1.16-2.37) (143). However there was a loss to follow up rate of around 45% that 
may have introduced a retention bias.  
In a Korean birth cohort (n=1824), Serum folate was measured in the second and third 
trimester in relation to asthma and atopic dermatitis at two years (144). Higher serum folate 
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(≥9.5 ng/ml) compared to low serum folate (<9.5 ng/ml) in the second trimester was associated 
with a decreased risk of atopic dermatitis (aOR 0.52, 95% CI 0.31-0.88). Serum folate in the 
third trimester was not associated with asthma or atopic dermatitis at two years.  The study 
was limited by maternal report of allergic disease being the main outcome and the poor follow 
up rate at the outcome endpoint (27% of the original enrolled cohort) (144). The important 
studies regarding maternal folate status and allergy outcomes are summarised in the table 
below (Table 2.2).  
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Table 2.2: Summary of the studies regarding maternal folate status and offspring allergic disease. 
Source 
(year) 
Country Study 
Design 
(n) 
Exposure  
Type 
Exposure 
measurement 
time point 
Outcome Findings 
Haberg  
et al (2009) 
(99) 
Norway Birth 
cohort  
(32077) 
Folic acid supplementation. First and Second 
trimester. 
Wheeze and respiratory 
outcomes up to 18 
months. 
Folic acid supplementation associated 
with increased risk of wheeze at 6-18 
months. 
Whitrow  
et al (2009) 
(100) 
Australia Birth 
cohort 
(557) 
Folic acid supplementation 
and dietary folate. 
First and Third 
trimester. 
Asthma up to 5.5 years. Folic acid supplementation associated 
with persisting asthma at 5.5 years. 
Bekkers  
et al (2012) 
(138) 
Netherlands Birth 
cohort 
(3786) 
Folic acid supplementation. Whole 
pregnancy. 
Atopy up to 8 years. No association between folic acid 
supplementation and atopy. 
Miyake  
et al (2011) 
(139) 
Japan Birth 
Cohort 
(1002) 
Dietary folate. 5-39 weeks of 
pregnancy. 
Wheeze and eczema at 
16-24 months. 
No association between folate intake 
and wheeze or eczema. 
Magdelijns 
et al (2011) 
(137) 
Netherlands Birth 
cohort 
(837) 
Folic acid supplementation/ 
RBC folate. 
Whole 
pregnancy/  
Third trimester. 
Allergy up to 7 years. High RBC folate associated with slight 
decreased asthma risk. 
Dunstan  
et al (2012) 
(34) 
Australia Birth 
cohort 
(484) 
Folic acid 
supplementation/serum 
folate. 
Third trimester. Allergy at 1 year. Folic acid supplementation associated 
with eczema at 1 year. Higher and 
lower serum folate associated with 
sensitisation. 
Granell  
et al (2007) 
(141) 
UK Birth 
cohort 
(5364) 
Folic acid supplementation 
and dietary folate/ MTHFR 
polymorphism. 
Third trimester. Atopy at 7-8 years. No association between impaired folate 
metabolism and allergy. 
Tuokkola 
et al (2016) 
(35) 
Finland Birth  
cohort 
(6288) 
Folic acid supplementation 
and dietary folate 
Third trimester Cow’s milk allergy at 3 
years. 
Increased total folate intake weakly 
associated with increased of cow’s milk 
allergy in offspring. 
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Source 
(year) 
Country Study 
Design 
(n) 
Exposure  
Type 
Exposure 
measurement 
time point 
Outcome Findings 
Kim 
et al (2015) 
(144)  
Korea Birth  
Cohort 
(1824) 
Serum folate Second and third 
trimester 
Asthma and atopic 
dermatitis up to 2 years.  
Higher serum folate in second trimester 
associated with decreased risk of atopic 
dermatitis at 2 years. No association 
between third trimester serum folate 
and asthma/atopic dermatitis at 2 
years. 
Kiefte-de 
Jong et al 
(2012)  
(142) 
Netherlands Birth 
cohort 
(8742) 
Serum folate. First trimester. Atopic dermatitis up to 
age 4. 
Higher levels of serum folate associated 
with atopic dermatitis. 
Haberg  
et al (2012) 
(143) 
Norway Birth 
cohort 
(1962) 
Serum folate. Second 
trimester. 
Asthma up to 3 years. Highest quintile of serum folate 
associated with asthma. 
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2.6 Conclusions regarding maternal folate status and food allergy among 
offspring 
There is a cogent theoretical basis for the hypothesis that excessive maternal folate status in 
pregnancy may influence the offspring’s risk of allergic disease via DNA methylation of immune 
related genes. In support of this, molecular and animal studies have shown that maternal folate 
status can influence the offspring’s immune profile. To date in human studies however, the 
evidence for an association between maternal folate status and food allergy in particular 
among offspring is very limited. Most previous studies relate to respiratory outcomes and a 
large proportion rely on proxy markers of folate status, such as maternally reported diet and 
folic acid supplementation. Furthermore, the majority of studies with biochemical folate 
measurement, rely on serum/plasma folate levels which are substantially influenced by recent 
(rather than summative) folate intake. RBC folate may be a superior measure as it reflects 
folate status over the preceding three-month period. It is also noteworthy that in each of the 
studies demonstrating a positive association between maternal folate status and allergy among 
the offspring, the magnitudes of association were small and the evidence was relatively weak. 
The potential relationship between elevated maternal folate status during pregnancy and 
allergy among the offspring remains an important public health issue, particularly in the context 
of widespread implementation of folic acid fortification of the food chain, specific folic acid 
supplementation during pregnancy and no accepted threshold of an excessive maternal folate 
status. Studies are required that relate a direct measure of maternal folate status over several 
months to robust and clinically relevant measures of offspring allergic disease, and investigate 
whether any such associations are sensitive to the use of the different definitions of elevated 
maternal folate status in current literature. This thesis therefore will test the following research 
hypothesis: That elevated maternal folate status is associated with an increased risk of IgE-
mediated food allergy and/or eczema among the offspring.   
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2.7 Vitamin D and its potential role in IgE-mediated food allergy 
Concordant with the food allergy epidemic in the developed world there has been a marked 
decrease in vitamin D levels in many of the same countries. The temporal correlation of these 
two biological processes has led to the hypothesis that low VDS may be involved in the 
development of food allergy. On the other hand, the modern practice of vitamin D fortification 
of foods and vitamin D supplementation has led to the converse hypothesis that vitamin D 
excess may in fact be driving the increase in allergic disease. Of note, the most dramatic 
increase in food allergy appears to be in countries where low VDS has been reported to be 
particularly common. Disentangling the relationship between VDS and food allergy is a complex 
task, as vitamin D has been independently associated with many of the established and 
emerging risk factors for food allergy (53). The aims of this section are to review the history of 
vitamin D and the mechanistic and epidemiological evidence of a relationship between VDS and 
IgE-mediated food allergy. 
2.7.1 Vitamin D history 
Vitamin D was discovered in the early twentieth century during studies on cod liver oil, which 
showed animals given cod liver oil or fat soluble rich foods did not develop rickets (145). Rickets 
is a bone deforming disease caused most commonly by vitamin D deficiency (146). Subsequent 
fortification of milk in the mid twentieth century eliminated rickets in the majority of 
populations (147). Rickets was common among children in the early twentieth century but 
there was little allergy, suggesting that vitamin D insufficiency (VDI) alone is not the cause of 
the rise of allergy (148) and there may be other factors involved. 
2.7.2 Vitamin D synthesis 
Exogenous vitamin D exists in two forms. Vitamin D2 known as ergocalciferol is sourced from 
diet and provides a small amount of the total vitamin D supply. Vitamin D3, known as 
cholecalciferol, provides about 90% of the total Vitamin D supply in humans (149). Vitamin D3 is 
sourced mostly from sunlight UVB exposure on the skin and some from diet (meat and dairy). 
Both forms undergo metabolism separately via the same pathway by being converted to 25-
hydroxyvitamin D2 (25(OH)D2) and 25-hydroxyvitamin D3 (25(OH)D3) respectively in the liver. 
Recent work has suggested hydroxyvitamin D2 (25(OH)D2) and 25-hydroxyvitamin D3 (25(OH)D3) 
individually may have separate health effects (150), but a detailed discussion of this is outside 
the scope of this review. The sum total of 25-hydroxyvitamin D2 (25(OH)D2) and 25-
hydroxyvitamin D3 (25(OH)D3) is 25-hydroxyvitamin D (25(OH)D). Subsequently, 25(OH)D is 
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hydroxylated to 1,25-dihydroxyvitamin D in the kidney and this form is biologically active 
(Figure 2.9) (151). Because sunlight stimulates the majority of vitamin D production, levels of 
serum 25(OH)D can fluctuate with season and geographical location. For example, in Sweden 
which lies at a latitude of 63 degrees north, 25% of preschool children were vitamin D 
insufficient (≤ 50 nmol/L) after the summer season, despite documented adequate oral vitamin 
D intake and light exposure (152). 
 
 
Figure 2.9: Vitamin D metabolism. Ca= Calcium, PTH= Parathyroid hormone. Figure taken from 
Thacher (151).  
 
2.7.3 What is low vitamin D status? 
There is continuing debate about what is the most reliable indicator of VDS. The 25(OH)D form 
is thought to be the most accurate as it gives an estimate of the total supply, combining dietary 
intake and skin production, but it does not measure the active form of Vitamin D (153). 
Measurement of the active metabolite 1,25-dihydroxyvitamin D may be misleading, as this 
form can be maintained at a normal level for some time due to elevated Parathyroid hormone 
levels when vitamin D supply is low (154). Hence serum 25(OH)D represents the most 
commonly used marker in vitamin D studies (153). 
The definition of low VDS in the context of this review and thesis is important, as there is a lack 
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of consensus internationally as to what level of vitamin D represents deficiency or what level is 
optimal. The recent trend has been to describe a level of <50 nmol/L as deficient and levels ≥75 
nmol/L as optimal (155). Most of the studies examining these thresholds have been done in 
adults, but in children it is currently acknowledged that levels of 50 nmol/L or greater represent 
sufficiency (156). Therefore, for this review low VDS is defined to be <50 nmol/L. Due to the 
lack of consensus regarding optimal levels of serum vitamin D, the ongoing project will analyse 
VDS as both a continuous and a categorical exposure. 
2.8 Vitamin D and food allergy - possible mechanisms 
Vitamin D is a pleiotropic hormone that influences the expression of greater than 200 human 
genes (157). There are a number of mechanisms proposed, by which vitamin D may influence 
the risk of developing food allergy (12). Vitamin D receptors are present on many cells of the 
immune system, such as activated T and B cells and dendritic cells (158, 159). Studies on the 
effect of vitamin D on Th1 and Th2 cells have yielded conflicting results. It has been shown that 
vitamin D can inhibit both Th1 and Th2 cells (160). In contrast, another study showed high dose 
vitamin D can enhance Th2 related cytokines (161). Of particular relevance to food allergy, 
vitamin D was able to promote the induction of IL-10 secreting Treg cells (38), which play a key 
role in the induction of oral tolerance (162). Vitamin D also has effects on the function of the 
intestinal barrier, through the actions of its active form, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) via regulation of tight junction proteins (39). Thus, it is plausible that low VDS 
may increase the risk of allergic sensitisation by increasing intestinal permeability to food 
allergens. 
2.8.1 Ecological evidence for an association between low vitamin D status and food allergy 
in childhood. 
Fall/Autumn or winter births have been associated with a higher risk of food allergy worldwide. 
A retrospective observational study from Boston in the USA found children with a diagnosis of 
food induced anaphylaxis, were more likely to be born in the fall/winter compared to 
spring/summer (Figure 2.10) (163). The same group also examined Emergency Department 
attendances, looking for the same trend and found that in children under five attending for 
food related allergic reactions, 59% were born in fall/winter compared to 41% in 
spring/summer. Children less than five years of age were also found to have 53% higher odds of 
food allergy compared to controls (Figure 2.11) (164). A Swedish study of 209 children followed 
from birth until 12 and 15 years of age, found higher rates of IgE-mediated food sensitisation to 
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egg white and cow’s milk in those born in autumn/winter compared to spring/summer (165). 
The children born in the winter months also had higher rates of atopic dermatitis. Mullins et al 
also demonstrated a higher rate of autumn/winter births among allergic children in Australia 
with a consistent seasonal pattern present for peanut and egg allergy (166). A large 
observational study from Finland (n=5920) found the highest rate of positive allergy tests 
(positive oral food challenge, SPT or serum IgE) were in children born in October/November, 
compared to other months of the year with this effect pronounced for milk and egg (167). The 
results of this study were limited, as only 20 % of the study participants were completely 
followed up with allergy testing over the duration of the study. Supporting the season of birth 
trend is a study that measured Vitamin D levels in neonates in New Zealand, which lies at 41 
degrees south latitude and does not fortify foods with vitamin D. The lowest level of serum 
vitamin D was detected in those born during the winter months, with 20% of the total children 
in the study having a serum vitamin D level of ≤25 nmol/L (168). Keet et al in the USA looked at 
two large study populations, the NHANES 3, (n=5862) and the John Hopkins Pediatric Allergy 
Clinic (JHPAC), (n=1514). In both populations, autumn birth was associated with a higher risk of 
food allergy. In NHANES 3, the odds of a history of a food reaction were 1.91 times higher (95% 
CI, 1.31–2.77) in those born in the autumn but this was only significant in Caucasian’s. In the 
JHPAC group the odds of being diagnosed with a food allergy were 1.32 times higher (95% CI, 
1.18–1.47) in those born in the autumn, but only in children who had eczema (169). In a large 
Japanese observational study (n=14,669) based on questionnaire data, there was a higher rate 
of food allergy and eczema before the age of six months among those born in autumn/winter 
compared to spring/summer. The season of birth effect was not significant in the group when 
food allergy alone was examined (170). Another USA based study of 650 food allergic children 
reported that children with a diagnosis of tree nut allergy were more likely to be born in winter 
than in summer. This association was not demonstrated for milk, egg or peanut allergy in the 
study (171). Of note, the HealthNuts study did not find a statistically significant association 
between season of birth and food allergy in their population group (21). 
A large Japanese cross-sectional cohort (n=1197) compared season of birth among food-allergic 
infants with the regional population (n=69,999) (172). Autumn/winter birth was higher among 
food-allergic infants compared to the regional population (OR 1.70, p<0.001). The study 
findings are limited by a lack of data on potential confounders and bias in the selection of the 
control group in the cohort. Another retrospective Japanese study (n=732) examined season of 
birth and related solar radiation exposure in relation to sensitisation to egg white, cows milk 
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and wheat before six months of age (173). Infants with Autumn/winter births had higher 
specific IgE titres to food compared to Infants with Spring/summer births. The study was limited 
by the retrospective nature of the analysis and bias in the selection of the study population. A 
weaker Korean study (n=3400) used parental report of a food allergy diagnosis in a school 
based questionnaire as an outcome. Winter birth was not associated with a diagnosis of food 
allergy (aOR 1.02, 95% CI 0.73-1.42) (174). 
 
 
Figure 2.10: Association between seasons of birth of Boston children with food induced anaphylaxis. 
Figure taken from Vassallo et al (163). 
 
 
Figure 2.11: Seasonal variation in birth dates in children <5 years treated for allergy in three Boston 
(northern hemisphere) Emergency Departments.  Figure taken from Vassallo et al (164). 
 
Several studies have examined the potential association of latitude and food allergy or allergic 
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disease, assuming latitude as a proxy marker of low VDS. Osborne et al in an observational 
study using parent reported allergy, found higher rates of food allergy and eczema among 
children residing further from the equator in Australia (37). This finding was replicated by 
another large observational study of over 17 million Emergency Department visits from 1993-
2005, where there was a higher attendance rate for acute allergic reactions in the northeast 
compared to southern regions of the USA (175). A Florida based study in 2011 demonstrated 
lower rates for presentation to the Emergency Departments in Florida with allergic reactions 
compared to other USA states (176). More recently in Chile, South America, a south to north 
gradient was demonstrated for food-induced anaphylaxis in children (177). The Chilean study 
results were limited however, by a lack of covariate data and the proxy outcome of hospital 
admissions for anaphylaxis with no specified cause in many cases, potentially missing 
community based incidence of anaphylaxis (177). 
In two studies in the USA and Australia, Epipen adrenaline autoinjector prescriptions were used 
as a proxy marker for rates of allergy and anaphylaxis. In the USA study in 2007, Camargo et al 
found a strong north-south gradient for Epipen prescriptions, with four times more Epipens 
being prescribed in northeast states compared to southern states (36). This finding was 
replicated by Mullins in Australia, who identified a strong north-south latitude gradient for 
Epipen prescriptions and in addition, anaphylaxis admissions. The gradient was independent of 
longitude and socio-economic status (178). When hypoallergenic formula prescription was used 
as a proxy marker of food allergy in Australia, a north-south latitude gradient was also 
demonstrated (41). In multiple studies food allergy has been more common in developed 
countries in races with a darker skin color, which may also reflect lower vitamin D levels in 
these individuals (179-181). However, subsequent work on vitamin D bioavailability (182) 
suggests that ethnicity may modify the relationship between VDS and allergy development 
through variable levels of vitamin D binding protein (183, 184). 
2.8.2 Evidence for an association between directly measured low serum vitamin D status in 
childhood and food allergy 
Low VDS is an endemic problem in the developed world. While several studies have examined 
the association between vitamin D and allergic disease such as asthma, allergic rhinitis and 
atopic dermatitis/eczema, relatively few have focused on the direct measurement of serum 
vitamin D and diagnosed food allergy.  
The Australian HealthNuts study recently used challenge-proven IgE-mediated food allergy as a 
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robust outcome and sampled a representative population (n=5276) for the potential role of 
vitamin D deficiency. This study found that one year old infants with low VDS (<50 nmol/L), who 
had Australian born parents were more likely to be allergic to peanut (aOR 11.51; 95% CI 2.01-
65.79; P=0.006) or egg (aOR 3.79; 95% CI 1.19-12.08; P=0.025) than children with vitamin D 
levels ≥50 nmol/L (21). Children with low VDS were also more likely to have multiple food 
allergies than a single food allergy (21). In a small supporting USA study of children with a 
documented diagnosis of food allergy (n=39), the children with atopic dermatitis and food 
allergy had lower levels of serum vitamin D compared to those with atopic dermatitis but no 
food allergy. They also showed that decreased serum vitamin D levels increased the risk of food 
allergy in the group (185). In a Middle Eastern study of 483 children, low VDS (defined in their 
study as serum vitamin D level ≤75 nmol/L) was significantly associated with a physician 
diagnosis of food allergy (186). These three preceding studies all had a documented diagnosis 
of food allergy as a positive strength in the studies. Compared to the HealthNuts strength of the 
population size (21), the other two studies are limited by numbers (185, 186). In a large 
observational USA study the NHANES 2005-06 examined IgE-mediated sensitisation (a 
limitation) to various foodstuffs and aeroallergens. A positive association was found between 
peanut and shrimp sensitisation and vitamin D levels less than 15 ng/ml (equivalent to ≤37.4 
nmol/L) in children and adolescents between one and twenty one years of age (187). In 
contrast, in a recent cross-sectional New Zealand study (n=1329) of children between two and 
five years, those with a vitamin D level of ≥75 nmol/L had a greater risk of doctor diagnosed 
food allergy than children with a vitamin D level of 50 -74.9 nmol/L (aOR 2.21, 95%CI 1.33–3.68) 
(188). There are a number of limitations to this finding including the cross sectional nature of 
the study, the questionnaire based outcome and the use of blood spots for vitamin D levels 
rather than serum samples. 
2.8.3 Evidence for an association between maternal vitamin D supplementation and food 
allergy in childhood 
When direct measurement of vitamin D levels have been used in studies, clear associations 
have been found between low VDS and food allergy. The question has arisen whether the 
potential effect of vitamin D occurs antenatally, possibly presenting an opportunity for 
intervention given the high prevalence of low VDS among pregnant women (40). 
A Finnish study by Nwaru suggested higher intake of vitamin D during pregnancy was 
associated with a decreased risk of sensitisation to food allergens by age five (aOR 0.56; 95% CI 
Chapter 2 
 34 
0.35–0.91, p<0.05) (189). This association was present despite the fact that mothers in the 
vitamin D supplement group received an overall mean daily intake of 6.25 µg/day, well below 
the national daily recommendation of 10 µg/day. Another limitation of this study was that no 
direct serum measurement of vitamin D was obtained. In a West Australian Study, they 
examined allergic outcomes during the first year of life in relation to antenatal vitamin D 
exposure in a cohort of high risk infants (n=231) (44). Maternal vitamin D supplementation in 
the third trimester was not associated with allergic outcomes in infancy including food allergy 
at one year (44). This study was limited by only having data available on maternal vitamin D 
supplementation in the third trimester of pregnancy in a high risk cohort limiting generalisation 
of the study results. Another Finnish birth cohort (n=6288) previously discussed in this chapter 
examined vitamin D intake in the eighth month of pregnancy and cow’s milk allergy in the 
offspring at 3 years (35). There was weak evidence of an association between vitamin D 
supplement intake and increased risk of cow’s milk allergy at three years (aOR 1.37, 95% CI 
1.03-1.81). Limitations of the study included the use of a questionnaire to estimate vitamin D 
intake rather than using direct measures. The authors also acknowledged that motivated more 
educated families with healthier lifestyles were retained in the study leading to possible 
confounding issues. 
2.8.4  Evidence for an association between directly measured antenatal and/or cord blood 
serum vitamin D and food allergy in childhood 
Studies utilising direct measurement of antenatal and cord blood vitamin D levels as exposures 
in relation to allergy in childhood have demonstrated conflicting findings with positive evidence 
for both low and high VDS.  
A USA study by Liu et al showed a persisting low vitamin D at birth (≤11 ng/ml, equivalent to 
≤30 nmol/L) and in early childhood (≤30 ng/ml, equivalent to ≤75 nmol/L) was associated with a 
higher risk of food sensitisation (OR=2.99; 95% CI 1.05-8.52). Those who had a low VDS at birth 
that subsequently normalised during early life had a much lower risk of food sensitisation, 
which suggests there may be opportunity for interventions postnatally (48). The majority of 
participants in this study were African-American, which may limit the significance of the results, 
as African-American children are more likely to have vitamin D deficiency (190). A Western 
Australia study in a cohort of high risk infants (n=231) demonstrated there was no association 
between low VDS (≤50 nmol/L) at birth and risk of developing IgE-mediated food allergy, but 
there was an increased risk of eczema (44). In this study it has been shown that dietary vitamin 
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D intake during pregnancy does not affect cord blood levels, while vitamin D supplementation 
significantly correlates with cord blood VDS, which further supports a possible intervention 
(44). In another USA based cohort study (n=707), vitamin D levels were sampled antenatally,at 
birth and 2 years. Increasing levels of vitamin D at each timepoint were not associated with 
food sensitisation at two years of age (49). The study findings were limited by the uncertain 
outcome of food sensitisation. Weisse et al in the German LINA cohort study found that a 
higher level of maternal and cord blood vitamin D were associated with a higher risk of food 
allergy during the second year of life (aOR 1.59; 95% CI 1.04-2.45) (42). A high proportion of the 
participants (65%) had atopic parents, which may have biased the outcomes. This study was 
also limited by the diagnosis of food allergy being based on parent reporting of a physician 
diagnosis and a substantial loss to follow-up. A more recent analysis of the cord blood vitamin D 
in the LINA cohort found that cord blood vitamin D levels were positively associated with food 
allergy diagnosis by 3 years of age (aOR 1.86, 95% CI 1.08-3.20) supporting the findings of 
Weisse (191).  
Pike et al in a study that followed 860 English mother-child pairs, reported no association 
between maternal VDS in late (34 weeks gestation) pregnancy and food sensitisation by the age 
of six years (192). Serum levels of vitamin D ≥80 nmol/L were found in 29% of women in the 
study and the average serum vitamin D level was 59 nmol/L. In a retrospective study, Mullins 
examined the neonatal vitamin D level in infants who had developed peanut allergy at less than 
72 months of age over a one year period and compared them to matched controls (43). Slightly 
higher vitamin D levels (75-99.9 nmol/L) were associated with a lower risk of peanut allergy. 
Excessive vitamin D levels (>100 nmol/L) did not reduce the risk of peanut allergy and at 
vitamin D levels of <50 nmol/L, the risk was not increased, with no linear risk relationship (43). 
A Taiwanese study examined maternal vitamin D levels in 164 mother-infant pairs and found 
maternal vitamin D deficiency (<20 ng/ml) was associated with allergic sensitisation in infants 
before the age of two. The study was notable for a high prevalence of VDI (80%) among 
mothers in the cohort and the suboptimal outcome of allergic sensitisation (193). A USA study 
examining two socio-economically diverse birth cohorts, the "URECA” (194) and the “COAST” 
(195) studies, did not demonstrate any association between VDS at birth and food allergy 
related outcomes at three to five years of age (51). The study results are limited by a single 
vitamin D measurement and suboptimal outcome measures.  
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2.8.5 Evidence for a genetic interaction with vitamin D status and development of food 
allergy in childhood 
It has been hypothesised that the effect of vitamin D on the development of food allergy may 
only exist in particular genotypes. In a prospective urban USA birth cohort study of 649 
children, Liu et al found no significant association between low vitamin D levels (≤11 ng/ml, 
equivalent to ≤30 nmol/L) in cord blood and food sensitisation. However, the risk of food 
sensitisation was higher in those children with high risk genotypes, such as CYP24A1, an 
enzyme involved in vitamin D degradation (196, 197). In a study based on the HealthNuts 
cohort, different genotypes at the polymorphism rs7041 selected as proxy makers of vitamin D 
binding protein levels, modified the relationship between VDS and development of food allergy 
(184). A comprehensive summary of the important studies examining VDS and food allergy is 
presented in the tables below (Table 2.3, Table 2.4, Table 2.5, Table 2.6, Table 2.7, Table 2.8 & 
Table 2.9) 
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Table 2.3: Summary of the important studies regarding season of birth and development of food allergy.  
ECOLOGICAL EVIDENCE 
Season of birth (SOB) and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Allen  
et al (2013) 
(21) 
Australia Population 
derived cohort 
study (n=5,300). 
No association between SOB 
and food allergy. 
Large sample size; 
population derived cohort; 
robust outcome measure; 
extensive data on covariates 
and comprehensive analytic 
strategy. 
VDS was not directly measured during 
either pregnancy or at birth. 
Kusunoki  
et al (2013) 
(170) 
Japan Questionnaire 
survey 
investigating 
season of birth 
and food allergy 
and eczema in 
infants 
(n=13,179). 
No association between 
season of birth and food 
allergy. 
Large population based survey. Parent report of allergy and eczema status 
only. 
Vassallo  
et al (2010) 
(164) 
USA Observational 
cohort study 
(n=1002). 
Association between 
winter/autumn birth and 
food allergy. 
Hospital coded diagnosis of 
food allergy provides strong 
outcome measure. 
Lack of detailed measurement and analysis 
of covariates; risk of outcome 
misclassification due to hospital coding. 
Vassallo  
et al (2010) 
(163) 
USA Observational 
study examining a 
potential 
association 
between SOB and 
food induced 
anaphylaxis 
(n=3792). 
Association between 
autumn/winter birth and 
food induced anaphylaxis. 
Hospital coded food induced 
anaphylaxis diagnosis provides 
strong outcome measure. 
Lack of detailed measurement and analysis 
of covariates. 
Chapter 2 
 38 
ECOLOGICAL EVIDENCE 
Season of birth (SOB) and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Keet  
et al (2012) 
(169) 
USA Analysis of data 
from a population 
based survey 
(NHANES, n= 
5862) and hospital 
derived sample of 
children with food 
allergy (n= 1,514). 
Autumn birth associated 
with food allergy. 
Large sample size. Lack of data on eczema in NHANES; lack of 
detailed measurement and analysis of 
covariates. 
Pyrhonen  
et al (2012) 
(167) 
Finland Population 
derived cohort 
(n=5920) with 
allergic 
sensitisation 
status determined 
up to four years of 
age. 
Children born in 
autumn/winter more likely 
to be food sensitised by four 
years of age. 
Population derived sampling 
strategy; 
large sample size. 
 
Methods for diagnosis of sensitisation and 
food allergy in study were non-
homogenous; 
lack of detailed measurement and analysis 
of covariates. 
Nilsson  
et al (1997) 
(165) 
Sweden Cohort study 
(n= 209) 
examining SOB 
and subsequent 
serum specific IgE 
antibodies to 
foods and pollens. 
Higher prevalence of IgE 
antibodies to food in 
children born in 
autumn/winter. 
Longitudinal design; 
Measurement of serum specific 
antibodies is a robust outcome. 
Lack of detailed measurement and analysis 
of covariates; 
high risk rather than population-
representative cohort; 
unknown clinical relevance of allergic 
sensitisation as a primary outcome. 
Mullins  
et al (2011) 
(166) 
Australia Case series  
(n= 835) 
examining season 
of birth and food 
allergy. 
Autumn/winter births more 
common in children with 
food allergy. 
Doctor diagnosis of food allergy 
providing robust outcome 
measure; regional UVR data 
available for analysis. 
Lack of detailed measurement and analysis 
of covariates; no control series. 
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ECOLOGICAL EVIDENCE 
Season of birth (SOB) and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Tanaka  
et al (2015) 
(172) 
Japan Cross-sectional 
cohort 
(n=1197) 
Autumn/winter 
births higher among 
food allergic infants 
Oral food challenge and 
clinically proven food allergy as 
outcome. 
Bias in control group selection, lack of data 
on potential confounders 
Matsui  
et al (2015) 
(173) 
Japan Retrospective 
observational  
study (n=732) 
Autumn winter births had 
higher specific IgE titres to 
food at six months 
Measurement of serum specific 
antibodies  
Retrospective study. Bias in selection of 
study subjects. 
Hwang  
et al (2016) 
(174) 
Korea Cross sectional 
observational 
study (n=3400) 
Winter birth was not 
associated with a diagnosis 
of food allergy. 
Large study size Questionnaire based report of food 
allergy, recall bias in data reported. 
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Table 2.4: Summary of the important studies regarding latitude gradient and development of food allergy. 
ECOLOGICAL EVIDENCE 
Latitude gradient and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Camargo 
et al (2007) 
(36) 
USA Ecological study 
mapping latitude to 
adrenaline 
autoinjector 
prescription rates 
(n=1,511,534). 
An association between 
higher latitude and higher 
rates of adrenaline 
autoinjector 
prescriptions. 
Large sample size; mandatory 
government record of 
documented adrenaline 
autoinjector prescriptions 
provide a well captured 
outcome measure. 
Insufficient data on potential 
confounding factors (e.g. SES); use of a 
proxy measure of food allergy status. 
Harduar-
Morano  
et al (2011) 
(176) 
USA Ecological study 
mapping latitude to 
emergency 
department 
presentations with 
anaphylaxis 
(n=2751). 
An association between 
higher latitude and 
increased presentations 
to emergency 
departments with 
anaphylaxis. 
Large sample size, 
hospital coded diagnosis of 
anaphylaxis provides well 
captured and direct outcome 
measure. 
Risk of outcome misclassification due to 
emergency department coding and 
large numbers of cases of anaphylaxis 
with unidentified cause (i.e. potentially 
not food related). 
Rudders  
et al (2010) 
(164) 
USA Ecological study 
mapping latitude to 
emergency 
department’s 
presentations for 
acute allergic 
reactions 
(n=17.3 million). 
An association between 
higher latitude and 
increased presentations 
to emergency 
departments for allergic 
reactions. 
Hospital coded diagnosis of 
allergic reactions and 
anaphylaxis provide well 
captured and direct outcome 
measure. 
Risk of outcome misclassification due to 
emergency department coding errors. 
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ECOLOGICAL EVIDENCE 
Latitude gradient and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Osborne  
et al (2012) 
(37) 
Australia Cohort study  
(n=7643). 
Higher latitude associated 
with a higher prevalence 
of eczema and food 
allergy. 
Population derived data. Self reporting of allergic disease status 
only. 
Mullins  
et al (2010) 
(41) 
Australia Ecological study 
mapping latitude to 
hypoallergenic 
formula 
prescriptions 
(n=36,165). 
Higher latitude associated 
with higher rates of 
hypoallergenic formula 
prescriptions. 
Mandatory government record 
of hypoallergenic formula 
prescriptions provides a well 
captured outcome. 
Use of non-specific proxy measure of 
food allergy status. 
Mullins  
et al (2009) 
(178) 
Australia Ecological study 
mapping latitude to 
adrenaline 
autoinjector 
prescription rates 
(n=69,227). 
Higher latitude associated 
with higher rates of 
adrenaline autoinjector 
prescriptions. 
Mandatory government record 
of adrenaline autoinjector 
prescriptions provides a well 
captured outcome. 
Use of non-specific proxy measure of 
food allergy status. 
Hoyos-
Bachiloglu 
et al (2014) 
(177) 
Chile Ecological study 
mapping 
geographical 
location and 
latitude to allergy 
and anaphylaxis 
admissions to 
hospital (n=2316). 
Higher latitude associated 
with higher rates of 
anaphylaxis admissions. 
Government record of rates of 
allergy/anaphylaxis admissions 
provides a well captured 
outcome. 
Cause of anaphylaxis unknown in many 
cases; lack of detailed measurement 
and analysis of covariates. 
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Table 2.5: Summary of the important studies regarding directly measured vitamin D and development of food allergy. 
EPIDEMIOLOGICAL EVIDENCE 
Directly measured VDS and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Allen  
et al (2013) 
(21) 
Australia VDS at 1 year among 
infants with and 
without IgE-
mediated food 
allergy from a 
population cohort 
(n=5,300); in 
subgroup study 
(n=481). 
Cross sectional association 
between VDI and IgE 
mediated food allergy 
among infants of Australian 
born parents, but not 
among infants of overseas 
born parents. 
Population derived sampling 
frame; 
large sample size; 
use of challenge-proven IgE- 
mediated food allergy to define 
outcome status; 
comprehensive analytic 
strategy. 
Cross sectional design; 
potential for selection bias among the 
negative controls who participated in 
the vitamin D study. 
Sharief  
et al (2011) 
(187) 
USA VDS among children 
and adolescents 
aged 1-21 years 
with and without 
food sensitisation in 
a population based 
cross-sectional 
study (n=3,136). 
Low VDS associated with 
peanut and shrimp 
sensitisation. 
Large sample size; 
allergic sensitisation is a 
standard measure.  
Cross sectional design; 
lack of detailed measurement and 
analysis of covariates;  
the clinical relevance of allergic 
sensitisation is uncertain. 
Mohiuddin  
et al (2013) 
(185) 
USA VDS in children with 
atopic dermatitis 
with and without 
food allergy in an 
observational study 
(n=39). 
Low VDS more common in 
children with food allergy 
and atopic dermatitis. 
Serum vitamin D measured as 
exposure. 
Small sample size, selected population. 
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EPIDEMIOLOGICAL EVIDENCE 
Directly measured VDS and food allergy 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Cairncross 
et al (2016) 
(188) 
New 
zealand 
Cross-sectional 
study 
(n=1329) 
Higher vitamin D levels 
associated with a higher risk 
of food allergy in children 
between two and five years 
Direct measure of vitamin D 
status,  
Parent reported diagnosis, bias in 
selection of study group. 
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Table 2.6: Summary of the important studies regarding maternal vitamin D intake and development of food allergy among offspring. 
EPIDEMIOLOGICAL EVIDENCE 
Maternal vitamin D intake and food allergy among offspring 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Nwaru  
etal(2010) 
(189) 
Finland A population derived 
birth cohort study 
(n=931). 
Higher intake of vitamin D during pregnancy 
was associated with lower risk of allergic 
sensitisation in offspring at 5 years. 
Prospective population 
based study; relatively 
large sample size. 
No direct measurement of VDS; 
the clinical relevance of allergic 
sensitisation is uncertain. 
Jones  
et al (2012) 
(44) 
Australia Birth cohort study of 
infants at high risk of 
allergy (n=231). 
Intake of vitamin D supplements in the third 
trimester was not associated with infant 
allergic outcomes at 1 year.  
Longitudinal design; 
direct measurement of 
VDS; 
robust measurement of 
allergy status. 
Small sample size; 
lack of detailed measurement 
and analysis of covariates (e.g. 
sun exposure). 
Tuokkola  
et al (2016) 
(35) 
Finland Population derived 
birth cohort study 
(n=6288) 
Intake of vitamin D supplements in third 
trimester associated with higher risk of cows 
milk allergy at three years.  
Longitudinal design, 
relatively large sample size 
Bias in project group, no direct 
measure of vitamin D status 
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Table 2.7: Summary of the important studies regarding directly measured antenatal/cord blood vitamin D and development of food allergy. 
EPIDEMIOLOGICAL EVIDENCE 
Directly measured antenatal/cord blood VDS and markers of food allergy status 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Jones  
et al (2012) 
(44) 
Australia Birth cohort 
study of infants 
at high risk of 
allergy (n=231). 
Low cord blood VDS 
associated with 
development of eczema, 
but not allergic 
sensitisation. 
Longitudinal design; 
direct measurement of VDS; 
robust measurement of allergy 
status. 
Small sample size; measurement of 
VDS at a single time-point; lack of 
detailed measurement and analysis of 
covariates (e.g. sun exposure). 
Pike  
et al (2012) 
(192) 
UK Population 
derived birth 
cohort study 
(n=860). 
No association between 
antenatal VDS and 
childhood atopy. 
Prospective study; antenatal 
serum VDS good measure of 
exposure. 
Measurement of VDS at a single time 
point and substantial loss to follow-
up. 
Chawes  
et al (2014) 
(52) 
Denmark Birth cohort 
study of children 
born to mothers 
with diagnosed 
asthma (n=257 in 
VDS substudy). 
No association between 
cord blood VDS and atopic 
disease. 
Longitudinal design; 
measurement of serum VDS. 
Small sample size; high risk cohort 
limiting generalisability of findings. 
Liu  
et al (2013) 
(48) 
USA Prospective birth 
cohort study 
(n=460). 
Persistent low VDS 
increased risk of 
subsequent food 
sensitisation. 
Measurement of VDS at several 
time points; genotyping of 
subjects in longitudinal study. 
Food sensitisation outcome measure 
rather than diagnosed food allergy 
and only limited number of genotypes 
examined. 
Chiu  
et al (2015) 
(193) 
Taiwan Prospective birth 
cohort 
(n=258) 
Maternal low VDS 
associated with allergic 
sensitisation including food  
Measurement of VDS at several 
timepoints.  
Allergic sensitisation outcome 
measure rather than diagnosed food 
allergy. Small sample size in follow up  
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Table 2.8: Summary of the important studies regarding high VDS and development of food allergy. 
EPIDEMIOLOGICAL EVIDENCE 
High VDS and markers of food allergy status 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Weisse  
et al (2013) 
(42) 
Germany Prospective birth 
cohort study 
(n=378). 
An association between higher levels of 
maternal, cord blood VDS and an 
increased risk of food allergy. 
Multiple serum measurements 
of VDS increase strength of 
exposure. 
Substantial loss to follow up in cohort. 
Mullins  
et al (2012) 
(43) 
Australia Cohort study 
(n=115). 
An association between higher levels of 
neonatal VDS and a lower risk of 
peanut allergy. 
Direct measurement of 
neonatal VDS. 
Single measure of VDS; lack of detailed 
measurement and analysis of 
covariates (e.g. infant feeding). 
Wegienka  
et al (2016) 
(49) 
USA Prospective birth 
cohort study. 
(n=707) 
Increasing vitamin D levels at each 
timepoint not associated with food 
sensitisation at 2 years of age. 
Direct measures of VDS at 
several timepoints. 
The clinical relevance of allergic 
sensitisation is uncertain. 
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Table 2.9: Summary of the important studies regarding genetic factors and VDS and development of food allergy. 
EPIDEMIOLOGICAL EVIDENCE 
Could the association between low VDS and food allergy be modified and/or confounded by genetic factors? 
Source 
(year) 
Country Design/ 
Number in study 
(n) 
Findings Study Strengths Study Limitations 
Keet  
et al (2012) 
(169) 
USA Retrospective 
analysis of a 
population based 
cohort and an 
observational study, 
(n=7376)  
An association between 
autumn birth and an 
increased risk of food 
allergy in Caucasians 
only. 
Large sample size. Insufficient ethnic diversity in cohort to 
examine ethnicity influence on season of 
birth and food allergy. 
Liu  
et al (2011) 
(196) 
USA Prospective birth 
cohort study 
(N=460). 
Low VDS increased the 
risk of food sensitisation 
in children carrying the 
single nucleotide 
polymorphism 
rs2243250 C allele. 
Longitudinal study; 
measurement of VDS at 
several time points provide 
strong measures of exposure; 
genotyping of subjects in 
study. 
Food sensitisation used as outcome 
measure and limited number of 
genotypes examined. 
Vimaleswaran 
et al (2012) 
(183) 
UK Prospective birth 
cohort study 
(n=8302). 
Association between low 
VDS and an increased 
allergy risk in certain 
genotypes. 
Serum VDS measured; 
genotyping of subjects. 
Caucasian only study population group 
limits strength of study results. 
Koplin  
et al (2016) 
(184) 
Australia VDS at 1 year 
among infants with 
and without IgE-
mediated food 
allergy from a 
population cohort 
(n=5,300); in 
subgroup study 
(n=607). 
Association between VDI 
and food allergy in 
infants, modified by 
genotypes in 
polymorphism analysed 
as proxy marker of 
vitamin D binding 
protein levels. 
Population derived sampling 
frame, 
large sample size, 
use of challenge-proven IgE 
mediated food allergy to 
define outcome status.  
Cross sectional design, 
Small numbers in substudy, proxy marker 
of vitamin D binding protein levels used. 
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2.9 Conclusions regarding vitamin D status and food allergy 
The epidemic of low VDS in the developed world has paralleled the dramatic rise in food allergy 
prevalence. It has been shown that vitamin D is an immunomodulator, and like the microbiome, 
has been implicated in a number of non-communicable disease processes, such as 
inflammatory bowel disease, multiple sclerosis and diabetes. There is ongoing interest in 
vitamin D’s potential role in allergic disease, although the studies completed so far have yielded 
conflicting results. While the optimum level of serum vitamin D in relation to immune health 
remains uncertain, some infant studies suggest that VDI defined as <50 nmol/L is associated 
with food allergy development. When vitamin D levels during pregnancy were analysed for 
potential association with food allergy or food sensitisation, results were again conflicting with 
studies suggesting both high and low Vitamin D levels may be associated with risk of offspring 
food allergy. It is clear there is an urgent need for further studies to examine whether simple 
cost effective interventions, such as routine vitamin D supplementation to optimise VDS would 
be useful as an infant food allergy prevention strategy. To date there is insufficient evidence to 
support such practices. This thesis will therefore test the following research hypothesis: That 
low VDS in the first six months of infancy is associated with increased risk of IgE-mediated food 
allergy and/or eczema in the first year of life.  
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2.10 Gut microbiota and IgE-mediated food allergy review 
It is hypothesised that early life gut microbiota may influence the risk of developing food 
allergy. The original ‘Hygiene Hypothesis’ by Strachan proposed that exposure to infection in 
early life through larger family sizes was protective against allergic disease (57). Subsequently, a 
range of evidence has supported an association between early life non-pathogenic microbial 
experience, immune development and allergic disease. The putative relationship between non-
pathogenic microbial experience and allergic disease has been described as ‘The Hygiene 
Hypothesis revised’ (67). There is increasing evidence and consensus that the early life 
microbial experience (of both the mother during pregnancy and the offspring during early 
infancy) modifies the composition of the human microbiome, which in turn influences immune 
development and risk of allergic disease. The aims of this section are to (i) explore the 
theoretical basis for a relationship between gut microbiota and IgE-mediated food allergy, (ii) 
summarise current evidence for the association between specific factors in the modern 
environment and both (a) the composition of the gut microbiota and (b) IgE-mediated food 
allergy in children, (iii) to examine the direct evidence linking the composition of the gut 
microbiota and food allergy.  
2.11 The theoretical basis for a relationship between gut microbiota 
development and IgE-mediated food allergy. 
Disruption in early gut microbiota development may alter gut epithelial integrity, affect 
immune development and potentiate the allergic response. The theoretical basis for this 
process is discussed below. 
2.11.1  Definition of terms – microbiota and microbiome 
The term gut microbiota describes the total population of microorganisms in the gut, there are 
an estimated 1013 to 1014 organisms present comprising at least 400 species of bacteria (198, 
199). The microbial population and the genes they encode is collectively known as the gut 
microbiome (200). The gut microbiome contains more than 100 times the number of genes in 
the human genome (201). Phase one of the Human Microbiome Project has demonstrated 
dramatic variation in the composition of gut microbiota, both between individuals, and within 
individuals over time (201), and the implications of such variation are the subject of intense 
research activity. 
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2.11.2  Development of the gut microbiome during early life and symbiosis in the gut 
The foetal gut was previously assumed to be essentially sterile (202). Recent work has 
suggested that there may be bacteria present in meconium of neonates (203) and evidence of 
bacterial colonisation has been found in the placenta (204) and amniotic fluid (205). In a vaginal 
birth the baby is colonised by maternal commensal bacteria from the maternal birth canal and 
gut (206), so the bacterial colonisation pattern of the neonate resembles that of the maternal 
birth canal and faeces (70, 207). By six months of age anaerobic species dominate the gut flora, 
a period which coincides with solid food introduction in most populations (208). By the age of 
two years the infant gut will have developed an adult type pattern, but full development may 
take several more years (207). 
The co-evolution of humans and their commensal gut organisms has resulted in an elegant 
symbiosis, in which gut microbiota plays a crucial role in the development and maintenance of 
gut barrier and immune function (209). If this relationship is unbalanced, pathological processes 
can occur, such as immune mediated bowel inflammation due to an overactive immune system, 
or conversely, sepsis due to invasion by opportunistic bacteria that may prove fatal to the host. 
Thus, in order to maintain an effective balance, the immune system has evolved a variety of 
mechanisms to provide benefits for both host and commensal organisms (Figure 2.12). One 
such mechanism is tolerance, which represents the ability of the immune system to recognise a 
harmless antigen and actively suppress an inflammatory response. Given the immense 
antigenic load presented by gut microbiota, the maintenance of tolerance is crucial to avoid 
excessive inflammation. The process of immune tolerance is assisted by anatomical isolation of 
microbiota within the gut lumen (210). Three major mechanisms contribute: Goblet cells in the 
epithelial wall produce a mucus barrier where the bacteria reside and are prevented from 
penetrating the inner epithelium (211). Epithelial cells also produce a range of antimicrobial 
proteins, belonging to the same family of proteins as defensins that have the capacity to kill 
bacteria by compromising bacterial cell wall integrity (212). Secretory Immunoglobulin A (IgA) is 
produced by B cells induced in the GALT, and secreted across the epithelial wall. Gut secretory 
IgA is thought to be involved in trapping bacteria in the mucus layer preventing pathological 
invasion (213). The GALT produce secretory IgA capable of reacting to gut microbiota, and as 
such, gut secretory IgA is thought to play a role in maintaining the normal host-microbiota 
balance (214). Secretory IgA may also play a role in oral tolerance through the binding of 
antigens in the gut and preventing systemic uptake of the antigen (215). In this context it has 
been shown that in mice sensitised to β-lactoglobulin (a protein in milk), intestinal IgA levels 
Chapter 2 
 51 
were depressed compared to those in mice tolerant to β-lactoglobulin (216); and furthermore 
food allergy rates are higher in children with IgA deficiency (217). 
In addition, the commensal bacteria occupying the gut are genetically programmed not to 
express factors that enable cell invasion. Consequently if commensal bacteria happen to invade 
the epithelium, they are quickly phagocytosed by the host (218). Pathogenic organisms that 
manage to evade these host barriers to invasion, can cause infection. For example, 
Campylobacter jejuni and Salmonella, which may result in life threatening illnesses, have 
flagella that aid invasion and appear resistant to antimicrobial proteins, and pathogenic 
organisms may also be able to downregulate factors that are microbicidal (219, 220). 
 
 
Figure 2.12: Diagram demonstrating how the gut microbiota coexists with the host gut.  Commensal 
bacteria are maintained in the outer mucus layer and the inner layer is resistant to bacterial 
penetration. Secretory IgA and antimicrobial proteins aid in killing any bacteria that invade the inner 
mucus layer. Figure taken from Hooper LV (221). 
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2.11.3 Host influences on microbiome development 
The early life colonisation of the gut by bacteria essential for normal immune development is 
affected by factors including mode of delivery, antibiotic exposure, dietary intake and 
developing versus developed world lifestyle. In addition to environmental factors, there is some 
evidence that host genotype may influence the pattern of gut colonisation during early life, 
which in turn, may predispose to specific gene-environment interactions (222). For example, in 
experimental models, inbred mice have more comparable gut microbiota profiles than outbred 
mice (223). Concordantly, in a study of twins conducted among children aged up to ten years, 
the faecal microbiota of identical twins, fraternal twins and unrelated individuals were 
compared (224) - the similarity of gut microbiota patterns was greatest among identical twins. 
However, a subsequent study among adult twins found no evidence of an association between 
host genotype and the composition of the gut microbiome (225). This may reflect difference in 
the relationship between genotype and the gut microbiome in children as compared to adults, 
but it may also reflect study differences. In particular, the study among children used temporal 
temperature gradient gel electrophoresis (TTGE) to characterise the gut microbiota, whereas 
the study among adults used pyrosequencing, which provides a far more detailed picture of the 
microbiome. 
2.11.4 The impact of the gut microbiome on the developing immune system and acquisition 
of tolerance 
The gut microbiota plays a significant role in the developing immune system promoting local 
gut immune development and acquisition of tolerance. This role has been explored in various 
immune studies on germ free mice. Early experiments demonstrated that GALT, comprising 
organised structures of lymphoid tissue such as Peyer’s patches are poorly developed or absent 
in germ free mice (226, 227). Subsequent work has shown that germ free mice have reduced 
numbers of functional (CD4+CD25+Foxp3+) Treg cells within the mesenteric lymph nodes and 
Peyer’s patches. These cells probably represent induced Treg’s, which play a key role in the 
induction of tolerance, providing a putative mechanism for failure of oral tolerance in such mice 
(228-230). It has been demonstrated that introduction of Bacteroides fragilis into the lower gut 
of germ free mice can redevelop the GALT and induce tolerance but only if done in the neonatal 
period. This is associated with induction of Treg’s cells via IL-10 dependent mechanisms, which 
may explain its role in tolerance induction (54). 
Allergic disease is, at least in part, related to enhanced responses from Th2 cells (81). During 
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pregnancy, the Th1 immune response of the foetus is suppressed to prevent excessive response 
to maternal antigens. Consequently, neonates are skewed toward a Th2 response to novel 
antigens (231). Th2 cells produce IL-4, IL-5 and IL-13, which promote the development of 
allergic inflammation. The gut microbiota is one of the environmental signals that promote T 
cell maturation (232), with exposure to gut microbiota promoting a Th1 response which favours 
immune tolerance and maintains a Th1/Th2 balance (54, 233). The capsular polysaccharide 
from Bacteroides fragilis has been shown to enhance T cell development and promote Th1 cell 
differentiation (54). A recent study highlighted that a lack of Bacteroides colonisation in 
humans may be associated with a poor Th1 response (207), while Germ free mice demonstrate 
a persistent Th2 skew as a result of absent intestinal microbiota. It should be noted however, 
that the Th1/Th2 balance is not the sole mechanism for maintaining immune tolerance. Indeed 
established allergic disease may be associated with increased numbers of Th1 cells and cytokine 
responses (234).  
2.11.5  Experimental evidence specifically linking the gut microbiota and development of 
food allergy 
Experimental work suggests that the interaction between gut microbiota and the immune 
system plays a key role in the induction of immune tolerance and prevention of food allergy. 
For example, IL4Rα gain-of-function mutant mice are particularly susceptible to allergic 
sensitisation. These mice have altered gut microbiota prior to sensitisation compared to allergy 
resistant mice (235). In a series of experiments the establishment of sensitisation in the IL4Rα 
mice was associated with an altered microbial signature, suggesting immune influence on the 
gut microbiota (235). When the gut microbiota from allergic mice was transferred to allergy 
resistant mice, food allergy could be induced in the previously resistant mice, suggesting the 
microbiota could modify the immune response (235). Finally, when allergen-specific Treg cells 
were transferred into the IL4Rα mice, the process induced tolerance and suppressed further 
sensitisation attempts. In another mouse study by Cahenzli et al, germ free mice demonstrated 
high levels of IgE production and exaggerated anaphylaxis in comparison to mice with diverse 
gut microbiota. They also demonstrated that increased diversity in the gut microbiota 
introduced into germ free mice in early life was essential in inhibiting IgE production (236). The 
role of particular bacterial species in the composition of gut microbiota was demonstrated by 
Stefka et al where a clostridia containing microbiota introduced into germ free mice and mice 
previously treated with antibiotics protected against allergic sensitisation to a food (237). The 
presence of a clostridia containing microbiota appeared to induce Il-22 that regulated allergen 
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access to the bloodstream (237). Previous work by Yamashita et al also showed that transfer of 
Treg cells from allergen tolerant mice into naïve mice suppressed subsequent attempts at food 
induced anaphylaxis (238).  
2.11.6 Direct evidence that the composition of the gut microbiome influences the risk of 
allergic disease in humans. 
There is limited work regarding the relationship between gut microbiota and food allergy in 
humans. The relationship between gut microbiota and eczema, however, has been extensively 
studied. Wang et al demonstrated reduced gut microbial diversity in one week old infants who 
subsequently developed eczema by eighteen months of age (239). This finding was reproduced 
in a prospective study of infants determined to be at high risk of allergic disease, which showed 
gut microbial diversity was reduced in the first week of life in children who developed atopic 
eczema by one year of age (240). The lack of diversity in both studies was determined using the 
older less precise molecular technique, Terminal Restriction Fragment Length Polymorphisms 
(T-RFLP), which has been superseded by more sophisticated methods. Concordantly, 
Abrahamsson et al showed using 16S Ribosomal ribonucleic acid (rRNA) sequencing that gut 
microbial diversity was reduced in one month old infants who subsequently developed IgE-
related eczema compared to infants with no allergy during the first two years of life (241). 
Bacteroides species levels were lower in infants with eczema compared to non-allergic infants 
(241). A recognised strength of these studies was that the analyses were performed prior to the 
onset of atopic disease. A more recent study by Nylund et al, using DNA microarray as a 
method of analysing the microbiota, found greater microbial diversity in infants with 
established atopic eczema at six and eighteen months of age compared to healthy infants (242). 
They also found there were higher counts of Firmicutes species such as Clostridium spp., and 
less Bacteroides (242) contrasting with previous studies that showed a lack of Bacteroides was 
associated with reduced microbial diversity (241). 
To date, evidence regarding the relationship between gut microbiota and food allergy is limited. 
A small Spanish prospective case-control study examined the faecal microbiota of infants at the 
point of diagnosis of IgE-mediated cow’s milk protein allergy (CMPA) and after six months 
treatment with extensively hydrolysed formula (243). They were compared with non-allergic 
controls. At diagnosis there was no difference in the percentage of bacterial species present in 
the faeces of CMPA infants and controls, but a higher overall bacterial count was observed in 
the allergic infants (243). Six months post diagnosis and treatment with extensively hydrolysed 
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formula, the allergic infants had higher proportions of Lactobacilli and less Bifidobacteria 
compared to controls. In addition, the levels of Bifidobacteria were greater in the faeces of 
CMPA infants at diagnosis than the Bifidobacteria levels in their faeces after six months of 
treatment (243). These results contrast with previous studies, as the gut bacteria appeared to 
be more numerous in the CMPA infants compared to controls (244). For example, in a study of 
76 infants considered high risk for development of atopy, total bacterial counts in faecal 
samples at three weeks of age were reduced in infants who developed atopy, compared to 
samples from non-atopic infants (245). An important limitation of these studies is that 
microbiota characterisation was based on culture based techniques alone. With the advent of 
molecular techniques for identifying and measuring microbiota, it has become apparent that 
culture-based techniques provide a strikingly incomplete picture of gut microbiota composition. 
Another study by Alderberth et al found no significant association between development of IgE-
mediated food sensitisation, eczema and stage of faecal microbe colonisation (246). They were 
also unable to find an association between Bifidobacterium species and protection against 
allergy development. There have been no studies examining gut microbiota composition prior 
to the onset of food allergy, nor utilising molecular technology for microbiota characterisation. 
2.12 What is the evidence that specific environmental factors are associated 
with both (a) the composition of gut microbiota, and (b) risk of food 
allergy?  
A variety of factors in the modern environment have been shown to influence the composition 
of the gut microbiome. These include mode of delivery, antibiotic exposure, Maternal Group B 
Streptococcus (GBS) colonisation in pregnancy, infant feeding practices, farming environment 
and differences between the developed and developing world (Table 2.10). However, the link 
between each of these factors and food allergy is substantially less clear.  
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Table 2.10: Summary of the association between specific environmental factors and (a) gut microbiota 
and (b) food allergy.  
Environmental Factors Evidence of an association 
with gut microbiota 
composition 
Evidence of an association 
with food allergy risk 
Mode of delivery Consistent Level 3(2) 
Evidence* 
(247-249) 
Conflicting Level 3(3) 
Evidence 
(20, 250-257) 
Antibiotic exposure Consistent Level 4 
Evidence 
(258, 259) 
Limited Level 4 
Evidence 
(20, 254, 256, 260) 
Maternal GBS colonisation 
in pregnancy 
Limited Level 3(2)  
Evidence 
(261, 262) 
Limited Level 4  
Evidence 
(256) 
Infant feeding/diet Strong Level 3(2) 
Evidence 
(247, 248) 
Conflicting level 4 
Evidence  
(263) 
Farming environment Limited Level 4 
Evidence 
(264) 
No Evidence 
Developing versus developed 
world 
Consistent Level 3(2) 
Evidence 
(14, 201) 
Limited Level 4  
Evidence 
(265) 
*Levels of evidence taken from NHMRC Evidence Hierarchy (266), level 1: evidence obtained from a 
systematic review of all relevant randomised controlled trials, level 2: evidence obtained from at least 
one properly designed randomised control trial, level 3(1): evidence obtained from well-designed 
pseudorandomised control trials, level 3(2): evidence obtained from comparative studies (including 
systematic reviews of such studies) with concurrent controls and allocation not randomised, cohort 
studies, case-control studies, or interrupted time series with a control group, level 3(3): evidence 
obtained from comparative studies with historical control, two or more single arm studies, or 
interrupted time series without a parallel control group, level 4: evidence obtained from case series, 
either post-test or pre-test/post-test. 
 
2.12.1 Mode of delivery 
Caesarean-section delivery rates are higher in the developed world compared to the developing 
world. In the United States, the proportion of infants who are delivered by Caesarean section 
has increased from 5% of births in 1970 to 31% of births in 2010 (267). In Canada, Caesarean 
section rates are more than 25% of total births, and in Australia, the rate of Caesarean section 
is 32% (248, 268). By contrast, in sub-Saharan Africa Caesarean section rates range from 4.1 to 
16.8 % (269). 
There is strong evidence that mode of delivery affects the composition of the infants gut 
microbiota. Caesarean section bypasses the birth canal and in elective Caesarean section, 
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membranes may only be broken at the time of surgery with the baby delivered through a sterile 
surface. The gut bacteria lacking in a baby delivered by Caesarean section include Bacteroides, 
E-shigella and E.coli (248), while they may have higher levels of Clostridium difficile than those 
born vaginally (247). In developing countries, Enterobacteriae colonisation in babies delivered 
by Caesarean section tends not to be delayed, though this is likely attributable to poorer 
hygiene standards (270). The altered gut microbiota pattern associated with Caesarean section 
can last several years. For example, a Finnish study found lower levels of clostridium in seven 
year old children delivered by Caesarean section, compared to those delivered vaginally (249). 
The evidence for a direct link between Caesarean section and food allergy is limited and 
conflicting. A meta-analysis presented at the American Academy of Asthma Allergy and 
Immunology reported children born to atopic mothers by Caesarean section, were more likely 
to be sensitised to milk, egg or peanut at two years of age (250). This association appeared to 
be independent of the mother’s allergy status. However, a link with challenge or exposure 
proven food allergy was not investigated. Concordantly, several observational studies in Europe 
have found a positive association between Caesarean section delivery and an increased risk of 
food allergy, especially cow’s milk allergy. In a number of studies the relationship between 
mode of delivery and risk of food allergy was stronger if the mother was atopic (251-255). By 
contrast, in the only population based study to use challenge-proven food allergy as the 
primary outcome, Koplin et al found no evidence for an association between egg allergy and 
Caesarean section in Australia (20). Similarly, a retrospective study from the USA found no 
difference between mode of delivery and food allergy (256), and a recent Finnish study on 
children up to four years was unable to demonstrate an association between Caesarean section 
and development of food allergy (257). The reasons for the conflicting nature of the evidence 
regarding mode of delivery and risk of food allergy are unknown. 
2.12.2 Antibiotic exposure and prematurity 
There is strong evidence that early life exposure to antibiotics influences an infant’s gut 
microbiota (271). In the developed world up to 35% of mothers and their babies will receive 
intrapartum antibiotics (272). Reasons include maternal GBS colonisation, maternal pyrexia 
during labour, postnatal sepsis or prematurity. Use of antibiotics have been associated with 
lower counts of Bifidobacterium in the neonatal gut within the first month of life (258). 
Evidence regarding the association between exposure to antibiotics and risk of food allergy is 
again conflicting. A large Finnish study found that perinatal exposure to antibiotics in infants 
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was associated with an increased risk of cow’s milk allergy, as defined by elevated serum 
specific IgE, positive SPT or open challenge test, with disappearance of symptoms after cow’s 
milk elimination from diet (260). In contrast, a retrospective USA study found no association 
between food allergy and perinatal antibiotics (256); the Australian HealthNuts study found no 
association between antibiotic use and development of egg allergy (20); and the EUROPREVAL 
birth study found no association between maternal antibiotic use in pregnancy and the 
development of food allergy in infants (254). 
The most frequent recipients of antibiotics are premature infants in the neonatal intensive care 
unit. In addition to being resident in a more hygienic environment than standard hospital 
wards, premature infants are also more likely to have been delivered by Caesarean section. 
With a prolonged neonatal stay, gut colonisation may be delayed (273). The preterm neonatal 
gut in infants delivered at less than 33 weeks gestation is dominated initially by coagulase 
negative Staphylococcus and Enterbacteriae (259). Of note, prematurity itself does not appear 
to be a risk factor for developing food allergy (274). 
2.12.3 Maternal Group B Streptococcus colonisation in pregnancy 
There is growing interest in the mechanisms through which the maternal microbiome in 
pregnancy may influence the offspring’s immune development and the risk of allergy via affects 
on foetal immune development (275). The maternal vaginal-enteric microbiome undergoes 
substantial changes over the course of pregnancy (276, 277), including an increase in 
streptococcal species colonisation (277). A member of this bacterial species, GBS may colonise 
the vaginal tract during pregnancy and is of particular interest due to the high morbidity and 
mortality associated with GBS sepsis in the neonate (278). Approximately 25% of pregnant 
women in Australia are GBS colonised and due to the associated risks of neonatal sepsis, 
screening for maternal GBS colonisation occurs in the third trimester of pregnancy (279), thus 
providing a relatively available measure of the maternal vaginal-enteric microbiome during 
pregnancy.  
The presence of maternal GBS may be intrinsically relevant, or alternatively, it may be a marker 
of broader aspects of the maternal vaginal-enteric microbiome. A Japanese study (n=4025) 
compared the composition of the vaginal flora, sampled between 22 and 36 weeks gestation, in 
GBS positive and GBS negative women (280). Gram-positive cocci and lactobacillus as 
percentages of the total bacterial strains cultured were significantly lower in GBS positive 
women compared to GBS negative women. This study however did not include data on the 
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important covariate of antibiotic usage by the participants during pregnancy and over 95% of 
the participants were Japanese, which limits the interpretation and generalisability of the 
findings (280).  
Theoretically, maternal GBS carriage may influence the risk of food allergy among the offspring 
via pathways relating to foetal immune programming during pregnancy, or alternatively via 
pathways involving inoculation of the infant during the birthing process. The mechanisms by 
which the maternal microbiome may influence foetal immune development include bacterial 
exposure of the foetus and placenta in utero (204, 205), exposure to maternal gut bacterial 
components bound to maternal immunoglobulin G (IgG) which crosses the placental blood 
barrier (275) or possibly through the indirect influence of gut bacteria metabolites such as short 
chain fatty acids (SCFA) (275). 
Alternatively, maternal GBS carriage may influence the offspring’s risk of food allergy via 
inoculation of the infant during the birth process. There is conflicting evidence of an association 
between maternal GBS status and the composition of the infant gut microbiome. A small study 
(n=262) examined infant stool samples at one and six months of age and related the stool 
bacterial composition to the mothers GBS status in pregnancy (261). Maternal GBS colonisation 
was associated with variation in the gut microbiota composition in the six months of age 
samples, but not the one month samples (261). These findings have not been replicated in 
more limited studies (262). 
The evidence to date regarding maternal GBS status in pregnancy and an effect on allergy risk 
among the offspring is limited. There was no evidence of an association between maternal GBS 
status and childhood asthma at four and a half to six years in a very large (n=136,098) 
prospective birth cohort (aOR 1.03, 95% CI 0.96-1.10) (281). Of note however, maternal GBS 
colonisation at delivery in this study was only 6% which is substantially lower than the 
colonisation rate among the pregnant female population reported in other studies (282, 283). 
This brings into question the accuracy of GBS detection and limits generalisability of the study 
results. In a retrospective study (n=492) of medical records that examined intrapartum 
antibiotics and risk of reported atopic dermatitis among offspring at two years, positive GBS 
status in pregnancy was not associated with atopic dermatitis among offspring (aRR 0.76, 95% 
CI, 0.48-1.20) including adjustment for intrapartum antibiotics (284). Maternal GBS status was 
not associated with an increased risk of food allergy among offspring (OR 1.14, 95% CI 0.56-
2.35) in another USA based retrospective study (n=281) (256). GBS status however was 
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determined in only 50% of women in the study (256). In the “WHEALS” birth cohort, antenatal 
medications and mode of delivery were examined in relation to eczema status among offspring 
at two years of age. Children born vaginally had a lower risk of eczema at two years compared 
to those born by Caesarean section, but maternal GBS status in pregnancy did not modify the 
relative risks in the analysis (285). Further studies of sufficient size are required, that combine a 
high level of GBS determination, thorough measurement and consideration of relevant 
covariates, and robust delineation of the food allergy phenotype. 
2.12.4 Infant feeding practices 
Infant feeding may influence the composition of the gut microbiota. An infant may be 
breastfed, formula-fed or experience a combination of the two. Reviewing available evidence, 
Adlerberth et al suggested the gut microbiota pattern of breast-fed infants showed little 
difference compared to that of formula-fed infants (247). It had been previously proposed that 
Lactobacilli and Bifidobacterium counts tend to be higher in breastfed babies but in most 
studies over the last 30 years no significant differences have been found. However, in a recent 
small Canadian study, Clostridium difficile levels were significantly lower in breastfed infants 
compared to the formula-fed infants (248). While certain species of Clostridium are well 
recognised as being pathological in older children and adults, the significance of the Clostridium 
genus in neonates is unknown. In the same study infants who were formula-fed had a more 
diverse gut microbiota compared to breastfed infants (248). 
Another small study looking at the gut metagenome in breastfed and formula fed infants, 
suggested that breastmilk promotes a positive interaction between the mucosal immune 
system and the gut microbiome through intestinal gene expression (286). Breastfeeding was 
also found to be associated with a more diverse gut microbiota. It has also been suggested that 
small mass oligosaccharides found in human breast milk, specifically promote the colonisation 
of the gut with a “healthy microbiota”, such as Bifidobacterium (287). 
The type of infant formula ingested may have an effect on the gut microbiota. A study of 18 
infants with cow’s milk protein allergy, compared a period of feeding with lactose free 
extensively hydrolysed formula, to a period of feeding with extensively hydrolysed formula 
containing lactose. The omission of lactose was associated with substantially lower faecal 
Bifidobacteria and lactobacilli as well as reduced concentrations of faecal short chain fatty acids 
(288). Another study evaluated the relationship between whey intake and microbiota 
composition during early infancy by comparing faecal specimens from infants who were fed 
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either high whey containing infant formula, low whey containing formula, or breast milk. There 
was no difference in Bifidobacterial counts between groups but Clostridia was less prevalent in 
the breast feeding group compared to the formula group (289). Of note, Fluorescent In-Situ 
Hybridization (FISH) was the method used to analyse the microbiota in this study. 
Intake of complex carbohydrates during infancy also affects the composition of the gut 
microbiota. In a study of 19 infants, intake of a formula high in complex carbohydrates was 
associated with a higher concentration of butyric acid (a SCFA) in the faeces, compared to the 
comparison group (290). In addition, intake of the formula high in complex carbohydrates was 
associated with elevated faecal secretory IgA levels, supporting the influence of complex 
carbohydrates on gut microbiota composition, as secretory IgA production is associated with a 
Bifidobacterium presence in the gut (291). 
Allergy prevention is hypothesised to be associated with greater microbial diversity, but 
previous studies have been unable to produce conclusive evidence that exclusive breastfeeding 
is protective against allergic disease (263). Human breastmilk is a rich source of secretory IgA in 
early postnatal life (292). It has been shown that intake of secretary IgA in breast milk in the 
first year of life may be associated with a reduced risk of atopic dermatitis (293). In another trial 
maternal avoidance of cow’s milk during breastfeeding was associated with a reduced level of 
β-lactogloblulin specific IgA in the breast milk and a higher rate of cow’s milk allergy in their 
offspring (294). 
The relationship between infant feeding, particularly breastfeeding and food allergy is difficult 
to disentangle as there are both ethical and feasibility barriers to conducting randomised trials.  
2.12.5 Farming environment 
The ‘hygiene hypothesis’ published by Strachan in 1989 proposed that exposure to infection in 
early life through larger family sizes was protective against allergic disease (57). However, 
subsequent work suggests that rather than infectious diseases per se, the early life microbial 
experience in general is a key determinate of immune development and risk of allergic disease. 
It would seem logical to assume that exposure to a less hygienic environment throughout 
childhood, such as a farm, would promote the acquisition of a more diverse human gut 
microbiota. However there is only circumstantial evidence to support this assumption, as little 
investigation has been done on the composition of the human gut microbiota in farming 
environments. A study in 2007, comparing children from several European countries, 
demonstrated children from farming backgrounds had less gut microbial diversity compared to 
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non-farming children from the same geographical area (264). 
For allergy, the most compelling evidence comes from studies demonstrating that farming 
environment is associated with a reduced risk of allergic disease and that most of this effect 
appears to be related to microbial exposure. For example, the European GABRIELA and 
PARSIFAL studies found that children raised in farming environments had a decreased rate of 
allergic disease, and that around 90% of this effect could be attributed to microbial exposure, 
rather than other factors in the farming environment, such as sun exposure and diet (58, 62, 
295). This may, in part, relate to higher and more efficient Treg cell numbers at birth among 
infants from a farming environment (296). 
In terms of food allergy, most of the studies on farming environment and its effects have used 
the limited allergic sensitisation as an outcome. In the PARSIFAL study, allergic sensitisation to 
food mix was included as an outcome measure, whereas the GABRIELA study measured 
aeroallergen sensitisation only, omitting foods. In the PARSIFAL study they also found that 
maternal work in stables during pregnancy was associated with a protective effect against 
atopic sensitisation in children at school age (61). In the PASTURE study however, specific IgE 
levels to food antigens in cord blood were higher in farm children compared to reference 
children (children living in rural areas but not resident on farms). The group attributed this 
finding to a higher consumption of boiled farm milk in farm mothers as it was hypothesised that 
microbial components would be inactivated in boiled milk reducing a potential foetal immune 
response (297). While the protective effect of farming environment has been shown for asthma 
and allergic sensitisation, studies into the relationship between farming environment and 
outcome of food allergy are still insufficient.  
2.12.6 Developing versus developed world 
Birth in a high versus low income country is associated with delayed gut colonisation, reduced 
microbial diversity (201), and reduced turnover of bacterial strains in the infant gut (14). There 
are a range of factors that may be involved, including hygiene practices and diet (298). 
Concordantly, birth in a high income country is associated with an increased risk of allergic 
disease (299). Furthermore, it has been observed that migration from a developing to a 
developed country is associated with an increased risk of allergic disease, but only if migration 
occurs during the first years of life (265). These associations were supported in recent 
Australian studies that found migration from South East Asia to Australia was associated with 
an increased risk of eczema and food allergy in the infants and children of such migrants (24, 
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300, 301). 
2.13 Conclusions regarding the microbiome and food allergy 
The human gut microbiome and its role in health and disease has become the target of intense 
scrutiny in recent years and there is evidence of its potential importance in autoimmune 
disease, obesity and allergic disease in general. It has been demonstrated the early life gut 
microbiota can influence immune development and balance of Treg cells which may increase 
the risk of food allergy. Environmental factors that may affect gut microbiota patterns in early 
life include obstetric interventions in pregnancy, antibiotic exposure, infant feeding practices 
and a modern Westernised lifestyle. Epidemiological studies have yielded consistently strong 
evidence for positive associations between these factors and the gut microbiota. In contrast, 
studies examining the same factors and the risk of food allergy have revealed at best weak 
associations. While there has only been to date limited examination of the relationship 
between gut microbiota and food allergy in humans, several studies on gut microbiota and 
other allergic disease such as eczema have yielded positive associations. Therefore, an altered 
pattern of gut microbiota colonisation in the gut in the early life period may directly increase 
the risk of food allergy in children. The thesis therefore will test the following research 
hypotheses: 
 Putative environmental and early life risk factors contribute to food allergy prevalence 
differences between urban and mixed regions. 
 That early life microbial exposures are associated with a reduced risk of IgE-mediated 
food allergy in the first year of life 
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CHAPTER 3 PROJECT METHODS 
3.1 Overview 
The overall aims of my project were to: 
1) Determine the prevalence of IgE-mediated food allergy in one year old infants in a 
regional setting and compare food allergy prevalence differences between urban and 
regional cohorts. 
2) Examine the potential influence of maternal folate status in the third trimester of 
pregnancy as a risk factor for IgE-mediated food allergy among the offspring. 
3) Examine the potential influence of infant VDS at birth and six months of age as a risk 
factor for IgE-mediated food allergy in one year old infants.  
4) Examine the potential influence of environmental and early life microbial exposures as 
risk factors for IgE-mediated food allergy in one year old infants.  
This chapter describes the overall research plan and general methods underpinning the conduct 
of the PhD project. BIS, a population based birth cohort provided the platform for the project 
(15). 
3.2 Research plan 
3.2.1 Background 
The primary prevention of allergic disease is an important public health goal. It has recently 
been demonstrated that over ten percent of one year old infants living in Melbourne Australia 
have challenge-proven IgE-mediated food allergy (3). This is the highest reported prevalence of 
challenge-proven food allergy in the world. Food related anaphylaxis, a life threatening 
condition, has become prominent with a three-fold increase in food anaphylaxis related 
hospital admissions in Australia between 1994 and 2005, primarily in children less than five 
years old (4), and the increase has continued in recent years (5). The cause of this epidemic is 
unknown and there is a clear need to understand why the modern environment is associated 
with an increased risk of food allergy. Modern lifestyle choices, such as micronutrient 
supplementation contribute to varied levels of folate and VDS in humans that may affect early 
life immune development and function (11, 39, 128, 129, 302). Furthermore, it is known the 
modern environment is associated with changes in the composition of the early life gut 
microbiota and human microbiome that may affect immune development and function (13, 14, 
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81).  
This PhD project comprised a longitudinal investigation of the associations between maternal 
folate status during the third trimester of pregnancy, infant VDS at birth and six months, early 
life microbial factors and the risk of IgE-mediated food allergy during infancy. The project 
utilised data and samples from BIS; an extensively detailed platform for investigating the early 
life origins of non-communicable diseases.  
3.3 Methodology 
3.3.1 Study Design: The Barwon Infant Study 
BIS is a population-derived birth cohort study (n=1,074 infants) with antenatal recruitment (15) 
between June 2010 and June 2013. The Barwon region (population approximately 260,000), 
which includes and surrounds the city of Geelong, incorporates metropolitan, rural and coastal 
areas (Figure 3.2). The population characteristics are similar to the Australian population 
overall, with the exception that there is a smaller proportion of families from non-English-
speaking backgrounds (15). Approximately 3000 live births per year take place in the Geelong 
maternity hospitals. The standard antenatal booking-in appointment is at 15 weeks gestation. 
Dependent on the resources available at the time, 3500 women were approached and invited 
to take part in BIS at the booking-in clinic. Inclusion and exclusion criteria are listed below 
(Table 3.1). The recruitment rate among those invited to participate was approximately 33% 
with differences between participants and non-responders detailed below (Table 3.2). 
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Table 3.1: Inclusion criteria for BIS recruitment. 
Inclusion criteria Exclusion criteria 
Residents of the Barwon Statistical Division 
(geographically defined region). 
Not an Australian permanent resident. 
Pregnant at no more than 28 weeks of gestation at 
the time of enrolment. 
Were unable to complete questionnaires without 
the assistance of an interpreter. 
Planning to give birth at either Geelong Hospital 
(public) or St John of God Hospital (private). 
Were unable to give informed consent for various 
reasons and no third party could be identified, or 
informed consent was not given. 
Intending to be available for the duration of the 
study. 
Were under the age of 18 years at the time of 
maternal blood sample collected at 28 weeks of 
pregnancy. 
 
Were previous participants of the Barwon Infant 
Study with at least one live-born child already 
included in the cohort. 
 Were planning to pay to have their infant’s cord blood stored privately for future use. 
 Had moved out of the Barwon Statistical Division 
by the time the baby was born. 
  
  
 Infants were excluded at birth if: 
 
Were born before 32 completed weeks of 
gestation. 
 Had a serious illness, identified during the first few days of life. 
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Table 3.2: Comparison of participating mothers and non-responders on baseline characteristics. 
Characteristics  Mothers of eligible infants  
(n = 1064) 
Non-responders  
(n = 2869) 
First-degree relative with asthma 539/1059 (50.9%) 506/1600 (24.1%) 
First-degree relative with eczema 475/1057 (44.9%) 362/2094 (17.3%) 
Socioeconomic index tertiles for area code 
 Low SEIFA 259 (25.6%) 772 (32.3%) 
 Medium SEIFA 194 (19.2%) 466 (19.5%) 
 High SEIFA 557 (55.1%) 1154 (48.2%) 
Remoteness classification for area code 
 Urban 276 (27.1%) 604 (25.1%) 
 Suburban 742 (72.8%) 1798 (74.7%) 
 Rural 1 (0.1%) 4 (0.2%) 
Number of people living in the family home 
 1 person 12 (1.1%) 17 (0.8%) 
 2 people 410 (38.9%) 800 (38.5%) 
 3 people 363 (34.5%) 698 (33.6%) 
 4 people 199 (18.9%) 357 (17.2%) 
 5 or more people 69 (6.6%) 207 (9.9%) 
SEIFA, socioeconomic index tertile for area. 
 
3.3.2 Sample size for study 
The main outcome of this PhD project, clinically-proven IgE-mediated food allergy was 
determined at the 12 month review. The inception cohort defined at birth was 1074. The 
overall participant retention rate for BIS at one year was 83% (894/1074) (Figure 3.1)(15). The 
baseline participant characteristics in the inception cohort and exposures relevant to each 
particular Study in this thesis are described in each Study Chapter (Table 4.2, Table 5.1, Table 
6.1 & Table 7.1). 
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Figure 3.1: Consort flow diagram for BIS. Eligible infants (1074) are infants of 1064 (ten twins included) 
participant mothers retained in BIS at the time of the definition of the inception cohort which is infant 
birth. The withdrawals prior to the inception cohort are maternal withdrawals. Figure taken from 
Vuillermin et al (15). 
3.3.3 Biospecimen and review schedule 
The BIS study protocol includes the longitudinal assembly of an extensively detailed array of 
epidemiological data, biological samples, as well as physiological and clinical outcome measures 
(15). Data for this PhD project were obtained from epidemiological records that were collected 
from the mother at 28-32 weeks of gestation, in addition to infants at birth, four weeks, three, 
six, nine and 12 months of age (Table 3.3). Biospecimens collected included antenatal maternal 
blood and stool, cord blood at birth and peripheral blood from infants at six and 12 months of 
age, and infant stool samples at four weeks of age from the entire cohort (Table 3.3). 
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Table 3.3: Epidemiological data, biospecimens and outcome data collection time points relevant to this project within BIS. 
Time point Questionnaire Blood  Faeces Urine Outcome Data 
28 -32 weeks 
gestation 
Yes 
(Chapter 4, 5,6,7) 
Maternal 
(Chapter  5,6) 
   
36 weeks No  Maternal Maternal  
Birth Yes 
(Chapter 4, 5,6,7) 
Cord blood 
(Chapter 6) 
   
4 weeks 
Yes 
(Chapter 4, 5,6,7)  Infant  Eczema 
3 months Yes (Chapter 4, 5,6,7)    
Eczema 
(Chapter 4, 5,6) 
6 months Yes 
(Chapter 4, 5,6,7) 
Infant 
(Chapter 6) 
  Eczema 
(Chapter 4, 5,6) 
9 months 
Yes 
(Chapter 4, 5,6,7)    
Eczema 
(Chapter 4, 5,6) 
12 months Yes 
(Chapter 4, 5,6,7) 
Infant 
(Chapter 6)   
Eczema, Food sensitisation, 
Challenge confirmed food allergy 
(Chapter 4, 5,6,7) 
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3.4 Study Measurements  
3.4.1  Exposures: circulating factors 
3.4.1.1 Maternal RBC folate  
Maternal RBC folate was measured at the start of the third trimester (28-32 weeks gestation). 
Levels were assessed by Chemiluminescence using a Siemens® Centaur XP analyser. The normal 
reference range for RBC folate in this chemiluminescent assay was defined as 634 to 1792 
nmol/L (303). The upper limit of measurement of the assay was 3000 nmol/L. RBC folate rather 
than serum folate was measured as it gives a better approximation of long term folate status 
compared to the more commonly measured serum folate (304). 
3.4.1.2 Serum and plasma vitamin D  
The best indicator of VDS is the major metabolite 25-hydroxyvitamin D (25OHD) (153). Levels of 
vitamin D2 (25(OH)D2), vitamin D3 (25(OH)D3), and the epimer of 25(OH)D3 (C3-epi-25(OH)D3) 
were measured in 28-32 gestation maternal serum samples, serum cord blood samples at birth, 
and six and 12 month plasma samples. Serum samples were derived from clotted blood within 
two hours, and for plasma, 5-10 ml of peripheral blood (at six and 12 months) were collected 
into pre-prepared polypropylene tubes containing 100 units preservative free heparin and 
stored at room temperature until processing. Plasma was separated within two hours, and both 
serum and plasma stored at -80 degrees Celsius. The 25(OH)D2, 25(OH)D3 metabolites (serum 
or plasma) and C3-epi-25(OH)D3 were measured, using two-dimensional ultra-performance 
liquid chromatography separation coupled tandem mass spectrometry detection (2D LC-
MS/MS) at Metabolomics Australia, University of Western Australia (305). 
3.4.2 Clinical outcomes: IgE-mediated food allergy 
Infants with IgE-mediated food allergy were identified on the basis of skin prick allergy testing 
at 12 months, plus clinical history and/or formal in-hospital open food challenge.  
3.4.2.1 Twelve month skin prick test  
At the twelve month review, SPT was performed on the participants back using commercial 
extracts of five foods, Raw egg, Cow’s milk, Peanut, Cashew and Sesame. Allergen extracts were 
supplied by ALK Abelló, Madrid, Spain. A Quintip device was used to introduce small amounts of 
food allergen into the superficial skin layers. The positive control test was a histamine solution 
(10 mg/ml) and the negative control was a saline solution. The wheal size was read after 15 
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minutes and a positive wheal size was at least 1 mm or greater than the negative control. Those 
with a SPT 2 mm or greater than the negative control in the presence of a positive histamine 
control (≥2 mm) were determined to be sensitised to the food (21, 306). In clinical practice the 
definition of sensitisation is a SPT wheal size 3 mm or greater than the negative control (307, 
308). As per the HealthNuts protocol, a food challenge was offered to all children with a SPT 
wheal size ≥1 mm to any food to ensure the study identified all cases of food allergy in BIS (3). 
Previous studies have shown that 33% of children sensitised to peanut and 55% sensitised to 
egg are challenge-proven allergic (3). The positive predictive value of SPT is variable depending 
on equipment and population tested (309). Hence challenge-proven IgE-mediated allergy was 
adopted as a robust outcome. 
3.4.2.2 Clinical history 
The infant was diagnosed as food allergic without oral challenge, if by the age of 12-18 months 
based on history and examination, the infant had experienced an acute IgE-mediated reaction 
with or without anaphylaxis to one of the five foods, raw egg, cow’s milk, peanut, cashew or 
sesame within the previous two months of a positive SPT. The criteria used to define a historical 
reaction were the same as the positive criteria used for formal food challenges in the study. 
3.4.2.3 Oral food challenge 
Food sensitised infants were offered a formal in hospital oral food challenge to determine 
clinical allergic status. The challenges were performed in the Geelong hospital, Barwon Health 
supervised by an allergy clinical nurse specialist (L. Thiele) and clinical doctor (J. Molloy), both 
with previous food challenge supervision experience. The challenge protocols followed those of 
the HealthNuts study in Melbourne which has validated outcomes: 
x A positive challenge was defined by the following criteria (3, 310): three or more 
concurrent non-contact urticaria lasting at least five minutes or longer, perioral 
or periorbital angioedema, vomiting, respiratory or circulatory compromise 
occurring within two hours of ingestion of the food. On the days of home based 
introduction after a negative challenge, if they displayed any of the above 
symptoms the challenge was deemed to be a positive challenge. 
x A negative food challenge was defined by a full ingestion of the top dose of the 
food without a reaction, and subsequently for the next seven days at home 
ingesting full servings of the food. The purpose of the continued challenge at 
home was to identify any infants having late reactions.  
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x If the challenge was not completed for reasons such as food refusal and the child 
did not display objective signs of a reaction, it was deemed inconclusive and the 
family were offered a repeat challenge on another date. 
3.4.3 Eczema status 
Eczema data were collected by questionnaires administered at postnatal time points 1, 3, 6, 9 
and 12 months and by clinical assessments at 1, 6 and 12 months. Eczema status was defined 
according to the analysis being performed. For analyses examining BIS data only (Chapter 5, 6 
and 7), eczema was defined according to the modified UK working party diagnostic criteria for 
atopic dermatitis. (311, 312). All infants had to have a history of itchy skin plus at least three of 
the following: a history of dry skin, a family history of allergy, a history of skin rash affecting the 
flexures or outer surfaces of the limbs or affecting the head or cheeks, visible dermatitis 
assessed during a study visit at either 1 month, 6 months or one year (240). The Scoring Atopic 
Dermatitis Scale (SCORAD) was used to quantify eczema severity (313, 314). For other analyses 
(Chapter 4), the parent report of doctor diagnosed eczema was used as a definition (24).  
3.4.4 Covariates 
A large number of covariates were created for the formal data analysis from the questionnaire 
data at multiple time points in BIS and hospital clinical records. Summaries of the covariates 
created and the data sources used are in the table below (Table 3.4). Copies of the BIS 
questionnaires and collections forms are available at http://www.barwoninfantstudy.org.au. 
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Table 3.4: Definitions of covariates examined/used in this thesis. 
Household 
characteristics  
Definition Data source 
Family history of 
allergy 
A family history of allergy was defined as a parental 
report of a doctor diagnosis of asthma, hay fever, 
eczema or food allergy in one or more first-degree 
relatives, either mother, father or siblings. 
First and second 
trimester 
questionnaire. 
Parent’s country of 
birth 
The country of birth of infant’s mother and father 
was recorded by a free text question. In the 
prevalence difference analysis, a categorical variable 
was created according to the following categories: 
both parents born in Australia, One parent born in 
South-East Asia, and at least one parent born in 
another “country”. 
First and second 
trimester 
questionnaire. 
Ethnicity Based on infant’s grandparents identified ancestry: 
British/Irish, European, Asian, Aboriginal/Torres 
strait Islander, “Don’t Know” and “other”. For the 
folate and vitamin D chapters, a categorical variable 
was created based on full Caucasian ethnicity or 
otherwise. 
First and second 
trimester 
questionnaire. 
Smoking Maternal self report of cigarette smoking 
preconception and in the first and second trimester. 
The categorical variable comprised the following 
categories: none, 1-10/day, 11-20/day, 21+/day. 
First and second 
trimester 
questionnaire. 
Maternal age At the time of the infant’s birth, the maternal age 
was calculated from the date of birth of the mother 
and date of birth of the infant. 
First and second 
trimester 
questionnaire. Birth 
data collection. 
Infant characteristics   
Gestation at delivery The gestational age at delivery was categorised as 
follows: 32-<37 weeks, 37-42 weeks and >42 weeks. 
Birth data collection. 
Birth weight A continuous variable described the child’s 
birthweight in grammes. 
Birth data collection. 
Sibling summary The number of siblings in the participant’s family was 
categorised as follows: none, 1 sibling, 2 siblings and 
3 or more siblings. 
First and second 
trimester 
questionnaire. 
Infant diet 
characteristics 
  
Formula feeding  Infant feeding was defined at six and twelve months 
of age. Data were gathered on exclusive 
breastfeeding (only food received by child), 
breastfeeding and expressed breastmilk combined, 
mixed breast and formula feeding, any other feeding.  
Subsequently a categorical variable was created for 
use in the analysis using the following categories: 
exclusive breastfeeding (including expressed breast 
milk (EBM)), exclusive formula feeding, all other 
types of feeding including combined breast and 
formula feeding. 
6 and 12 month infant 
questionnaires. 
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Age of introduction of 
solid foods 
Defined as the age when solid foods are introduced 
into the diet. A categorical variable was created as 
follows: less than 3 months, 3-6 months, 6-9 months 
and 9-12 months. 
3, 6, 9 and 12 month 
questionnaires. 
Introduction to solid 
foods questionnaire. 
Age of introduction of 
egg 
Defined as the age when egg in any form was 
introduced into the infant’s diet. A categorical 
variable was created using the following categories: 
egg introduced by six months, egg introduced by 
twelve months of age. 
3, 6, 9 and 12 month 
questionnaires. 
Introduction to solid 
foods questionnaire. 
Age of introduction of 
peanut 
Defined as the age when peanut in any form was 
introduced into the infant’s diet. A categorical 
variable was created using the following categories: 
peanut introduced by four-nine months, peanut 
introduced between ten and twelve months and 
peanut introduced after twelve months. 
3, 6, 9 and 12 month 
questionnaires. 
Introduction to solid 
foods questionnaire. 
Infant intake of 
supplements  
Defined as the ingestion of vitamin supplements 
containing vitamin D during the first year of life. For 
vitamin D ingestion a binary variable was created for 
each relevant BIS questionnaire time point, 3, 6, 9 
and 12 months. 
3, 6, 9 and 12 month 
questionnaires. 
Maternal diet 
characteristics 
  
Maternal use of 
supplements in 
pregnancy 
Defined as the ingestion of vitamin supplements 
containing vitamin D or folate during pregnancy. For 
vitamin D ingestion for mother, a binary variable was 
created for each BIS questionnaire time point, first 
and second trimester and third trimester. 
For folic acid supplementation, in addition to the 
formulation of the folic acid supplement, data 
gathered on daily dosage from the first and second 
trimester were combined to estimate total daily folic 
acid supplementation intake. The following 
categories were devised: <500 mcg/day, 500-999 
mcg/day and ≥1000 mcg/day. 
First, second and third 
trimester 
questionnaire. 
Maternal alcohol 
intake in pregnancy  
Defined as alcoholic drinks ingested during the first 
and second trimester of pregnancy. Categorised in 
the first trimester as none, <1 per week, 1-6 per 
week, 1-3 per day and 4+ per day. Categorised in the 
second trimester as none, <1 per week, 1-6 per week 
and 1-3 per day and 4+ per day. 
First and second 
trimester 
questionnaire. 
Factors previously 
associated with 
microbial exposure 
  
Number of siblings Described previously. First and second 
trimester 
questionnaire. 
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Domestic pet 
ownership 
Data were collected at the first and second trimester 
and the 12 month questionnaire on the possession of 
a pet by the participant’s family and the type of pet 
(dog, cat, fish, reptile etc.). Further data were 
acquired on the location of the pet, within the family 
home, outside the family home or both inside and 
outside the family home.  
First and second 
trimester 
questionnaire. 12 
month questionnaire. 
Mode of delivery A categorical variable was created with the following 
categories: vaginal delivery, elective caesarean 
delivery, emergency caesarean delivery. 
Birth data collection. 
Livestock exposure Whether the participant’s residence had livestock 
onsite. 
First and second 
trimester 
questionnaire. 
Maternal group B 
Streptococcus status 
Data on maternal vaginal colonisation with GBS 
during pregnancy were obtained from hospital 
clinical records and categorised as a 
positive/negative binary variable. 
Birth data collection 
Antibiotics in labour  The administration of antibiotics to mothers in 
labour was gathered from hospital clinical records 
and categorised as a yes/no binary variable. 
Birth data collection 
Infant study outcomes   
Food sensitisation Defined as a skin prick test wheal size 2mm or 
greater than the negative (saline) control in the 
presence of a positive histamine (wheal size 2mm or 
greater) control. Skin Prick tests with a non-positive 
histamine control were deemed invalid. 
12 month review.  
Food allergy Defined as a positive oral challenge to the index food 
(described previously in methods.) or a definite 
clinical history of previous reaction to the index food 
within the previous two months with a positive skin 
prick test and continued avoidance of the food. 
Those with a) negative skin prick test at 12 twelve 
months to all foods, b) a positive skin prick test to an 
index food but regularly ingesting the food or c) a 
positive skin prick test to an index food with a 
subsequent negative oral index food challenge were 
defined as non-food allergic. 
12 month review with 
follow up oral 
challenge. 
Eczema A robust definition of eczema according to the 
modified UK working party criteria (311, 312) was 
adopted in the primary BIS analysis and is described 
in detail in section 3.4.3. Other definitions adopted in 
other analyses in the thesis were as follows: 
x Parent report of doctor diagnosis of eczema. 
x Parent report of history of itchy rash treated 
with topical steroids. 
1,3,6,9 and 12 month 
questionnaires.  
6 and 12 month 
clinical reviews. 
 
3.5 Statistical methods and considerations 
This section summarises the statistical methods used in the analyses in this thesis. In depth 
descriptions of analyses used are described in each chapter.  
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Regression techniques were used to examine the relationship between the exposure in 
question and the outcomes of food allergy and where appropriate, eczema. The estimates were 
expressed as adjusted relative risk ratios or adjusted odds ratios with 95% confidence intervals.  
3.5.1 Covariates considered as potential confounders 
The following were considered as potential confounders in regressions as stated in each 
individual chapter: family history of allergy, ethnicity, parents country of birth, socioeconomic 
status, infant sex, gestational age at delivery, number of siblings, formula feeding, pet 
ownership, livestock exposure, maternal and infant vitamin D supplementation, folic acid 
supplementation, UVR exposure, sunscreen use, egg avoidance, maternal smoking, mode of 
delivery, season of birth, age of solid introduction, age of eczema diagnosis.  
Each of these variables was compiled from validated questionnaire data in BIS. The analyses 
used causal directed acyclic graphs to determine if variables were considered confounders or 
effect modifiers. A directed acyclic graph is composed of variables with arrows between the 
variables so that the graph is acyclic. In such a graph it is not possible to start at a variable, 
follow the arrows and reach the same variable (315). A causal directed acyclic graph is a graph 
where the arrows between variables can be interpreted as causal relations (315). In each 
analysis covariates were included in the model a priori if published evidence existed for an 
association with both the exposure and outcome. Other covariates were included if they 
effected a greater than 10% change in the relative risk ratio in the regression model. To 
investigate for effect modification by covariates, interaction terms between exposure variables 
were generated in the regression models. The interaction term was retained in the model if it 
had a p-value of <0.05. Stata statistical software (version 14.1, Statacorp, College Station, 
Texas) was used for all the data analyses. 
3.5.2 HealthNuts study and use of HealthNuts data in this thesis 
The HealthNuts study is a population based single centre multi-wave longitudinal cohort study 
(316). The original design of the study was to determine the prevalence of challenge-proven 
IgE-mediated food allergy among one-year-old infants in urban Melbourne, Australia and to 
address determinants of food allergy development. The cohort of 5276 infants, aged between 
11 and 15 months (inclusive), were recruited between September 2007 and August 2011 at 
childhood immunisation sessions using a pre-determined population-based sampling frame 
from greater metropolitan Melbourne (population 3.9 million in 2008) with 74% participating 
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(316). Participating infants were similar to the general population of all births in Victoria (310) 
in terms of gender, birth weight and delivery method, while their mothers were slightly older 
on average and were slightly more likely to be born in Asia (316). All infants underwent skin 
prick testing to peanut, raw egg, sesame, cow’s milk or shellfish. Those with detectable SPT 
wheals underwent formal oral food challenge to determine food allergy status (316). Extensive 
epidemiological questionnaire data were also collected. The study has continued with follow-
ups assessments of food allergy status at ages four, six and the next wave of assessments are 
scheduled for age ten. The HealthNuts food allergy prevalence and epidemiological data at one 
year were utilised as the urban comparison cohort for Study 1 in Chapter 4. The geographical 
locations of both the HealthNuts study and BIS, urban Melbourne and regional Geelong (both 
within the state of Victoria, Australia.), are shown in the figure below. 
 
 
Figure 3.2: Map showing the geographical position of Geelong and Melbourne, Victoria, Australia.  
© Commonwealth of Australia (Geoscience Australia) 2017. CC-BY. 
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CHAPTER 4 STUDY 1: COMPARISON OF FOOD ALLERGY 
PREVALENCE’S BETWEEN TWO HARMONISED AUSTRALIAN INFANT 
COHORTS AND CONTRIBUTION OF PUTATIVE RISK FACTORS 
4.1 Introductory statement 
This Chapter describes Study 1, the aim of which was to establish the prevalence of IgE-
mediated food allergy in infants in the Barwon region and to compare food allergy prevalence’s 
with the proximal urban centre Melbourne through comparison with the HealthNuts study. The 
determination of similar outcomes at the same age in both cohorts enabled the investigation of 
recognised food allergy development risk factors in both cohorts as contributors to food allergy 
prevalence differences. The hypotheses tested within this Chapter were (a) that the prevalence 
of IgE-mediated food allergy among one year old infants in the Barwon region is the same as 
the prevalence previously reported for Melbourne and (b) putative environmental and early life 
risk factors contribute to food allergy prevalence differences between urban and mixed regions. 
4.2 Abstract 
4.2.1 Background 
Insight into the rise in food allergy may be gained by comparing the distribution of putative risk 
factors between urban and regional areas that differ in food allergy prevalence.  
4.2.2 Objective 
To assess the impact of previously identified risk factors on differences in food allergy 
prevalence across two harmonised Australian cohort studies. 
4.2.3 Methods 
Infants in the metropolitan HealthNuts (n=5276) and regional BIS (n=1074) underwent skin 
prick testing and food challenges to egg and peanut at age 12 months. Standardisation was 
used to adjust for compositional differences in risk factors in BIS compared with HealthNuts.  
The study then compared fully-adjusted and partially-adjusted prevalence estimates between 
the cohorts, calculating the percentage change attributable to each factor, to obtain a measure 
of its contribution to the prevalence difference. 
4.2.4 Results  
Peanut and egg allergy were more common in HealthNuts (3.1% [95%CI 2.5; 3.5] and 9.4% [8.6; 
Chapter 4 
 79 
10.2] respectively) than BIS (1.5% [0.6; 2.3] and 6.5% [5.0; 8.4]). Earlier consumption of peanut 
made the largest statistical contribution to lower peanut allergy prevalence in BIS, with more 
dog ownership and a lower frequency of Asian-born parents also contributing. Earlier 
introduction of egg statistically contributed to a lesser extent to the lower egg allergy 
prevalence in BIS. Collectively, these factors statistically accounted for 82% and 66% of the 
lower peanut and egg allergy prevalence differences, respectively. Further adjustment for 
differences in infant eczema prevalence reduced the remaining difference.  
4.2.5 Conclusions 
A lower prevalence of food allergy in a regional setting was largely statistically accounted for by 
earlier allergenic solid introduction, increased dog ownership and less parental migration from 
Asia. Lower rates of early onset eczema were also important, either because of a causal role of 
eczema in food allergy or an unmeasured common cause of both conditions. 
4.3 Introduction  
Several major hypotheses have been proposed to explain the increase in IgE-mediated food 
allergy among children in many parts of the world, with an emerging body of evidence 
supporting each hypothesis (95). 
The dual allergen exposure hypothesis suggests early life food sensitisation via cutaneous 
exposure prior to oral ingestion of food increases the risk of food allergy, particularly in the 
setting of disrupted skin barrier function (28). In murine models, food sensitisation can be 
induced through a disrupted skin barrier (90). In subsequent human studies, proxy markers of a 
disrupted skin barrier, including filaggrin gene null mutations (91), increased transepidermal 
water loss in the neonatal period (92) and early onset eczema (25), have each been associated 
with subsequent food allergy development. Observational studies suggest that earlier oral 
introduction of allergenic foods in the infant diet is associated with a decreased risk of 
subsequent food allergy (20, 317). Recent trials such as the LEAP study (318) offer level one 
evidence to support the hypothesis that timely introduction of peanut reduces the risk of 
peanut allergy among high-risk infants. The evidence to support early introduction of other 
allergenic foods is less clear (319, 320), and the role of improving skin health during early 
infancy in reducing the risk of subsequent food sensitisation is still under investigation (321). 
The microbial hypothesis proposes that more diverse environmental microbial exposures in 
early life stimulate optimal immune homeostasis (28, 57). Proxy markers of increased microbial 
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exposure, such as living or working on a farm, have been consistently associated with a reduced 
risk of allergic sensitisation and asthma (58, 62, 295). More recently associations were reported 
between both pet ownership, increased family size, and a reduced risk of food allergy (20). This 
effect may be mediated by effects on the maternal and/or infant microbiome (322).  
The migration hypothesis suggests that the increase in food allergy risk in offspring of 
individuals who have migrated from a less westernised to a more westernised environment 
relates to inter-generational changes in lifestyle exposures such as diet, allergen exposure, 
microbial environment and/or vitamin D (184, 323). In Australia, there is evidence of an Asian 
migration effect from studies which show that food allergy is more common in Australian-born 
infants of Asian-born parents who have migrated from Asia, compared with Australian-born 
infants born to Caucasian parents (300, 301). Conversely, food allergy is uncommon in children 
born in Asia who subsequently migrate to Australia (300, 301).  
Differences in disease prevalence between populations in close geographical proximity to each 
other, but resident in different environments, have been analysed to identify risk factors for 
immune-related diseases (62, 324). This approach is yet to be specifically applied to IgE-
mediated food allergy.  
The aims of this study were to determine the prevalence of clinically-proven food allergy in BIS 
and compare clinically-proven food allergy prevalence’s between BIS and a harmonised cohort, 
the HealthNuts study in Melbourne, Australia. The comparison was then utilised to assess the 
contribution of compositional differences between the studies in environmental risk factors on 
food allergy prevalence differences, with an additional consideration of the potential role of 
infant eczema. 
4.4 Methods  
4.4.1 HealthNuts study recruitment  
The HealthNuts study design is described in Chapter 3, section 3.5.2. Infants underwent a skin 
prick test to four foods on the day of recruitment (details below). 
4.4.2 Barwon Infant Study recruitment 
The BIS study design is described in Chapter 3, section 3.3.1. 
4.4.3 Measurement of food sensitisation and food allergy at twelve months of age  
SPT’s were performed using single-tine metal lancet devices at a 90 degree angle on the infants’ 
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upper back (Stallergenes Lancet in HealthNuts, Quintip in BIS). Allergens (peanut, egg, cow’s 
milk and sesame) were supplied by ALK Abelló, Madrid, Spain. There was failure to obtain ethics 
approval for cows milk SPT for the first half of HealthNuts, so Cow’s milk SPT was performed in 
the second half of the HealthNuts cohort only (n=2,715) and challenges to cow’s milk were not 
conducted (3). SPT and challenge protocols and training were standardised across the studies 
and one nurse led the team of nurses performing challenges in both studies under medical 
supervision (J. Molloy and K. Allen) (3, 325).  
Sensitisation was defined as a SPT wheal ≥2 mm (20). Food allergy was defined as a positive 
oral food challenge or recent clear history of IgE-mediated reaction to a food accompanied by a 
SPT≥2 mm. Challenges were undertaken in infants with any detectable wheal irrespective of 
wheal size. If sensitised infants had reacted within the previous two months (peanut and 
sesame) or one month (egg) with objective symptoms and timing consistent with an IgE-
mediated reaction they were also defined as food-allergic (3). Egg allergy can rapidly resolve in 
infancy so a shorter time window for clinical reactions was utilised. Pre-determined criteria 
used to define a positive challenge were development of one or more of the following: ≥three 
urticaria lasting for ≥five minutes, angioedema, vomiting (excluding gag reflex) or anaphylaxis 
(evidence of circulatory or respiratory compromise including wheeze) (3).  
4.4.4 Skin prick test and oral food challenge participation  
4.4.4.1 HealthNuts 
Of the 5,276 participating infants, 5,127 (97%) had a valid SPT at one year of age and 84% of 
infants with a positive SPT wheal ≥1 mm than the negative control subsequently attended a 
formal in-hospital food challenge (3, 325).  
4.4.4.2 BIS 
Of the 1074 eligible infants in the inception cohort, 83.2% (894) completed the one year review. 
91.6% (819/894) of these had a valid SPT; and 82% (92/114) infants with a skin prick reaction to 
a food at least 1 mm larger than the negative control subsequently attended a formal in-
hospital food challenge.  Reasons for not attending a formal food challenge included refusal of 
the offer of a food challenge by the family and loss to follow-up in the study (3, 325). Infants 
regularly ingesting the sensitised food at the time of SPT were defined as sensitised tolerant 
without formal challenge (n=12). Three infants had a clinical history and reaction consistent 
with a diagnosis of IgE-mediated food allergy within two months of the one year review and a 
positive SPT. They were defined as food allergic without proceeding to food challenge (3). The 
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refusal of the infant to eat the challenge food or complete all doses in the challenge protocol 
was deemed an inconclusive challenge (n=5). 
4.4.5 Eczema 
In both studies eczema was measured using multiple criteria, including parental report of a 
diagnosis of eczema in the first year of life, history of itchy rash and use of topical steroid 
treatment, and clinical assessment at 12 months of age. For this comparative analysis, parental 
report of a doctor diagnosis of eczema during the first year of life was used (24). Infant eczema 
was defined as a categorical variable according to age at diagnosis: No eczema; eczema first 
diagnosed at ≤3 months; eczema first diagnosed at 4-6 months; eczema first diagnosed at 7-9 
months; eczema first diagnosed at 10-12 months. 
4.4.6 Measurement of environmental exposures and demographic factors in both studies 
Information on environmental and demographic factors was collected for both studies at 
recruitment (i.e. at age 12 months in HealthNuts and antenatal in BIS). Additional 
questionnaires in BIS were completed at three-monthly intervals throughout the first year of 
life. A comparison of the questionnaire data collected in both studies and information on how 
exposure variables were defined for this analysis is provided in Table 4.1.  
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Table 4.1: Sources of environmental and demographic information in HealthNuts and BIS. 
Variable HealthNuts  
(12 month questionnaire) 
BIS Definition 
Family history of allergic 
disease (eczema, asthma, 
hay fever and food 
allergy) 
Does anyone in your family suffer 
from: Separate questions for asthma, 
eczema, hay fever, food allergy (specify 
food), and for mother/father/siblings. 
Have you (or your child's father, siblings) 
ever been told by a doctor that you (or 
they) had… asthma, hay fever, eczema, 
food allergy (specify food). (Trimester 1 
and 2 questionnaire). 
four variables were defined and 
included in the analysis, as follows: 
FHx asthma (yes/no), 
FHx eczema (yes/no), 
FHx hay fever (yes/no), 
FHx food allergy (yes/no). 
Maternal smoking during 
pregnancy 
Did the mother smoke in pregnancy? 
(yes/no). 
Number of cigs/day. 
During the 3 months before conception, 
and the 1st & 2nd trimesters of your 
pregnancy, how many cigarettes and/or 
tobacco products did you smoke (on 
average) per day? (Option to fill in answer 
for preconception, trimester 1 and 2) 
(Trimester 1 and 2 questionnaire). 
Maternal smoking during pregnancy 
was defined as an affirmative answer to 
“did the mother smoke in pregnancy?” 
(HealthNuts) and an affirmative answer 
to smoking in 1st & 2nd trimester of 
pregnancy in BIS. 
Living on a farm with 
animals 
Do you live on a farm with animals? Do you live on a farm or property with any 
animals (livestock)? (Trimester 1 and 2 
questionnaire). 
Binary variable (yes/no). 
Pet ownership (cat, dog 
and other pets) 
Do you have pets at home? Separate 
questions for cat, dog, bird, other, 
indicate whether inside/outside/both. 
Do you have any pets? Indication of type 
of pet (options for dog, cat, bird, 
fish/reptile, or other) Do your pet(s) 
usually live inside or outside the house? 
(Asked at trimester 1 and 2 questionnaire) 
(Also asked at 12 months questionnaire, 
“Since 28 weeks pregnancy, have you had 
a pet?”. Same options as Trimester 1 and 2 
questionnaire) Question from 12 month 
questionnaire used in this study to match 
with HealthNuts questionnaire. 
Separate categorical variables for pet 
cat and pet dog, defined as follows: 
No pet dog, 
Dog allowed inside the house at least 
some of the time, 
Dog only kept outside the house. 
Cat: 
No pet cat, 
Pet cat (not divided into 
inside/outside). 
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Variable HealthNuts  
(12 month questionnaire) 
BIS Definition 
Sibling number Does your 12 month old have other 
brothers and sisters? Date of birth/sex 
for each. 
Only older siblings were included in the 
analysis for consistency with BIS. 
Does your unborn child have any siblings? 
Provide details in birth order DOB/sex for 
each. (Trimester 1 and 2 questionnaire). 
Categorical variable: 
No siblings, one sibling, two siblings, 
three or more siblings. 
Country of birth of 
parents 
In what country was the child's 
mother/father born? 
Mother’s country of birth, Father’s 
country of birth (Trimester 1 and 2 
questionnaire). 
Based on the previous work within 
HealthNuts which showed that food 
allergy was increased in infants of East 
Asian parents but not parents from 
other regions of the world (1), the 
following 3-category variable was 
created: 
Both parents born in Australia, 
One or both parents born in East Asia,* 
Any other combination. 
Maternal age Mother's date of birth (DOB) (linked 
with child's DOB for maternal age at 
birth of child). 
Mother's date of birth (linked with child's 
DOB for maternal age at birth of child) 
(Trimester 1 and 2 questionnaire for 
mothers DOB. Birth collection form for 
child’s DOB). 
Continuous variable (in years). 
Infant feeding practices 
(breastfeeding and 
formula feeding) 
Age started breastfeeding (days), still 
breastfed (at 12 months), age 
breastfeeding stopped, age formula 
started/stopped. 
How is your baby currently being fed with 
regard to milk? Breastfed only, Breastfed 
and Expressed breast milk, Expressed 
Breast milk only, Breast and formula 
feeds, formula feeding only. Infant feeding 
practices data collected at 6 month and 12 
month questionnaire. Data taken from 
both questionnaires to identify those 
breastfeeding continuously throughout 
infancy. 
3 category variable for breastfeeding 
status at 6-12 months of age in infancy 
was included in the model: 
Formula fed only at 6 and 12 months 
(no breastmilk), 
Breastfeeding only at 6 and 12 months 
(no formula), 
Any combination of breastmilk and 
formula between 6 and 12 months of 
age. 
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Variable HealthNuts  
(12 month questionnaire) 
BIS Definition 
Gestational age at 
delivery 
At how many weeks gestation did you 
deliver this baby? 
Has a doctor or midwife provider given 
you a due date? If so what is it? (Trimester 
1 and 2 questionnaire). Gestational age at 
delivery calculated from child’s DOB and 
estimated due date. 
Three category variable: <37 weeks, 
37-42 weeks, 
>42 weeks. 
Mode of delivery How was this child born (caesarean or 
vaginal) – data on elective vs 
emergency not currently available. 
Sourced from BIS database and hospital 
records mode of delivery – data on vaginal 
delivery, elective caesarean or emergency 
caesarean. 
Caesarean section delivery vs vaginal 
delivery. 
Age of introduction of egg Has your child ever eaten egg? 
(Categories for soft boiled/scrambled, 
hard boiled, meringue, cake, biscuits 
with egg, other forms). Age in months 
at which this was first given recorded. 
Has your baby ever consumed any form of 
eggs (such as the following…)? Age on 
introduction of egg? (In completed 
weeks). (Infant feeding questionnaire). 
Age at first introduction of egg or egg 
products, categorised as: 
<4 months, 4-6 months, 7-9 months, 
10-12 months, after 12 months 
(including not yet introduced at time of 
12 month questionnaire). 
Age of introduction of 
peanut 
Has your child ever eaten peanut or 
peanut products? (Categories for 
peanut butter, foods containing peanut 
and whole peanuts). Age in months at 
which this was first given recorded. 
Has your baby ever consumed nuts or nut 
product? If yes, peanut based products? 
(Infant feeding questionnaire). 
Age at first introduction of peanut 
products, categorised as: 
4-9 months, 10-12 months, after 12 
months (including not yet introduced at 
time of 12 month questionnaire). 
Note that no infants introduced peanut 
before 4 months. 4-6 months and 7-9 
months were combined into a single 
category to avoid small cell numbers 
for the analysis because introduction 
before 10 months was uncommon 
(particularly in HealthNuts). 
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Variable HealthNuts  
(12 month questionnaire) 
BIS Definition 
Age of introduction of 
solid (complementary) 
foods 
When was solid food first introduced? 
Age (months). 
Have you ever given your baby solid food? 
(3, 6, 9 and 12 month questionnaire). Data 
from all four questionnaires used to 
construct variable with categories on age 
of introducing solid (complementary) 
foods in infancy. 
Age at first introduction of solid 
(complementary) foods categorised as: 
3 category variable: < 4 months, 4-6 
months, >6 months 
Infant eczema Has your child ever been diagnosed 
with eczema? If yes, specify age 
(months). 
Has as a doctor ever told you that your 
child has eczema? If yes, how old was your 
child when the doctor first told you he/she 
has eczema? (Age in completed weeks). 4 
category variable created based on 
completed week’s text. 
(12 month questionnaire). 
Age at first diagnosis of eczema 
categorised as: 
≤3months, 4-6 months, 7-9 months, >9 
months. 
Socioeconomic status 
(SES)  
Participant’s home postcode was linked with socioeconomic index for areas (SEIFA) 
using data from the Australian Bureau of Statistics. The index assesses relative 
socioeconomic advantage/disadvantage, economic resources (income, assets and 
expenditure) and educational and occupational characteristics, with higher values 
indicating greater socioeconomic disadvantage. 
BIS: Home postcode from Trimester 1 and 2 questionnaire was used for linkage. 
Australian data were used to generate 
a SEIFA variable in tertiles (lowest, 
middle and highest) for inclusion in the 
analysis. 
*East Asia was defined according to the Standard Australian Classification of Countries (SACC), which were developed to be relevant to Australia’s multicultural 
society for use in analysing Australian-based country of origin data (http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup). Groups in the SACC comprise 
geographically proximate countries which have broadly similar social, cultural, economic and political characteristics. “East Asia” includes both North East Asia 
(China, Hong Kong, Macau, Taiwan, Japan, North Korea, South Korea) and South East Asia (Cambodia, Laos, Thailand, Vietnam, Indonesia, Malaysia, Philippines, 
Singapore and Timor-Leste) (301, 326).
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4.4.7 Statistical analysis 
4.4.7.1 Standardisation for family history of allergy 
Family histories of asthma, eczema, hay fever and food allergy were less common among 
infants in the HealthNuts cohort compared with the BIS cohort. This is likely due to 
participation bias towards families with allergy in BIS, which had an overall lower participation 
rate compared to HealthNuts (15). Therefore, crude prevalence differences observed between 
the two cohorts may relate to compositional differences both in family history of allergy as well 
as environmental factors. Since the study was primarily interested in the impact of differences 
in environmental factors, the first step was to estimate a BIS prevalence that would be 
expected if the BIS composition with regards to family history of allergy were the same as in the 
HealthNuts cohort, which represents the reference population (Melbourne). In other words, 
the BIS data were standardised with respect to family history, with the standard being the 
proportion of participants with a family history of each allergic disease among the HealthNuts 
cohort (327, 328).  
4.4.7.2 Impact of environmental factors on prevalence differences 
Having standardised for family history, the impact of compositional differences in BIS on the BIS 
prevalence compared with HealthNuts was assessed with respect to each risk factor of interest. 
To isolate the impact of a given risk factor, the variation due to the remaining factors was 
eliminated. This was again achieved by standardisation of BIS to the HealthNuts population. 
First, a fully-adjusted BIS prevalence estimate was produced, obtained by standardisation for all 
risk factors. Then for each factor, a partially-adjusted BIS prevalence estimate was produced, 
obtained by standardising for all factors except the factor of interest. The impact on the BIS 
prevalence of compositional differences in a given risk factor was determined by the difference 
between the partially-adjusted and fully-adjusted estimates, expressed as a percentage of the 
fully-adjusted estimate. The total impact on the BIS prevalence of compositional differences in 
all risk factors was determined by subtracting the fully-adjusted BIS prevalence from the family-
history-adjusted BIS prevalence, also expressed as a percentage of the fully-adjusted BIS 
prevalence. 
Finally, the fully-adjusted prevalence difference between BIS and HealthNuts, based on the 
fully-adjusted BIS prevalence, was expressed as a percentage of the family-history-adjusted 
prevalence difference, to obtain a measure of the proportion of the prevalence difference that 
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is unexplained by differences in the composition of the entire set of measured risk factors. 
Confidence intervals for all measures were obtained using a bootstrap procedure. 
4.4.7.3 Model 1: Contribution of environmental risk factors and parent country of birth only  
Risk factors included in this model were timing of introduction of allergenic foods (egg and 
peanut), having siblings, parental country of birth in East Asia and domestic pets (20, 317, 329). 
Additional potential confounders considered were mode of delivery, duration of breastfeeding, 
and socioeconomic status defined according to the Australian SEIFA index (326). 
4.4.7.4 Model 2: Exploring the role of infant eczema  
An extension analysis included the environmental risk factors as described above, as well as 
infant eczema status, in the model. This analysis used the four category variable for age at 
eczema onset described above, to capture a potentially stronger effect of early versus later 
onset eczema on food allergy development. The aim of this analysis was to explore the 
additional contribution of infant eczema. Eczema may play a causal role in the development of 
food allergy, by leading to sensitisation to food allergens in the environment absorbed through 
a damaged skin barrier (28). Alternatively, both eczema and food allergy may be the result of a 
common cause (genetic or environmental). For the other exposures described above, eczema 
may also act as a confounder (e.g. for timing of introduction of allergenic foods) or a mediator 
(e.g. for parental country of birth). The analyses therefore present and compare estimates for 
each environmental factor from both model 1 (without adjusting for eczema) and model 2 (with 
adjustment for eczema).  
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4.5 Results 
4.5.1 Cohort characteristics and differences in environmental risk factors between the 
cohorts 
Characteristics of the HealthNuts and BIS cohorts and differences in environmental risk factors 
between the cohorts are shown in Table 4.2, Figure 4.1, Figure 4.2 & Figure 4.3. 
A history of eczema, asthma, hay fever or food allergy in an immediate family member was 
reported by 69.4% of HealthNuts families compared to 86.1% in BIS, with BIS mothers, fathers 
and siblings each being more likely to have asthma, hay fever, eczema or food allergy (Figure 
4.1). 
Infants in the BIS cohort were slightly less likely to be diagnosed with eczema, particularly in the 
first three months of life (Figure 4.2). A greater proportion of infants in BIS were introduced to 
egg and peanut in the first year of life, while there was no difference in age at first introduction 
of any solid foods (Figure 4.2). The vast majority of infants in both cohorts (>90%) had some 
breastfeeding, while formula feeding at any time in the first 12 months was less common for 
BIS infants (Table 4.2).  
BIS families were more likely to have a pet dog (54% vs 30% in HealthNuts) and livestock 
exposure (7% vs 0.8% in HealthNuts), and there were smaller differences also in pet cat 
ownership and having siblings, both of which were more common in BIS (Figure 4.3). There was 
little difference in Caesarean section rates between the two cohorts (Figure 4.3). Fewer 
participants in BIS (1.7%) had at least one parent born in Asia compared to HealthNuts (10.5%). 
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Table 4.2: Demographics of the HealthNuts and BIS cohorts. 
 
HealthNuts 
(n=5,276) 
Metropolitan  
BIS 
(n=818) 
Regional 
Maternal age mean 
(SD) 
33.0  
(4.8) 
32.6  
(4.5) 
Paternal age mean 
(SD) 
35.1  
(5.6) 
34.6 
(5.6) 
Maternal smoking during pregnancy 4.7% 7.5% 
Gestational age at delivery  
 
<=37 weeks 6.2% 7.6% 
37-39 weeks 41.4% 31.4% 
40-42 weeks 51.7% 61.0% 
>=43 weeks 0.8% 0% 
Any breastfeeding in first year  94.4% 98.4% 
Breastfeeding 6-12 months   
Breastfeeding only 16.0 % 28.2 % 
Formula fed only 37.0 % 33.2 % 
Mixed breast/formula fed 47.0% 38.6 % 
Socioeconomic status (SEIFA 
disadvantage index by postcode)*   
Tertile 1 (more disadvantaged) 6.9% 22.3% 
Tertile 2 (intermediate)  26.8% 19.4% 
Tertile 3 (least disadvantaged)  66.3% 58.3% 
*Each participant’s home postcode was linked with SEIFA using data from the Australian Bureau of 
Statistics. The index assesses relative socioeconomic advantage/disadvantage, economic resources 
(income, assets and expenditure) and educational and occupational characteristics. 
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Figure 4.1: Differences in the prevalence of family history of allergy between the two cohorts.  (The 
percentage of infants with a sibling history of allergy was calculated as a proportion of infants who 
have one or more siblings). 
 
 
Figure 4.2: Differences in the prevalences of factors associated with the dual allergen exposure 
hypothesis between the two cohorts. 
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Figure 4.3: Differences in the prevalences of factors associated with the hygiene hypothesis between 
the two cohorts. 
 
4.5.2 Food allergy prevalence in the BIS cohort 
Of the 1074 eligible infants in the BIS inception cohort, 83.2% (894) completed the one year 
review. 91.6% (819/894) of these had a valid SPT; and 82% (92/114) infants with a skin prick 
reaction to a food at least 1 mm larger than the negative control subsequently attended a 
formal in-hospital food challenge. A total of 58 had positive food challenges and three had 
previous clinical reactions meeting the criteria for clinically proven IgE-mediated food allergy. 
The prevalence of clinically-proven food allergy among infants completing the one year review 
with valid outcome measures was 7.7% (95% CI, 6.0-9.8), with egg allergy the most common, 
6.5% (95% CI, 5.0-8.4) (Table 4.3). 
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Table 4.3: Food allergy prevalence in the BIS cohort at one year of age.  
Food 
tested 
+Sensitised 
≥1 mm (n) 
#Sensitised 
≥2 mm (n) 
Prevalence 
sensitised 
≥2 mm 
% 
95% CI 
Clinically-
proven food 
allergy (n) 
Food allergy 
prevalence 
%  
95% CI 
All Foods 114/805 93/804 11.6 
(9.5; 13.9) 
61/786 7.7 
(6.0; 9.8) 
Raw Egg 83/818 70/818 8.6 
(6.8; 10.6) 
53/808 6.5 
(5.0; 8.4) 
Peanut 41/817 28/817 3.4 
(2.3; 4.9) 
12/812 1.5 
(0.6; 2.3) 
Cashew 21/818 15/818 1.8 
(1.1; 3.0) 
4/816 0.4 
(0.1; 1.3) 
Cow’s 
Milk 
11/818 10/818 1.2 
(0.6; 2.2) 
4/815 0.4 
(0.1; 1.3) 
Sesame 3/802 2/802 0.2 
(0.0;0.9) 
1/801 0.1 
(0.0; 0.8) 
+All foods 1 mm sensitised: Infants with a SPT 1 mm or more to one or more of the five foods were 
compared to infants with negative SPT’s to all five foods. 
#All foods 2 mm sensitised: Infants with a SPT 2 mm or more to one of more of the five foods were 
compared to infants with negative SPT to all five foods. (A single infant had a 1 mm SPT to a single food 
but had missing data on other SPT’s so had an incomplete SPT and was excluded from the 2 mm 
sensitisation analysis). 
 
4.5.3 Comparison of egg and peanut sensitisation and allergy prevalence’s between the 
HealthNuts and BIS cohorts  
The observed prevalence of both egg and peanut allergy was lower in BIS compared with 
HealthNuts (6.5% vs 9.4% for egg allergy and 1.5% vs 3.1% for peanut allergy) (Table 4.4). The 
differences became more pronounced after accounting for the higher rate of family history of 
allergy in BIS (family history adjusted BIS prevalence: 5.8% egg allergy and 1.4% peanut allergy) 
(Table 4.5).  
Among sensitised infants, the proportion with a positive challenge was the same between the 
two cohorts (BIS 64% vs. HealthNuts 64%). 
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Table 4.4: Prevalence of food sensitisation and allergy at age 12 months in the BIS and HealthNuts cohorts. 
 Food sensitisation (SPT ≥ 2mm)   Clinically-proven food allergy 
 BIS  
(n=818) 
HealthNuts 
(n=5127) 
 
 
P value  
BIS  
(n=818) 
HealthNuts  
(n=5127) 
 
 Prevalence  
(95% CI) 
Prevalence  
(95% CI) 
Prevalence  
(95% CI) 
Prevalence  
(95% CI) 
P value 
Raw egg 8.6  
(6.8; 10.6) 
13.5  
(12.6; 14.5) 
<0.001 6.5  
(5.0; 8.4) 
9.4  
(8.6; 10.2) 
0.009 
Peanut 3.4  
(2.3; 4.9) 
7.6  
(6.9; 8.3) 
<0.001 1.5  
(0.6; 2.3) 
3.1  
(2.5; 3.5) 
0.011 
Sesame 0.2  
(0.0; 0.9) 
1.9  
(1.5; 2.3) 
0.001 0.1  
(0.0; 0.8) 
0.6  
(0.4; 0.8) 
0.069 
Cow’s milk* 1.2  
(0.6; 2.2) 
2.2  
(1.7; 2.8) 
0.076 - -  
*Cow’s milk – n=2,715 for HealthNuts. Challenges to cow’s milk not performed for HealthNuts infants.
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Table 4.5: Analysis of prevalence difference between the HealthNuts and BIS cohorts. 
  Egg allergy Peanut allergy 
  Estimate 
(%) 
95% CI Estimate 
(%) 
95% CI 
Observed HealthNuts prevalence 9.4 (8.6; 10.2) 3.1 (2.6; 3.5) 
Observed BIS prevalence 6.5 (4.9; 8.3) 1.5 (0.6; 2.3) 
Family history adjusted BIS 
prevalence* 
5.8 (4.2; 7.4) 1.4 (0.6; 2.2) 
Family history adjusted 
prevalence difference 
3.6 (1.8; 5.3) 1.7 (0.8; 2.6) 
Model 1: Environmental risk 
factors 
    
Fully adjusted BIS prevalence†  8.1 (5.7; 10.5) 2.8 (1.1; 4.6) 
Fully adjusted prevalence 
difference 
1.3 (-1.4; 3.8) 0.3 (-1.6; 2.2) 
Prevalence difference 
unexplained (%)‡ 
33.8 (-131.2; 71.5) 17.8 (-315.6; 83.0) 
Model 2: Environmental risk 
factors + eczema  
    
Fully adjusted BIS prevalence†  9.1 (6.6; 11.8) 3.3 (1.3; 5.4) 
Fully adjusted prevalence 
difference 
0.3 (-2.3; 3.2) -0.2 (-2.2; 2.0) 
Prevalence difference 
unexplained (%)‡ 
12.4 (-208.8; 61.1) -6.4 (-457.8; 68.9) 
*BIS prevalence standardised with respect to family history of allergic disease, with the standard being 
the proportion of participants with a family history of allergic disease among the HealthNuts cohort. 
† The fully adjusted BIS prevalence estimate was obtained by standardising for family history of allergic 
disease, timing of introduction of allergenic foods (egg and peanut), having siblings, parental country of 
birth in East Asia, domestic pets, mode of delivery, breastfeeding, and socioeconomic status (Model 1) 
and infant eczema (Model 2). 
‡ To obtain a measure of the proportion of the prevalence difference that is unexplained by differences 
in the composition of the entire set of measured risk factors, the fully-adjusted prevalence difference 
between BIS and HealthNuts, based on the fully-adjusted BIS prevalence, was expressed as a percentage 
of the family-history-adjusted prevalence difference. 
 
4.5.4 Prevalence difference explained by measured risk factors  
Adjusting for the measured environmental factors and Asian ethnicity statistically accounted 
for around two thirds of the difference in egg allergy and over three quarters of the difference 
in peanut allergy (Model 1, Table 4.5): 33.8% of the difference in egg allergy and 17.8% of the 
difference in peanut allergy remained statistically unaccounted after controlling for all of the 
above factors (Model 1, Table 4.5). The addition of infant eczema to the model greatly reduced 
the remaining difference in egg allergy between the two cohorts: only 12% remained 
statistically unaccounted  (Model 2, Table 4.5). For peanut allergy, the addition of infant 
Chapter 4 
96 
eczema to the model statistically accounted for the lower peanut allergy prevalence in BIS, with 
the adjusted peanut allergy prevalence in BIS (3.3%) being slightly higher than the observed 
peanut allergy prevalence in HealthNuts (3.1%).  
4.5.5 Impact of early introduction of allergenic foods on prevalence difference 
Age at peanut introduction was the largest single statistical contributor to the prevalence 
difference in peanut allergy, while age at introduction of egg appeared to play a lesser role in 
the prevalence difference in egg allergy. An earlier age of egg introduction in BIS resulted in a 
percentage change of -9.4% in the adjusted BIS egg allergy prevalence (Table 4.6), while for 
peanut allergy, the percentage change related to earlier age of peanut introduction was -25% 
(Table 4.7). Both estimates were slightly attenuated in the models, which included adjustment 
for infant eczema (Table 4.6 & Table 4.7). 
 
Table 4.6: Contribution of individual factors to egg allergy prevalence difference between BIS and 
HealthNuts. 
Factor Partially-adjusted BIS 
Prevalence (%) 
(95% CI)# 
Change w.r.t. fully-
adjusted BIS 
prevalence 
(95% CI)* 
Percentage change 
w.r.t. fully-adjusted BIS 
prevalence 
(95% CI)* 
Model 1: 
Environmental factors 
   
Pet dog in infancy 7.8 
(5.4; 10.1) 
-0.5 
(-0.9; -0.2) 
-6.4 
(-10.5; -2.2) 
Parents’ country of 
birth-  
Australia/Asia/other 
7.1 
(4.9; 9.4) 
-1.2 
(-1.7; -0.7) 
-14.2 
(-18.1; -9.2) 
Age at first 
introduction of egg 
7.6 
(5.4; 9.7) 
-0.8 
(-1.5; 0.1) 
-9.4 
(-16.8; 1.3) 
Number of siblings 8.3 
(5.8; 10.8) 
-0.1  
(-0.3; 0.1) 
-1.6  
(-4.1; 1.7) 
Mode of delivery- 
vaginal/Caesarean 
section 
8.3  
(5.8; 10.8) 
-0.01 
(-0.1; 0.1) 
-0.1 
(-1.3; 1.0) 
SES 8.5 
(6.0; 11.0) 
0.2 
(-0.4; 0.8) 
2.3 
(-4.3; 10.3) 
Pet Cat in infancy 
8.1 
(5.7; 10.5) 
-0.04 
(-0.2; 0.1) 
-0.5 
(-1.8; 0.9) 
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Factor Partially-adjusted BIS 
Prevalence (%) 
(95% CI)# 
Change w.r.t. fully-
adjusted BIS 
prevalence 
(95% CI)* 
Percentage change 
w.r.t. fully-adjusted BIS 
prevalence 
(95% CI)* 
Infant feeding 
(breastfed, formula 
fed, mixed bf + ff) 
8.1 
(5.7; 10.5) 
-0.3 
(-0.8; 0.4) 
-3.1 
(-9.3; 5.3) 
Model 2: 
Environmental factors 
+ eczema  
   
Infant eczema 
age of diagnosis 
8.3 
(5.8; 10.8) 
-0.8 
(-1.4; 0.2) 
-9.0 
(-15.2; 1.8) 
Pet dog in infancy 8.7 
(6.2; 11.1) 
-0.5 
(-0.9; -0.1) 
-5.1 
(-8.8; -1.1) 
Parents’ country of 
birth-  
Australia/Asia/other 
8.1 
(5.8; 10.5) 
-1.0 
(-1.3; -0.5) 
-11.0 
(-14.7; -6.4) 
Age at first 
introduction of egg 
8.5  
(6.2; 10.8) 
-0.7 
(-1.5; 0.2) 
-7.4 
(-15.2; 3.1) 
Number of siblings 9.1 
(6.5; 11.7) 
-0.1 
(-0.3; 0.1) 
-0.8 
(-3.3; 1.3) 
Mode of delivery 
vaginal/Caesarean 
section 
9.1 
(6.6; 11.7) 
-0.01 
(-0.1; 0.1) 
-0.1 
(-1.6; 1.2) 
SES 9.3 
(6.8; 11.9) 
0.2 
(-0.4; 0.8) 
1.9 
(-4.3; 9.5) 
Pet Cat in infancy 9.1 
(6.5; 11.7) 
-0.05 
(-0.2; 0.1) 
-0.5 
(-2.5; 0.8) 
Infant feeding 
(breastfed, formula 
fed, mixed bf + ff) 
9.0 
(6.5; 11.5) 
-0.2 
(-0.7; 0.6) 
-1.8 
(-8.2; 5.9) 
#The partially-adjusted BIS prevalence estimate was obtained by standardising for all risk factors except 
the risk factor of interest. 
*The impact on the BIS prevalence of compositional differences in a given risk factor was determined by 
the difference between the partially-adjusted and fully-adjusted estimates (fully-adjusted estimate 
shown in Table 4.5), expressed as a percentage of the fully-adjusted estimate. 
 
4.5.6 Impact of variables associated with increased microbial exposure on prevalence 
difference  
For egg allergy, increased exposure to pet dogs and cats in BIS compared with HealthNuts 
resulted in a percentage change of -6.4% and -0.5% in the adjusted BIS prevalence respectively 
(Table 4.6). For peanut allergy, increased exposure to pet dogs and cats in BIS resulted in a 
percentage change of -11.0% and -0.2% in the adjusted BIS prevalence respectively (Table 4.7). 
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Estimates were similar in both models (with and without eczema).  
A greater proportion of families with siblings in BIS resulted in a percentage change of -1.6% 
and -1.1% in the adjusted BIS egg and peanut allergy prevalence respectively (Table 4.6 & Table 
4.7). Caesarean birth rates in the two cohorts were similar, and resulted in only a -0.4% change 
in the adjusted BIS prevalence for egg allergy, and -0.1% for peanut allergy (Table 4.6 & Table 
4.7). 
 
Table 4.7: Contribution of individual factors to peanut allergy prevalence difference between BIS and 
HealthNuts. 
Factor Partially-adjusted BIS 
Prevalence  
(%) (95% CI)# 
Change w.r.t. fully-
adjusted  BIS 
prevalence  
(95% CI)*  
Percentage change 
w.r.t. fully-adjusted BIS 
prevalence 
(95% CI)* 
Model 1: 
Environmental 
factors 
   
Pet dog in infancy 2.5 
(0.9; 4.1) 
-0.3 
(-0.6; -0.1) 
-11.0 
(-18.3; -3.7) 
Parents’ country of 
birth-  
Australia/Asia/other 
2.3 
(0.9; 3.8) 
-0.5 
(-0.9; -0.2) 
-17.6 
(-24.6; -8.7) 
Age at first 
introduction of 
peanut 
2.1 
(0.8; 3.3) 
-0.7 
(-1.7; -0.2) 
-25.0 
(-38.3; -9.1) 
Number of siblings 2.8 
(1.0; 4.6) 
-0.03 
(-0.2; 0.1) 
-1.1 
(-6.7; 3.9) 
Mode of delivery 
vaginal/Caesarean 
section 
2.8 
(1.1; 4.6) 
-0.01 
(-0.1; 0.1) 
-0.4 
(-2.2; 1.2) 
SES 2.9 
(1.2; 4.7) 
0.1 
(-0.4; 0.7) 
3.0 
(-12.7; 37.4) 
Pet cat in infancy 2.8 
(1.1; 4.6) 
-0.01 
(-0.1; 0.1) 
-0.2 
(-2.8; 1.1) 
Infant feeding 
(breastfed, formula 
fed, mixed bf + ff) 
2.8 
(1.0; 4.5) 
-0.1 
(-0.4; 0.2) 
-2.0 
(-12.5; 8.4) 
Model 2: 
Environmental 
factors + eczema 
   
Infant eczema 
age of diagnosis  
2.8 
(1.1; 4.6) 
-0.5 
(-1.1; 0.1) 
-15.1 
(-25.0; 2.2) 
Pet dog in infancy 2.9 
(1.2; 4.7) 
-0.4  
(-0.9; -0.1) 
-12.2 
(-21.8; -2.5) 
Parents’ country of 
birth-  
Australia/Asia/other  
2.9 
(1.1; 4.6) 
-0.5 
(-0.9; -0.1) 
-13.9 
(-23.6; -6.2) 
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Factor Partially-adjusted BIS 
Prevalence  
(%) (95% CI)# 
Change w.r.t. fully-
adjusted  BIS 
prevalence  
(95% CI)*  
Percentage change 
w.r.t. fully-adjusted BIS 
prevalence 
(95% CI)* 
Age at first 
introduction of 
peanut 
2.6 
(1.1; 4.0) 
-0.8 
(-1.6; -0.2) 
-23.5 
(-37.6; -8.2) 
Number of siblings 3.3 
(1.3; 5.2) 
-0.1 
(-0.3; 0.2) 
-2.1 
(-9.0; 5.1) 
Mode of delivery 
vaginal/Caesarean 
section 
3.3 
(1.3; 5.3) 
-0.01 
(-0.1; 0.1) 
-0.1 
(-2.4; 1.8) 
SES 3.4 
(1.4; 5.3) 
0.03 
(-0.6; 0.8) 
0.8 
(-15.3; 32.7) 
Pet cat in infancy 3.3 
(1.3; 5.3) 
-0.01 
(-0.1; 0.1) 
-0.3 
(-3.2; 1.3) 
Infant feeding 
(breastfed, formula 
fed, mixed bf + ff) 
3.3 
(1.3; 5.3) 
-0.04 
(-0.5; 0.3) 
-1.4 
(-14.1; 9.4) 
# The partially-adjusted BIS prevalence estimate was obtained by standardising for all risk factors except 
the risk factor of interest. 
* The impact on the BIS prevalence of compositional differences in a given risk factor was determined 
by the difference between the partially-adjusted and fully-adjusted estimates (fully-adjusted estimate 
shown in Table 4.5), expressed as a percentage of the fully-adjusted estimate. 
 
4.5.7 Impact of migration on prevalence differences   
For egg allergy, the lower frequency of Asian-born parents in BIS resulted in a percentage 
change of -14.2% in the adjusted BIS egg allergy prevalence (Table 4.6), and -17.6% in the 
adjusted BIS peanut allergy prevalence (Table 4.7).  
4.5.8 Other factors (breastfeeding, socioeconomic status)  
Differences in breastfeeding (more persistent in BIS), and socioeconomic status (more 
disadvantaged families in BIS) had only a small impact on the adjusted BIS prevalence of egg 
and peanut allergy (Table 4.6 & Table 4.7).  
4.6 Discussion 
This is the first study to investigate the impact of compositional differences in environmental 
risk factors on food allergy prevalence differences between a regional and major metropolitan 
setting, using cohort studies with harmonised protocols, each using clinically-proven food 
allergy as an outcome. The current study determined the relative statistical contribution of 
multiple potential risk factors and found that a substantial proportion of the difference in 
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peanut and egg allergy prevalence between the two cohorts was statistically accounted for  by 
potentially modifiable risk factors including timing of introduction of allergenic solids, migration 
from Asia and exposure to pet dogs.  
The current study corroborates existing evidence that delayed timing of introduction of 
allergenic solids is an important risk factor for food allergy and thus provides support for 
recently revised international infant feeding guidelines for food allergy prevention (330). Earlier 
introduction of peanut was the factor that made the largest statistical contribution to the lower 
prevalence of peanut allergy in the regional BIS cohort, with age at introduction of egg 
potentially playing a lesser role in the prevalence difference in egg allergy. We were unable to 
identify a specific month range as the optimum time to introduce allergenic solids. 
The lower prevalence of eczema in BIS, particularly in the first three months of life, appeared to 
statistically contribute to the difference in egg and peanut allergy prevalence between the two 
cohorts. Eczema is strongly associated with onset of food allergy, particularly if eczema 
develops in the first months of life (25). Eczema may play a causal role in the development of 
food allergy by allowing penetration of food allergens present in the environment through a 
damaged skin barrier leading to food sensitisation (28). In this case, optimising infant skin 
barrier function in early life may be an effective prevention strategy for food allergy (25, 28, 92, 
318). It is also plausible that some of the association between infant eczema and food allergy is 
the result of a common antecedent cause preceding both conditions, which may be genetic or 
environmental. This is consistent with findings in the BIS cohort of a non-classical Th2 pattern, 
evident in cord blood cells at birth that could predict food allergy at 12 months (136).  
The apparent role of greater exposure to pet dogs in BIS in reducing allergy prevalence, 
supports the hypothesis that insufficient microbial exposure is a risk factor for food allergy. 
Other factors previously associated with altered microbial exposure, including siblings (57), 
Caesarean sections (207) and cat ownership (20), appeared to have less statistical impact on 
the prevalence difference, potentially reflecting the smaller magnitude of difference in these 
exposures between the two cohorts. Exposures related to a farm environment have been 
suggested to be protective for a range of other allergic diseases (62) but have not previously 
been examined with respect to food allergy. Of note, although more children in BIS were 
exposed to livestock, it was still a small proportion of the cohort (7%) thus farm exposure is 
unlikely to be a major determinant of reduced food allergy relative to HealthNuts. 
Infants born in Australia to Asian-born parents have previously been shown to have higher 
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rates of food allergy (300, 301), and in the current study, the low prevalence of Asian parents in 
BIS contributed to the lower food allergy prevalence. This supports the hypothesis that 
increased parental migration from Asia may be one factor driving an increase in early life food 
allergy in Australia (20, 301).  
The strengths of this study include the collection of data using standardised assessment of food 
sensitisation and allergy outcomes in two large cohorts, conducted in relatively similar 
communities, but with some specific and quantifiable differences in both cohort composition 
and environmental factors. The large sample size makes chance an unlikely explanation for the 
difference in food allergy prevalence between the cohorts. The studies were conducted during 
overlapping time periods, with HealthNuts recruitment completed in 2011 while BIS 
recruitment started in 2010. Although there is evidence of a change in timing of introduction of 
allergenic solids (including peanut and egg) over the course of the HealthNuts recruitment 
period (331), there was no evidence of a change in prevalence of food allergy over time within 
either study (data not shown), nor across the six years of the two studies combined, thus 
temporal factors alone are unlikely to explain the findings. Egg challenges were conducted 
using raw egg, thus the rate of positive challenges among those undergoing egg challenge is 
probably higher than it would have been if challenges were conducted with cooked egg. This 
may have contributed to the higher prevalence of egg allergy in both cohorts compared to 
other international studies (92, 332, 333). However, high rates of sensitisation to egg on skin 
prick testing, which was conducted using commercial egg allergen reagents, supports a true 
high prevalence of egg allergy in the study populations. The analysis of peanut allergy was 
limited in statistical precision because of its lower prevalence and the modest sample size of 
BIS. There was a higher participation rate in HealthNuts than BIS, with possible bias in the latter 
towards more allergy-prone families. Although this may have inflated estimates of food allergy 
prevalence in BIS, family history of allergy was standardised across the analyses. Finally, the 
role of infant eczema in the food allergy development pathway remains unclear, therefore the 
current study presented alternative models, with and without adjustment for infant eczema.  
In conclusion, the current study identified a difference in food sensitisation and allergy 
prevalence rates in two harmonised cohorts in Australia; and further shows that this difference 
is largely statistically accounted for by earlier introduction of allergenic solids, particularly 
peanut, with an additional contribution of increased pet/microbial exposure, and slightly lower 
rates of early onset eczema in the regional BIS cohort. Recently released guidelines 
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recommending timely introduction of allergenic solids for all infants have the potential to 
substantially reduce peanut allergy prevalence, by increasing timely introduction of peanut in 
populations where delayed peanut introduction was previously common. These guidelines may 
have less impact on the prevalence of other food allergies such as egg, which is already less 
commonly avoided in infancy.  
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CHAPTER 5 STUDY 2: MATERNAL ANTENATAL FOLATE STATUS AND 
FOOD ALLERGY AMONG OFFSPRING 
5.1 Introductory statement 
This Chapter describes Study 2 the aim of which was to investigate the potential relationship 
between maternal folate status in pregnancy and IgE-mediated food allergy among offspring at 
one year of age. The hypothesis tested within this chapter is that elevated maternal folate 
status is associated with an increased risk of IgE-mediated food allergy and/or eczema among 
the offspring.  
5.2 Abstract 
5.2.1 Background 
Many countries have implemented folic acid fortification of flour and recommend routine 
pre/antenatal folic acid supplementation primarily to reduce the incidence of congenital NTDS. 
It has been proposed that this may be one factor driving the increase in allergic disease among 
infants and children. There are however no published data relating directly measured maternal 
folate status during pregnancy to clinically-proven IgE-mediated food allergy in the offspring. 
5.2.2 Objective  
To estimate the distribution of RBC folate levels in late pregnancy among Australian women 
and to examine the association between maternal RBC folate status and food allergy among the 
offspring.  
5.2.3 Methods 
Maternal RBC folate levels were measured at 28-32 weeks gestation in a prospective birth 
cohort (n=1074). Food allergy outcomes were assessed in one year old infants by skin prick 
testing and subsequent food challenge. Eczema was assessed by questionnaire and clinic visits. 
Elevated maternal RBC folate was defined as >1360 nmol/L, corresponding to the 97th centile 
for RBC folate from the NHANES (1999-2004). Log-link binomial regression was used to examine 
associations between maternal RBC folate and allergic outcomes, including adjustment for 
potential confounding. 
5.2.4 Results 
RBC folate levels were measured in 88% (894/1064) of women in the birth cohort. The mean 
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concentration was 1695.6 nmol/L (SD 415.4) with 82% (731/894) >1360 nmol/L. There was no 
evidence of either linear or non-linear relationships between maternal RBC folate and allergic 
outcomes in offspring, nor compelling evidence of a positive association between elevated 
maternal RBC folate and either food allergy (aRR 2.89, 95% CI 0.90-9.35) or eczema (aRR 0.98, 
95% CI 0.68-1.40) in the offspring. 
5.2.5 Conclusions 
The majority of pregnant women in this study had elevated RBC folate levels. There was no 
evidence of a positive association between maternal RBC folate and food allergy or eczema 
among the offspring, although larger studies are required.  
5.3 Introduction 
Public health strategies that improve maternal nutritional status pre-conception, such as 
micronutrient supplementation, can potentially prevent devastating neonatal morbidity (334). 
Widespread recommendation of antenatal folic acid supplementation since the 1990’s to 
reduce the risk of NTDS in pregnancy is a highly successful example (29). However, as a large 
proportion of pregnancies are unintended (335), such guidelines are unlikely to lead to 
adequate periconceptional folate levels (336, 337). Accordingly, population wide strategies 
have been employed to promote adequate folate levels in the childbearing population, 
including the voluntary fortification of foodstuffs with folic acid (mostly in Europe) (337). 
Because of concerns about the adequacy of voluntary programs (338), mandatory fortification 
of cereal grains and wheat flour with folic acid has been introduced over the last twenty years 
in many countries worldwide (339). The value of such an approach is clear with a virtual 
elimination of folate deficiency and approximately 50% decrease in the prevalence of 
hyperhomocysteinemia (340). Mandatory folic acid foodstuff fortification is associated with a 
decrease in the incidence of NTDS (341, 342) and stroke-associated mortality (343), but also 
with an increased incidence of colorectal cancer (344) and possible harm to the relatively large 
proportion of the population with low vitamin B12 status (345). 
There is emerging evidence that the combination of folic acid supplementation and folic acid 
fortified diets in these countries is leading to a supraphysiologic maternal folate status among 
the childbearing population (98, 346). It has been suggested that elevated maternal folate 
status may be a factor in the well documented increase in allergic disease among infants and 
children (3, 5, 17-19, 24, 347, 348). Folate is a key methyl donor in the one carbon metabolic 
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pathway, essential for a myriad of biological processes, including the establishment of the early 
life epigenetic profile (30, 349) and subsequent activity of genes related to immune 
development and function (102, 103). In humans, some epidemiological studies suggest a 
positive association between antenatal folic acid supplementation and allergic disorders among 
offspring including asthma (99, 100) and atopic dermatitis (142), but others have been unable 
to replicate these findings (138, 139). A recent report found weak evidence of a positive 
association between high maternal serum folate and allergic sensitisation in offspring (34), but 
there are currently no data relating directly measured maternal folate status to the more 
relevant outcome measure of clinically-proven IgE-mediated food allergy. Further, the majority 
of studies in this field have relied on serum measures of folate status, which are highly sensitive 
to recent dietary intake (111). RBC folate, by contrast, provides an estimate of folate status 
over the preceding four months and is therefore considered a more reliable long term measure 
of folate status (111).  
While optimal RBC folate status in women to prevent NTDS has been established as greater 
than 906 nmol/L (107), the definition of a “elevated” maternal folate status in pregnancy 
remains uncertain. Some studies (96) have adopted a level of greater than 1360 nmol/L 
reflecting the 97th percentile and above, from the American post fortification NHANES (1999-
2004) (97). 
The aims of this study were to utilise a population-derived birth cohort with detailed and 
comprehensive measurement of relevant covariates to: (a) establish the distribution of RBC 
folate levels among Australian women during pregnancy; and (b) prospectively evaluate the 
relationship between maternal RBC folate during late pregnancy and clinically-proven IgE-
mediated food allergy or eczema among offspring.  
5.4 Methods 
5.4.1 Study design 
The aims and methodology of BIS are described in Chapter 3. Relationships were investigated 
between maternal RBC folate, maternal folic acid supplementation and infant food 
sensitisation, clinically-proven food allergy and eczema.  
5.4.2 Exposure measures 
5.4.2.1 Red blood cell folate 
Blood samples were collected at 28-32 weeks gestation. RBC folate was measured by the ADVIA 
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Centaur XP Immunoassay System (Siemens Healthineers, Australia). The normal reference 
range for this chemiluminescent assay was defined as 634 to 1792 nmol/L (303). The upper 
limit of measurement of the assay was 3000 nmol/L. Maternal RBC folate was investigated as a 
continuous variable in the primary analysis. In the secondary analyses a threshold of >1360 
nmol/L (previously reported in the NHANES study (1999-2004) (97)) was adopted for elevated 
RBC folate. Low RBC folate (based on a sufficient level to maximise reduction of risk of NTDS 
(107)) was defined as <906 nmol/L, and folate deficiency was defined as <340 nmol/L (113).  
5.4.2.2 Dietary folate 
Daily dietary folate intake in mothers was estimated using the Dietary Questionnaire for 
Epidemiological Studies V.2 (DQES) (350) developed by the Cancer Council, Victoria, Australia. 
The DQES estimate of dietary folate intake did not take into account the mandatory 
fortification of bread flour in Australia and the questionnaire analysis could not be modified. 
For the purposes of comparison and to account for the different bioavailability and absorption 
of folic acid and natural folates, the folate intake estimations from dietary sources and folic acid 
supplementation were converted to dietary folate equivalents (1 DFE = 1 mcg dietary folate or 
0.6 mcg folic acid) units (351). The recommended daily total intake of folate for women during 
pregnancy in Australia is at least 600 mcg/day expressed as DFE’s (351, 352).  
5.4.2.3 Folic acid supplementation  
Maternal folic acid supplementation data were acquired from the trimester one and two 
questionnaire in BIS. The reported amount of folic acid ingested daily was calculated from the 
constituents of the supplement brand, combined with the daily supplement tablet intake 
reported by mothers in the study. The total daily folic acid intake estimated through 
supplementation was divided into the following categories: <500 mcg/day, 500-999 mcg/day 
and ≥1000 mcg/day, based on the Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists (RANZCOG) guidelines for recommended folic acid supplementation in 
pregnancy of 400 mcg/day (353). The recommended tolerable upper limit of folic acid 
supplementation per day without adverse effects is 1000 mcg/day, although it is thought that 
higher intakes in women of childbearing age are likely to be safe (354). 
5.4.3 Outcome measures 
5.4.3.1 Food sensitisation  
The determination of food sensitisation status in BIS is described in Chapter 3, section 3.4.2. 
The study used 2 mm as a threshold for sensitisation in primary analyses (21) and 3 mm as a 
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threshold in a secondary analysis. 
5.4.3.2 Food allergy status 
All participants with SPT wheals 1 mm or greater than the negative control were offered an in-
hospital open food challenge (3). The clinically-proven food allergy protocol and outcome 
criteria are described in Chapter 3, section 3.4.2. 
5.4.3.3 Eczema status 
The definition and categorisation of eczema status in BIS is described in Chapter 3, section 
3.4.3. Eczema status in this study was defined according to the modified UK working party 
criteria for infants under 12 months (311, 312). 
5.4.4 Statistical analysis 
Categorical variables were summarised using proportions. Associations between antenatal 
covariates and maternal RBC folate were investigated using multivariate linear regression. 
Family history of allergy, ethnicity, maternal age, number of siblings, household income as a 
measure of SES, maternal folic acid supplementation, smoking and alcohol intake in pregnancy 
were included in the model. Infants who completed the one year review but had an 
inconclusive hospital food challenge result or indeterminate food allergy status were excluded 
from the food allergy analysis (n=30). Log-link binomial regression models were fitted to 
estimate risk ratios for associations between the exposures, maternal RBC folate, maternal folic 
acid supplementation and food sensitisation, subsequent food allergy or eczema (355). Linear 
regression was used to examine potential associations between maternal RBC folate and skin 
prick wheal size as continuous variables. Ethnicity, family history of allergy and number of 
siblings were included as potential confounders in the model as they have each been related to 
both folate and risk of allergic disease. Other potential confounders included the maternal 
factors: smoking in pregnancy, markers of SES (SEIFA (326), parental education, household 
income), alcohol consumption in pregnancy, folic acid supplementation, maternal age, pet 
ownership in pregnancy and the infant factors of birth weight and sex. These covariates were 
retained in the model if they made a greater than 10% change to the risk ratio point estimate. 
An interaction term was generated to investigate whether the relative risk relationship 
between maternal RBC folate and food allergy among offspring was modified by the infant’s 
eczema status. Analyses were performed using Stata (version 14.1, College Station, Texas). 
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5.4.5 Ethics 
The study was approved by Barwon Health Human Research and Ethics Committee (HREC 
10/24). Parents or guardians provided written informed consent for this study. 
5.5 Results 
5.5.1 Participant characteristics 
The participant’s characteristics in this study are summarised in Table 5.1. The majority of 
participants were full term Caucasian infants of Australian born parents in the middle to high 
SES groups.   
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Table 5.1: Participant baseline characteristics for the BIS maternal folate and food allergy study. 
Characteristic Inception birth 
cohort 
(n =1074) 
Participants with 
Maternal RBC 
folate (n=903)  
Food allergic 
(n=61) 
Eczema 
(n=192) 
Twins 20 (1.9%) 18 (1.9%) 2 (3.2%) 4 (2.1%) 
Sex of child 
Male 
Female 
 
557 (51.9%) 
517 (48.1%) 
 
470 (52.0%) 
433 (48.0%) 
 
34 (55.7%) 
27 (44.3%) 
 
107(55.7%) 
85 (44.3%) 
Maternal country of birth 
Australia 
Other 
unknown 
 
946 (88%)  
107 (10%) 
21   (2%) 
 
793 (88.0%) 
91 (8.8%) 
19 (2.1%) 
 
56 (91.8%) 
5 (8.2%) 
0 (0.0%) 
 
177 (92.2%) 
13 (6.7%) 
2 (1.1%) 
Paternal country of birth 
Australia 
other  
unknown 
 
923 (85.9%) 
109 (10.2%) 
42   (3.9%) 
 
767 (84.9%) 
89 (9.9%) 
47 (5.2%) 
 
49 (80.3%) 
8 (13.1%) 
4 (6.6%) 
 
169 (88.0%) 
17 (8.9%) 
6 (3.1%) 
Participant Caucasian 
ethnicity 
yes 
no 
unknown 
 
 
772 (71.9%) 
299 (27.8%) 
3 (0.3%) 
 
 
657 (72.8%) 
246 (27.2%) 
0 (0.0%) 
 
 
43 (70.5%) 
17 (27.9%) 
1 (1.6%) 
 
 
139 (72.4%) 
52 (27.1%) 
1 (0.5%) 
Number of siblings 
0 
1 
2 
3 or more 
 
453 (42.2%) 
383 (35.7%) 
183 (17.0%) 
55 (5.1%) 
 
371 (41.1%) 
327 (36.2%) 
156 (17.3%) 
49 (5.4%) 
 
22 (36.2%) 
28 (45.9%) 
10 (16.3%) 
1 (1.6%) 
 
78 (40.6%) 
71 (37.0%) 
37 (19.3%) 
6 (3.1%) 
Family history in a degree 
relative of 
asthma 
hay fever 
eczema 
food allergy 
 
 
542 (50.5%) 
674 (62.8%) 
480 (44.7%) 
265 (24.7%) 
 
 
454 (50.3%) 
577 (63.9%) 
410 (45.4%) 
225 (24.9%) 
 
 
43 (70.5%) 
47 (77.1%) 
40 (65.6%) 
16 (26.2%) 
 
 
124 (64.6%) 
143 (74.5%) 
128 (66.7%) 
55 (28.7%) 
Delivery via caesarean section 332 (30.9%) 271 (30.0%) 20 (32.8%) 64 (33.3%) 
Birth weight (kg), mean (SD) 3.53 (0.525) 3.54 (0.527) 3.51 (0.459) 3.57 (0.504) 
Smoking 
yes 
no 
unknown 
 
165 (15.4%) 
891 (83.0%) 
18 (1.6%) 
 
131 (14.5%) 
755 (83.6%) 
17 (1.9%) 
 
9 (14.8%) 
52 (85.2%) 
0 (0.0%) 
 
28 (14.6%) 
162 (84.4%) 
2 (1.0%) 
SEIFA 
low 
middle 
high 
unknown 
 
268 (25.0%) 
204 (19%) 
582 (54.2%) 
20 (1.9%) 
 
231 (25.6%) 
166 (18.4%) 
488 (54.0%) 
18 (2.0%) 
 
15 (24.6%) 
9 (14.8%) 
35 (57.4%) 
2 (3.2%) 
 
44 (22.9%) 
36 (18.7%) 
109 (56.8%) 
3 (1.6%) 
Household income 
less than 25,000 
25,000 to 49,999 
50,000 to 74,999 
75,000 to 99,999 
100,000 to 149,999 
More than 150,000 
unknown 
 
26 (2.4%) 
99 (9.2%) 
186 (17.3%) 
266 (24.8%) 
343 (31.9%) 
121 (11.3%) 
33 (3.1%) 
 
20 (2.2 %) 
83 (9.2%) 
167 (18.5%) 
231 (25.6%) 
271 (30.1%) 
97 (10.7%) 
33 (3.6%) 
 
0 (0.0%) 
4 (6.6%) 
7 (11.5%) 
18 (29.5%) 
23 (37.7%) 
8 (13.1%) 
1 (1.6%) 
 
1 (0.5%) 
14 (7.3%) 
23 (12.0%) 
48 (25.0%) 
79 (41.2%) 
21 (10.9%) 
6 (3.1%)  
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Characteristic Inception birth 
cohort 
(n =1074) 
Participants with 
Maternal RBC 
folate (n=903)  
Food allergic 
(n=61) 
Eczema 
(n=192) 
Maternal Alcohol 
consumption-trimester 2 
none 
<1 per wk 
1-6 per wk 
1-3 per day 
4+ per day 
unknown 
 
 
738 (68.7%) 
274 (25.5%) 
50 (4.7%) 
3 (0.3%) 
0 (0.0%) 
9 (0.8%) 
 
 
614 (68.0%) 
234 (25.9%) 
43 (4.8%) 
3 (0.3%) 
0 (0.0%) 
9 (1.0%) 
 
 
45 (73.8%) 
12 (19.7%) 
4 (6.6%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
130 (67.7%) 
53 (27.6%) 
7 (3.7%) 
1 (0.5%) 
0 (0.0%) 
0 (0.0%) 
Formula feeding  
(at twelve months) 
breastfed 
formula fed 
mixed 
unknown 
 
 
271 (25.2%) 
354 (33.0%) 
260 (24.2%) 
189 (17.6%) 
 
 
222 (24.6%) 
292 (32.3%) 
235 (26.0%) 
154 (17.1%) 
 
 
18 (29.5%) 
23 (37.7%) 
18 (29.5%) 
2 (3.3%) 
 
 
58 (30.2%) 
75 (39.1%) 
51 (26.6%) 
8 (4.1%) 
Maternal Folate 
supplementation 
yes 
No 
unknown 
 
 
987 (91.9%) 
31 (2.9%) 
56 (5.2%) 
 
 
828 (91.7%) 
26 (2.9%) 
49 (5.4%) 
 
 
56 (91.8%) 
3 (4.9%) 
2 (3.3%) 
 
 
179 (93.2%) 
5 (2.6%) 
8 (4.2%) 
Folate supplementation levels 
in women supplemented 
throughout T1 and T2.  
*Unknown 
<500 mcg/day 
500-999 mcg/day 
≥1000 mcg/day 
 
 
 
211 (19.6%) 
47 (4.4%) 
626 (58.3%) 
190 (17.7%)  
 
 
 
188 (20.8%) 
41 (4.6%) 
504 (55.8%) 
170 (18.8%) 
 
 
 
13 (21.3%) 
4 (6.6 %) 
34 (55.7%) 
10 (16.4%) 
 
 
 
36 (18.7%) 
7 (3.7%) 
120 (62.5%) 
29 (15.1%) 
#SEIFA, (Tertiles). 
*missing data in questionnaires meant it was not possible to determine supplementation level. 
 
5.5.2 Maternal RBC folate status 
RBC folate was measured in 88% (894/1064) of mothers in the third trimester of pregnancy. 
The distribution of maternal RBC folate levels in the inception cohort is shown in Figure 5.1. The 
median RBC folate concentration was 1633.5 nmol/L, (Inter-quartile range (IQR) 1424-1908 
nmol/L) and mean concentration was 1695.6 nmol/L, SD 415.4 (95% CI 1668.4-1722.9 nmol/L). 
Only 1% (10/894) of women had a folate level below 906 nmol/L, the level previously 
associated with increased risk of NTDS. Folate deficiency (<340 nmol/L) was apparent in only 
one participant (0.1%), whereas RBC folate >1360 nmol/L was evident in 82% (731/894) of 
women, with 34% (306/894) greater than the upper limit of the assay normal reference range 
(1792 nmol/L). Maternal RBC folate status was associated with a maternal age of <25 years, but 
there was no association with any measure of socioeconomic status (SEIFA, parental education 
or household income), maternal smoking or alcohol intake during pregnancy (Table 5.2). 
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Figure 5.1: Distribution of maternal RBC folate levels among the inception cohort. 
 
Table 5.2: Relationship between maternal exposures and maternal RBC folate in the BIS cohort. 
Maternal exposure β (95% CI) P value 
Family history of allergy 61.4 -25.1 147.8 0.16 
Caucasian ethnicity 13.1 -52.5, 78.8 0.70 
Maternal age<25 years  -177.7 -290.0, 65.3 0.002 
Household income 
-0 to 49,999 
 
Ref (0) 
  
-50,000 to 74,999 17.3 -91.3, 125.9 0.75 
-75,000 to 99,999 70.0 -33.5, 173.6 0.19 
-100,000 to 149,999 32.4 -72.8, 137.6 0.55 
-More than 150,000 -29.2 -156.3, 97.9 0.65 
Maternal smoking -55.8 -142.4, 30.90 0.21 
Maternal alcohol 
consumption in 
pregnancy trimester 2-
none Ref (0) 
  
              <1 per week -14.9 -79.9, 50.1 0.65 
              >1 per week -75.2 -196.2, 45.8 0.22 
Folic acid 
supplementation in 
pregnancy 
118.9 12.3, 250.0 0.08 
Number of siblings-none Ref(0)   
-one 6.1 -63.4, 75.5 0.86 
-two  -82.9 -162.3, -3.5 0.04 
-three or more -93.1 -219.4, 33.3 0.15 
Family history of allergy, maternal age, ethnicity, household income, maternal smoking, maternal 
alcohol intake in pregnancy, folic acid supplementation in pregnancy and number of siblings were 
included in the model. 
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5.5.3 Maternal dietary folate intake and folic acid supplementation 
In those with maternal RBC folate measurements, the mean estimated maternal dietary folate 
intake was 267.4 mcg/day (SD 95.0). Only 0.08% (7/848) had a documented dietary folate 
intake above the recommended daily intake (RDI) for folate in pregnancy (600 mcg/day) and 
69% (581/848) had a documented dietary folate intake of less than half of the folate RDI. 
Maternal folate supplementation rates were high with more than 90% (819/894) reporting 
taking a supplement containing folic acid. In those reporting folic acid supplementation, 71% 
(580/819) ingested a folic acid supplement throughout the first and second trimester and 98% 
(570/580) of those were taking at least 500 mcg/day (Table 5.1) equivalent to at least 830 
DFE’s/day.  
There was evidence of a weak correlation between dietary folate and maternal RBC folate 
(r=0.08, p=0.01). There was no evidence of a positive association between folic acid 
supplementation and maternal RBC folate status (Table 5.2).  
5.5.4 Food sensitisation, food allergy and eczema prevalence 
Among the inception birth cohort of 1074 infants, 894 (83%) attended the one year review. The 
prevalence of food sensitisation was 11.6% (93/804) (95% CI 9.5-13.9%) and clinically-proven 
food allergy prevalence was 7.7 % (61/786) (95% CI 6.0-9.8%) (Table 4.3). Eczema prevalence 
over the first year was 24.0% (192/800) with an average SCORAD at six months of 9.9 (SD 11.4) 
and at one year 6.6 (SD 8.4), corresponding to mild disease (314). Eczema severity at 6 months 
of age was not associated with food allergy development (p=0.52).  
5.5.5 Maternal RBC folate status and allergic outcomes among offspring 
Examining maternal RBC folate in quintiles did not reveal evidence of linear or non-linear 
associations with food sensitisation at either ≥2 mm (Figure 5.2 & Table 5.3) or ≥3 mm wheal 
size (Table 5.3), clinically-proven food allergy (Figure 5.3 & Table 5.3) or eczema (Figure 5.4 & 
Table 5.3). 
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Figure 5.2: Association between maternal RBC folate quintiles and food sensitisation (≥2 mm). 
Adjusted for family history of allergy, ethnicity, number of siblings and SES. Whiskers represent 95% 
CI for RR estimates. 
 
 
Figure 5.3: Association between maternal RBC folate quintiles and food allergy. Adjusted for family 
history of allergy, ethnicity, number of siblings and SES. Whiskers represent 95% CI for RR estimates. 
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Figure 5.4: Association between maternal RBC folate quintiles and eczema. Adjusted for family history 
of allergy, ethnicity, number of siblings and SES. Whiskers represent 95% CI for RR estimates. 
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Table 5.3: Association between maternal RBC folate quintiles and allergy outcomes.  
 Food Sensitisation (≥2 mm) Food Sensitisation (≥3 mm) Food allergy Eczema 
Maternal  
RBC Folate Quintiles 
Relative 
Risk Ratio 
(95% CI) 
*Adjusted 
Relative 
Risk Ratio  
(95% CI) 
Relative 
Risk Ratio 
(95% CI) 
*Adjusted 
Relative  
Risk Ratio 
(95% CI) 
Relative 
Risk Ratio 
(95% CI) 
*Adjusted 
Relative 
Risk Ratio 
(95% CI) 
Relative 
Risk Ratio 
(95% CI) 
*Adjusted 
Relative  
Risk Ratio 
(95% CI) 
Lowest quintile-1 
(318-1388 nmol/L) 
1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
2 
(1389-1555 nmol/L) 
2.08   
(0.98-4.43) 
1.90 
(0.88-4.08) 
2.96     
(0.98-8.94) 
2.82 
(0.93-8.51) 
2.90  
(1.09-7.77) 
2.64  
(0.97-7.23) 
1.0 
(0.66-1.52) 
0.98 
(0.65-1.48) 
3 
(1556-1721 nmol/L) 
1.20 
(0.51-2.79) 
1.12  
(0.48-2.60) 
2.44 
(0.79-7.61) 
2.33  
(0.75-7.23) 
1.33 
(0.43-4.08) 
1.21  
(0.39-3.80) 
0.86 
(0.55-1.34) 
0.88 
(0.57-1.37) 
4 
(1722-1976 nmol/L) 
2.22  
(1.05-4.70) 
1.95 
(0.92-4.12) 
4.0  
(1.37-11.66) 
3.51  
(1.21-10.24) 
2.18  
(0.78-6.11) 
1.90  
(0.67-5.40) 
0.86 
(0.55-1.34) 
0.81 
(0.52-1.27) 
Highest quintile-5 
(1984-3000 nmol/L) 
2.18  
(1.04-4.60) 
1.90  
(0.91-3.99) 
2.34  
(0.75-7.29) 
2.01 
(0.65-6.21) 
2.19  
(0.79-6.06) 
1.92 
(0.72-5.17) 
1.03 
(0.68-1.56) 
1.01 
(0.67-1.52) 
* Adjusted for family history of allergy, ethnicity, number of siblings, and SES.
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In a secondary analysis, there was some weak evidence of a positive association between 
maternal RBC folate >1360 nmol/L and food sensitisation in offspring at both ≥2 mm (aRR 1.72, 
95% CI 0.85-3.49) (Figure 5.5) and ≥3 mm wheal size (aRR 3.17, 95% CI 0.99-10.13) respectively 
(Table 5.4). There was no evidence of an association between maternal RBC folate and skin 
prick test wheal size (β 0.0001, 95% CI -0.0001,-0.0003, p=0.271).  
There was minimal evidence of a positive association between maternal RBC folate >1360 
nmol/L and food allergy in offspring (aRR 2.89, 95% CI 0.90-9.35) (Figure 5.5 & Table 5.4). There 
was no evidence of a positive association between maternal RBC folate >1360 nmol/L and 
eczema (aRR 0.98, 95% CI 0.68-1.40) (Figure 5.5 & Table 5.4). There was no evidence that the 
relationship between elevated maternal RBC folate and food allergy was modified by eczema 
status (p=0.75). 
 
 
Figure 5.5: Association between maternal RBC folate >1360 nmol/L and allergic outcomes. Adjusted 
for family history of allergy, ethnicity, number of siblings and SES. Whiskers represent 95% CI for RR 
estimates. 
 
Food sensitisation (≥2mm)
Food Allergy
Eczema 
1 2 3 5 10
Risk Ratio (Log Scale)
Unadjusted Adjusted
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Table 5.4: Association between maternal RBC folate thresholds and allergy outcomes.  
 Maternal RBC folate 
>1360 nmol/L 
Maternal RBC folate 
>1792 nmol/L 
Allergy 
outcome 
Maternal RBC 
folate 
measured  
n (%) 
RBC folate 
nmol/L, mean 
(SD) 
Relative 
Risk Ratio 
(95% CI) 
≠Adjusted Relative 
Risk Ratio 
(95% CI) 
Relative 
Risk Ratio 
(95% CI) 
≠Adjusted Relative 
Risk Ratio 
(95% CI) 
Food sensitisation 
(≥2 mm) 
Cases 82/93 
(88%) 
1810.2 
(467.3) 
1.91 
(0.95-3.86) 
1.72 
(0.85-3.49) 
1.30 
(0.86-1.98) 
1.23  
(0.81-1.85) 
Controls 621/711 
(87%) 
1693.7 
(399.9) 
Food sensitisation 
(≥3 mm) 
Cases 54/62 
(87%) 
1792.1 
(427.8) 
3.47 
(1.10-10.94) 
3.17 
(0.99-10.13) 
1.07 
(0.62-1.84) 
0.97 
(0.57-1.67) 
Controls 649/740 
(88%) 
1700.2 
(407.7) 
Food allergy Cases 51/61 
(84%) 
1779.2 
(455.7) 
3.28 
(1.04-10.35) 
2.89 
(0.90-9.35) 
1.23 
(0.71-2.11) 
1.16  
(0.69-1.96) 
Controls 636/725  
(88 %) 
1702.3 
(406.0) 
Eczema Cases 162/192  
(84%) 
1693.6 
(412.7) 
1.01 
(0.71-1.46) 
0.98 
(0.68-1.40) 
1.06 
(0.79-1.41) 
1.05  
(0.79-1.38) 
Controls 523/608  
(86%) 
1700.1 
(406.8) 
≠Adjusted for family history of allergy, ethnicity, number of siblings and SES.
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5.5.6 Maternal folic acid supplementation in the first and second trimester and allergic 
outcomes 
With less than 500 mcg/day as a reference group, maternal folic acid supplementation of 
between 500 and 999 mcg/day in the first and second trimester, was not associated with food 
sensitisation ≥2 mm (aRR 0.88, 95% CI 0.29-2.67), clinically-proven food allergy (aRR 0.43, 95% 
CI 0.16-1.15) or eczema (aRR 0.78, 95% CI 0.39-1.57) (Table 5.5). There was no evidence of a 
positive association between maternal folic acid supplementation of ≥1000 mcg/day in the first 
and second trimester and allergic outcomes (Table 5.5).  
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Table 5.5: Association between reported maternal folic acid supplementation and allergy outcomes.  
 Food Sensitisation (≥2mm) Food allergy Eczema 
Maternal  
folic acid supplementation 
Relative 
Risk Ratio 
(95% CI) 
#Adjusted Relative 
Risk Ratio 
(95% CI) 
Relative  
Risk Ratio  
(95% CI) 
#Adjusted Relative  
Risk Ratio 
(95% CI) 
Relative  
Risk Ratio  
(95% CI) 
#Adjusted Relative  
Risk Ratio 
(95% CI) 
Up to 500 mcg/day 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
500-999 mcg/day 1.12 
(0.37-3.37) 
0.88 
(0.29-2.67) 
0.53 
(0.20-1.38) 
0.43 
(0.16-1.15) 
0.92 
(0.48-1.76) 
0.78 
(0.39-1.57) 
≥1000 mcg/day 1.16 
(0.37-3.67) 
0.99  
(0.31-3.20) 
0.49  
(0.17-1.46) 
0.44  
(0.15-1.30) 
0.67 
(0.33-1.38) 
0.58 
(0.27-1.25) 
# Adjusted for family history of allergy, ethnicity, number of siblings and SES.
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5.6 Discussion 
In a birth cohort derived from a population with mandatory folic acid fortification of wheat 
flour and high levels of folic acid supplementation in pregnancy, over 80% of women tested had 
elevated RBC folate concentrations (>1360 nmol/L) in late pregnancy. There was no clear 
evidence of an association between maternal folate status and food allergy or eczema among 
offspring, however larger studies are required. 
High folic acid supplementation rates and doses are now prevalent among maternal 
populations in developed countries such as the USA and Canada (346, 356), but variable in the 
UK (357) and Australia (122, 358). In BIS, reported folic acid supplementation rates were high 
with the majority of women supplementing throughout the first and second trimester. 
Consistent with this, in the NHANES study from 1999 to 2006, folic acid supplementation was 
reported by 60-80% of participants in the first and second trimester with a mean daily intake of 
>800 mcg/day (346). In the recent PREFORM study from Canada, at least 90% of participants 
reported folic acid supplementation in pregnancy with supplementation doses of at least 1000 
mcg/day in 83% of participants in the first trimester (98). Thus the majority of women in both 
BIS and PREFORM report taking folic acid doses of greater than 500 mcg/day. This is in excess of 
the Australian RANZCOG recommendation for standard risk pregnancies of 400 mcg/day (353), 
although higher doses are recommended in the USA (359) and Canada (360).  
The high folic acid supplementation dosages in NHANES and PREFORM reflected the higher 
maternal RBC folate levels in the third trimester in both studies compared to BIS (BIS median 
1634 nmol/L vs NHANES median 1773 nmol/L (346); BIS mean 1695.6 nmol/L vs PREFORM 
mean 2793 nmol/L (98)). Maternal RBC folate status in BIS was independent of self-reported 
folic acid supplementation and traditional risk factors for low maternal folate status including 
low socioeconomic status, cigarette smoking and alcohol intake during pregnancy (96, 361). 
Similarly, in PREFORM there was no evidence that RBC folate levels associated with maternal 
folic acid supplementation or markers of SES (98). Lower maternal folate status in BIS was 
associated with maternal age less than 25 years, similar to NHANES (346). Collectively, these 
findings suggest that the elevated levels of RBC folate observed in current pregnancy cohorts 
may be primarily driven by folic acid fortification of common and ubiquitously accessible 
foodstuffs, such as wheat flour, in combination with high antenatal folic acid supplementation. 
Of note, in all the cohorts the groups with high folic acid supplementation tended to be in high 
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SES categories, suggesting the impact of mandatory folic acid fortification of foodstuffs to 
prevent folate insufficiency may be of greater importance in lower SES groups (357, 358). The 
current study was unable to fully assess the impact of folic acid fortified foods as the dietary 
assessment tool used in BIS predated fortification (350).  
The evidence from human studies for an association between maternal folate status during 
pregnancy and allergy in offspring is limited. At a molecular level, folate status is important for 
one carbon metabolism, a key regulator of the early epigenome, including DNA methylation 
profile (30, 135, 362). Variation in DNA methylation of immune related genes may contribute to 
the Th2 skew in asthma (128) and food allergy (134, 135). Maternal serum or plasma folate 
status measured in early (142) or late (34) pregnancy has been positively associated with atopic 
dermatitis (142) and allergic sensitisation (34) in offspring. By contrast, in the current study’s 
primary analysis, there was no evidence of linear or non-linear relationships between maternal 
RBC folate quintiles (34, 137) and food sensitisation ≥2 mm, clinically-proven IgE-mediated food 
allergy or eczema among the offspring. These findings are thus consistent with the Dutch 
KOALA cohort’s negative findings regarding maternal RBC (intracellular) folate and allergic 
outcomes in offspring (137) and the negative findings of the Western Australian study regarding 
maternal serum folate status and offspring food allergy and eczema (34). In both these studies 
maternal folate was sampled in the third trimester, but the use of intracellular folate in the 
KOALA study makes their findings comparable with the current study. 
In a secondary analysis, there was also no evidence of a positive association between elevated 
maternal RBC folate status (defined as greater than the 97th percentile from maternal RBC 
folate levels in the NHANES cohort (1999-2004) (97)) and food allergy or eczema in offspring. 
There was weak evidence of a positive association between elevated maternal RBC folate and 
food sensitisation of ≥3 mm. Importantly, the relationship between maternal RBC folate and 
food sensitisation in offspring however, was influenced by the use of varying thresholds of 
elevated RBC folate status (97, 303), with no strong, consistent or biologically plausible 
evidence for a single threshold apparent. Furthermore, given the uncertain clinical relevance of 
allergic sensitisation, the lack of evidence of an association between elevated maternal RBC 
folate and clinically-proven IgE-mediated food allergy reported in the current study is the more 
important finding.  
 
Conflicting and limited evidence exists for folic acid supplementation in pregnancy and allergic 
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outcomes (34, 99, 100, 137, 138, 141, 142) among offspring. It has been speculated that 
maternal folic acid supplementation may influence allergy among offspring through the 
increased bioavailability of folate from folic acid supplements relative to natural foods (100). An 
early study demonstrated no association between third trimester folic acid supplementation 
and childhood atopy (141). Subsequent studies reported folic acid supplementation in the first 
(99) and third (34, 100) trimesters of pregnancy was positively associated with infant wheeze 
(99), eczema (34) and childhood asthma (100). Of note in more recent work, folic acid 
supplementation throughout pregnancy was not associated with allergic outcomes in offspring 
(35, 137, 138). Differences in these studies findings appear to relate largely to trimester of folic 
acid supplementation, maternal reported exposures which can be subject to recall bias, varied 
outcome definitions and the population food fortification policy during the study period (10). 
No study however has examined folic acid supplementation in relation to clinically-proven food 
allergy in offspring. The findings of the current study extend the existing evidence against a 
potential association between folic acid supplementation and food allergy by examining folic 
acid supplementation at internationally recommended thresholds (352, 360) and using the 
clinically relevant outcome of clinically-proven food allergy.  
Strengths of the current study include the use of an antenatally recruited birth cohort with 
good retention rates and detailed measurement of relevant covariates, the measure of 
maternal RBC folate status compared to the more labile serum folate status and the robust 
study outcomes of clinically-proven food allergy and eczema status determined in accordance 
with the modified UK working party criteria for infants. Limitations include only a single 
maternal folate status measure in the third trimester of pregnancy, with no data on intake of 
folic acid fortified foods and incomplete data on levels of antenatal folic acid supplementation. 
The predominantly Caucasian cohort limits the generalisability of the study findings but assists 
internal validity. Perhaps most importantly, the low prevalence of folate deficiency in the 
cohort limited the study’s capacity to compare allergic outcomes among infants with elevated 
versus low in-utero folate exposure. In addition, the number of cases of the primary outcome 
was small potentially limiting the study’s power to detect an association. Consequently, the 
confidence intervals around the key estimates include magnitudes of association that would be 
considered clinically important.  
In conclusion, in a population exposed to mandatory folic acid fortification in which most 
women also take folic acid supplements during pregnancy, virtually all had a RBC folate level 
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above that required to reduce the risk of offspring NTDS, and the majority had levels above the 
NHANES 97th percentile of 1360 nmol/L. While it is unclear whether such elevated levels are 
problematic there is also no evidence of added benefit, and given the striking biological activity 
of folate, it may be safer to aim for levels which are only modestly higher than 906 nmol/L. In a 
secondary analysis there was weak evidence for a positive association between elevated 
maternal RBC folate and food sensitisation ≥3 mm in offspring, but this association was 
sensitive to the RBC folate threshold used in the analysis with no evidence of a statistically or 
biologically important threshold or pattern of association. The findings therefore provide 
reassurance the widespread policy of folic acid fortification of the food chain and 
supplementation during pregnancy has all but eliminated folate deficiency during late 
pregnancy. There appears to be no consistent or compelling evidence that elevated maternal 
folate status is associated with an increased risk of clinically relevant allergic outcomes among 
offspring, but larger studies are required to confidently exclude harmful effects. 
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CHAPTER 6 STUDY 3: VITAMIN D STATUS IN THE FIRST SIX 
MONTHS OF INFANCY AND CLINICALLY-PROVEN IGE-MEDIATED FOOD 
ALLERGY AT ONE YEAR OF AGE: A CASE-COHORT STUDY. 
6.1 Introductory statement 
This Chapter describes Study 3, the aim of which was to examine the association between VDS 
during the first six months of infancy and subsequent food allergy at one year. The hypothesis 
tested within this Chapter is that low VDS in the first six months of infancy is associated with 
increased risk of IgE-mediated food allergy and/or eczema in the first year of life. 
6.2 Abstract 
6.2.1 Background  
Ecological evidence suggests VDI due to lower ambient ultraviolet radiation (UVR) exposure 
may be a risk factor for IgE-mediated food allergy. However there are no studies relating 
directly measured VDI during early infancy to subsequent clinically-proven food allergy. 
6.2.2 Objective  
To prospectively investigate the association between VDI during infancy and clinically-proven 
food allergy at one year.  
6.2.3 Methods 
In a birth cohort (n=1074), a case-cohort design was used to compare (25(OH)D3) levels among 
infants with food allergy versus a random subcohort (n=274). The primary exposures were VDI 
(25(OH)D3<50 nmol/L) at birth and six months of age. Ambient UVR and time in the sun were 
combined to estimate UVR exposure dose. IgE-mediated food allergy status at one year was 
determined by formal challenge. Binomial regression was used to examine associations 
between VDI, UVR exposure dose and food allergy, and investigate potential confounding. 
6.2.4 Results  
Within the random subcohort VDI was present in 45% (105/233) of newborns and 24% (55/227) 
of infants at six months. Food allergy prevalence at one year was 7.7% (61/786) and 6.5% 
(53/808) were egg allergic. There was no evidence of an association between VDI at either birth 
(aRR 1.25, 95% CI 0.70-2.22) or six months (aRR 0.93, 95% CI 0.41-2.14) and food allergy at one 
year.  
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6.2.5 Conclusions  
There was no evidence that VDI during the first six months of infancy is a risk factor for food 
allergy at one year of age. These findings primarily relate to egg allergy and larger studies are 
required. 
6.3 Introduction  
A concordant increase in allergic disease prevalence (3, 17-19, 24, 348) and decrease in VDS 
(40) has been reported in both developed and developing countries. This correlation has led to 
the hypothesis that low VDS may influence the development of allergic disease including food 
allergy and eczema (12). Consistent with this, observational studies have found associations 
between proxy markers of UVR exposure, the major source of vitamin D (363), and allergic 
disease. Latitudes further from the equator appear to be associated with higher rates of food 
allergy and eczema (36, 37, 178); and less consistently, autumn and winter births (periods of 
low UVR exposure (364)) may be more common among infants and children with food allergy 
(164, 166). There is substantial literature describing the biological mechanisms by which 
vitamin D may influence the risk of developing allergic disease (12) including effects on Treg 
cells (38) and bowel epithelial integrity (39). Moreover, ambient UVR has also been shown to 
affect immune modulation via non-vitamin D pathways (365) and may independently protect 
against allergic disease development (366). 
A previous study reported a cross-sectional association between vitamin D3 insufficiency; 
(25(OH)D3 <50 nmol/L) and clinically-proven IgE-mediated food allergy among one-year-old 
infants of Australian-born parents, with evidence of a dose-response relationship (21). However 
the findings from prospective studies regarding directly measured maternal and infant vitamin 
D (25(OH)D) (43, 45, 46, 49, 52) or 25(OH)D3 (42, 44) and subsequent allergic outcomes are 
conflicting, and limited by incomplete measurement of potential confounding factors and 
suboptimal case definition (42-46, 49, 52). Furthermore, there has been minimal investigation 
of the potential role of UVR exposure in reducing risk of allergic disease independent of 
25(OH)D pathways (367); and the hypothesis that the association between VDI and food allergy 
may be modified by microbial exposure has not been adequately tested (12). 
The primary objective of this study was to utilise a population-derived birth cohort with 
detailed measurement of relevant covariates to prospectively evaluate the relationship 
between VDI during the first six months of infancy and clinically-proven IgE-mediated food 
allergy at one year of age. In addition, the study evaluated the relationship between UVR 
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exposure and food allergy; as well as the relationship between VDI, UVR exposure and eczema. 
6.4 Methods 
6.4.1 Study design 
The aims and methodology for BIS are described in Chapter 3. It was estimated that with 60-80 
cases of food allergy in the cohort, four non-cases to every case in the case cohort would 
optimise the size of the random subcohort to obtain the statistical power of 80%. Among the 
infants who completed the one year review and were more likely to have vitamin D measured 
at each timepoint, 31% (274/894) were randomly selected to comprise the ‘random subcohort’. 
25(OH)D3 was measured among infants in this subcohort as well as in those who had a positive 
food SPT and/or had clinically-proven food allergy. To minimise selection bias, analysis of the 
distribution and determinants of 25(OH)D3, and analysis of the association between 25(OH)D3 
and eczema, was restricted to infants within the random subcohort. Relationships between 
UVR exposure dose and food allergy or eczema were investigated in the full BIS cohort.  
6.4.2 Exposure measures 
6.4.2.1 Vitamin D status 
Blood samples were collected at four time points: maternal at 28-32 weeks gestation, infant at 
birth (cord blood), six months and one year (mean 13.03 months ± SD 0.83). The 25(OH)D3 
metabolites (serum or plasma), the epimeric form of 25(OH)D3 C3-epi-25(OH)D3 and 25(OH)D2 
were measured using two-dimensional ultra-performance liquid chromatography separation 
coupled tandem mass spectrometry detection (2D LC-MS/MS) (305). VDI was defined as 
25(OH)D3 <50 nmol/L and vitamin D deficiency as 25(OH)D3 <25 nmol/L, levels which are based 
predominantly on markers of bone health (156, 368). An appropriate definition of VDI in 
relation to immune health remains uncertain.  
6.4.2.2 UVR exposure 
Questionnaire data quantifying exposure to direct sunlight daily were recorded during 
trimesters one and two of pregnancy, and at four weeks, six months and one year. The ambient 
UVR was estimated using monthly averages of daily total ambient UVR in standard erythemal 
doses (369) for Melbourne from 2010 to 2014, provided by the Australian Radiation Protection 
and Nuclear Safety Agency. Total UVR exposure dose was calculated as the product of time in 
direct sun and the average of the daily ambient UVR exposure. A total cumulative postnatal 
UVR exposure dose over the first year of life was estimated by dividing UVR exposure at four 
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weeks, six months and twelve months into tertiles and assigning each tertile a score (0=lowest, 
1=moderate and 2=highest). These scores were then summed to generate a cumulative 
postnatal UVR exposure dose score (lowest=0, highest=6) (370). A categorical score was 
created describing the parental report of sunscreen use during infant sun exposure. The score 
was included in a secondary analysis to test for the modifying effect sunscreen may have on 
actual personal UVR exposure (370). 
6.4.3 Outcome measures 
6.4.3.1 Food allergy status 
The determination of sensitisation and food allergy status at one year in BIS is described in 
Chapter 3, section 3.4.2. At the one year review those regularly ingesting the sensitised food at 
the time of SPT were defined as sensitised tolerant without formal challenge (n=12). If on 
clinical review, the participant had a clinical history and reaction consistent with a diagnosis of 
IgE-mediated food allergy within two months of the one year review and a positive SPT, they 
were defined as food allergic without proceeding to food challenge (n=3) (3). The refusal of the 
child to eat the challenge food or complete all doses in the challenge protocol was deemed an 
inconclusive challenge (n=5). 
6.4.3.2 Eczema status 
The definition of eczema status in BIS is described in Chapter 3, section 3.4.3. In this study, 
eczema was defined according to the modified UK working party criteria for infants (311, 312).  
6.4.4 Statistical analysis 
Infants with an inconclusive hospital food challenge result or indeterminate food allergy status 
were excluded from the food allergy analysis (n=30). For the food allergy case-cohort analysis, 
the study applied inverse probability weighting, where the probability of selection for non-
cases in the random subcohort was estimated by the fraction of infants included in the 
subcohort from the total cohort reviewed at 12 months in the BIS study (274/894). The 
probability of selection for food allergy cases was 1 (371). 
Categorical variables were summarised using proportions. A propensity weighting approach 
was used to adjust the eczema prevalence to account for loss to follow-up over the first year of 
the study and provide an estimated eczema prevalence over the first year for the inception 
cohort (372). T-tests were used to compare the mean 25(OH)D3 levels between food allergic 
infants and the random subcohort, and between infants within the random subcohort with and 
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without eczema (Table 6.3 & Table 6.6). Binomial regression models were fitted to estimate risk 
ratios for associations between exposures (VDI and UVR exposure dose) and food allergy at one 
year of age or eczema. A further analysis examined the associations between VDI and food 
sensitisation. 25(OH)D3 was also divided into quintiles to assess potential non-linear 
associations and thresholds other than 50 nmol/L (Figure 6.5 & Figure 6.6). 
Ethnicity, family history of allergy, number of siblings, formula feeding and pet ownership were 
selected a priori to be included as covariates in the model, as they have each been related to 
both 25(OH)D3 and allergic disease. Smoking, livestock ownership, SES, birth weight, gender, 
season of birth, egg avoidance and time of solid introduction in infancy, maternal and infant 
vitamin D supplementation, C3-epi-25(OH)D3  concentration and mode of delivery at birth were 
retained in the model if they made a greater than 10% change to the risk ratio point estimate.  
The relationship between change in 25(OH)D3 status over the first six months of life and food 
allergy at one year of age was investigated by fitting a multivariable binomial regression model, 
using 25(OH)D3 at birth as a baseline variable, and change in 25(OH)D3 status from birth to six 
months of age as an explanatory variable (373). An interaction term was specified to investigate 
effect modification by pet ownership (12).  
To adjust for seasonal variation in 25(OH)D3 levels, the study fitted a sinusoidal curve with a 
period of 12 months to 25(OH)D3 data using linear regression, and added the residuals from 
this model to the population average 25(OH)D3 levels (184). For the C3-epi-25(OH)D3 sensitivity 
analysis, C3-epi-25(OH)D3 and 25(OH)D3 were summed as a new variable representing total 
vitamin D exposure for the binary regression. A further sensitivity analysis was performed using 
25(OH)D, the sum of 25(OH)D3 and 25(OH)D2. Analyses were performed using Stata (version 
14.1, College Station, Texas). 
6.4.5 Ethics 
The study was approved by Barwon Health Human Research and Ethics Committee (HREC 
10/24). Parents or guardians provided written informed consent for this study.  
6.5 Results 
6.5.1 Study population 
The majority of participants were full term, Caucasian infants with Australian born parents 
(Table 6.1). The majority of mothers took vitamin D supplements during pregnancy and up to 
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one third of infants were exposed to formula feeding (Table 6.1). 
Table 6.1: Participant baseline characteristics for the BIS vitamin D and food allergy study. 
Characteristic Inception birth 
cohort  
(n=1074) 
Random subcohort 
(n=274) 
Food allergic 
(n=61) 
Sex of child 
 Male 
 Female 
 
557 (51.9%) 
517 (48.1%) 
 
153 (55.8%) 
121 (44.2%) 
 
34 (55.7%) 
27 (44.3%) 
Maternal country of birth 
 Australia 
 Other 
 unknown 
 
946 (88%)  
107 (10%) 
21   (2%) 
 
235 (85.8%) 
32 (11.7%) 
7 (2.5%) 
 
56 (91.8%) 
5 (8.2%) 
0 (0.0%) 
Paternal country of birth 
 Australia 
 other  
 unknown 
 
923 (85.9%) 
109 (10.2%) 
42   (3.9%) 
 
233 (85.0%) 
25 (9.1%) 
16 (5.8%) 
 
49 (80.3%) 
8 (13.1%) 
4 (6.6%) 
Participant Caucasian ethnicity 
 yes 
 no 
 unknown 
 
772 (71.9%) 
299 (27.8%) 
3 (0.3%) 
 
206 (75.2%) 
67 (24.4%) 
1 (0.4%) 
 
43 (70.5%). 
17 (27.9%) 
1 (1.6%) 
Number of siblings 
 0 
 1 
 2 
 3 or more 
 
453 (42.2%) 
383 (35.7%) 
183 (17.0%) 
55 (5.1%) 
 
98 (35.8%) 
112 (40.9%) 
52 (18.9%) 
12 (4.4%) 
 
22 (36.07%) 
28 (45.9%) 
10 (16.3%) 
1 (1.6%) 
Pet ownership 
 yes 
 no 
 unknown 
 
815 (75.9%) 
197 (18.3%) 
62 (5.8%) 
 
215 (78.5%) 
55 (20.0%) 
4 (1.5%) 
 
35 (55.7%) 
25 (44.3%) 
1 (0.0%) 
Livestock ownership 
 yes 
 no 
 unknown 
 
73 (6.8%) 
985 (91.7%) 
16 (1.5%) 
 
16 (5.9%) 
253 (92.3%) 
5 (1.8%) 
 
1 (1.6%) 
59 (96.7%) 
1 (1.6%) 
Family history in a first degree 
relative of 
 asthma 
 hay fever 
 eczema 
 food allergy 
 
 
542 (50.5%) 
674 (62.8%) 
480 (44.7%) 
265 (24.7%) 
 
 
144 (52.5%) 
183 (66.8%) 
135 (49.3%) 
65   (23.7%) 
 
 
43 (70.5%) 
47 (77.1%) 
40 (65.6%) 
16 (26.2%) 
Delivery via caesarean section 332 (30.9%) 93 (33.9%) 20 (32.8%) 
Gestational age at birth 
 32 to 36 completed weeks 
 37 to 42 completed weeks 
 > 42 completed weeks 
 
47 (4.4%)  
1,027 (95.6%) 
0 (0.0%) 
 
11 (4.0%) 
263 (96.0%) 
0 (0.0%) 
 
0 (0.0%) 
61 (100%) 
0 (0.0%) 
Birth weight (kg), mean (SD) 3.53 (0.525) 3.56 (0.556) 3.51 (0.459) 
Smoking 
 yes 
 no 
 unknown 
 
165 (15.4%) 
891 (83.0%) 
18 (1.6%) 
 
30 (11.0%) 
242 (88.3%) 
2 (0.7%) 
 
9 (14.8%) 
52 (85.2%) 
0 (0.0%) 
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Characteristic Inception birth 
cohort  
(n=1074) 
Random subcohort 
(n=274) 
Food allergic 
(n=61) 
#SEIFA 
 low 
 middle 
 high 
 unknown 
 
268 (25.0%) 
204 (19%) 
582 (54.2%) 
20 (1.9%) 
 
66 (24.1%) 
59 (21.5%) 
146 (53.3%) 
3 (1.1%) 
 
15 (24.6%) 
9 (14.8%) 
35 (57.4%) 
2 (3.2%) 
Season of birth 
 autumn 
 winter 
 spring 
 summer 
 
274 (25.5%)  
275 (25.6%) 
309 (28.8%) 
216 (20.1%) 
 
66 (24.1%) 
77 (28.1%) 
52 (19.0%) 
79 (28.8%) 
 
10 (16.4%) 
19 (31.2%) 
17 (27.9%) 
15 (24.6%) 
Infant feeding (at six months) 
 breastfed exclusively 
 formula fed exclusively 
 mixed breast/formula 
 unknown  
 
429 (39.9%) 
320 (29.8%) 
171 (15.9%) 
154 (14.4%) 
 
113 (41.2%) 
104 (38.0%) 
46 (16.8%) 
11 (4.0%) 
 
29 (47.5%) 
15 (24.6%) 
14 (22.9%) 
3 (5.0%) 
Infant feeding (at twelve months) 
 breastfed exclusively 
 formula fed exclusively 
 mixed breast/formula 
 unknown 
 
271 (25.2%) 
354 (33.0%) 
260 (24.2%) 
189 (17.6%) 
 
83 (30.3%) 
111 (40.5%) 
89 (28.1%) 
3 (1.1%) 
 
18 (29.5%) 
23 (37.7%) 
18 (29.5%) 
2 (3.3%) 
Introduction of solids in infancy by 
six months of age 
 yes 
 no 
 unknown 
 
 
896 (83.4%) 
24 (2.2%) 
154 (14.4%) 
 
 
256 (93.4%) 
7 (2.6%) 
11 (4.0%) 
 
 
55 (90.2%) 
3 (4.9%) 
3 (4.9%) 
Maternal antenatal vitamin D 
supplementation 
 yes 
 no 
 unknown 
 
 
917 (85.4%) 
10 (0.9%) 
147 (13.7%) 
 
 
226 (82.5%) 
1 (0.4%)  
47 (17.1%) 
 
 
54 (88.5%) 
1 (1.6%) 
6 (9.8%) 
#SEIFA, (tertiles) 
6.5.2 Vitamin D levels within the random subcohort  
Within the random subcohort 25(OH)D3 levels were measured among 233 infants at birth and 
227 infants at six months (Figure 6.1). Forty five percent (105/233) of infants had VDI at birth 
and 24% (55/227) at six months (Figure 6.2). More than 82% of mothers reported taking a 
supplement containing vitamin D during pregnancy and maternal VDI was uncommon (9%) 
(Table 6.1 & Figure 6.2). The average ratio of birth 25(OH)D3 to maternal 25(OH)D3 was 0.61. 
The mean change in 25(OH)D3 status from birth to 6 months was +15.0 nmol/L ± SD 34.0 
nmol/L. 
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Maternal 25(OH)D3 
 
 
Birth 25(OH)D3 
 
 
Six month 25(OH)D3 
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12 month 25(OH)D3 
 
Figure 6.1: Distribution of 25(OH)D3 at each time point in the random subcohort. 
 
 
Figure 6.2: Prevalence of 25(OH)D3 insufficiency and sufficiency in participants in the random 
subcohort. 
6.5.3 Determinants of vitamin D status 
At each time point, ambient UVR six weeks prior to blood draw was associated with 25(OH)D3 
status (Table 6.2). VDI in the first six months of life was less common among infants who were 
formula fed and who had no siblings (Table 6.2).  
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Table 6.2: Associations between antenatal and postnatal exposures and VDI in the random subcohort. 
Vitamin D ≥50nmol/L 
n (%) 
<50nmol/L 
n (%) 
OR 
(95% CI) 
P  
value 
Maternal  
 
Ambient UVR 6 
week (wk) lag prior 
to maternal full 
blood count (FBC) 
-lowest quintile 
44 (78) 12 (22) 1 (ref)  
 2 53 (90) 6 (10) 0.42  
(0.14-1.20) 
0.103 
 3 52 (93) 4 (7) 0.28 
(0.08-0.94) 
0.04 
 4 56 (100) 0 (0) Not calculated  
 5-highest 44 (98) 1 (2) 0.08 
(0.01-0.67) 
0.02 
 Vitamin D 
supplementation in 
Trimester 2-no 
3 (75) 1 (25) 1 (ref)  
                     -yes 199 (93) 16 (7) 0.24 
(0.02-2.45) 
0.230 
Birth  Ambient UVR 6 wk 
lag prior to cord 
FBC 
–lowest quintile  
23 (43) 31 (56) 1 (ref)  
 2 8 (24) 26 (76) 2.41 
(0.92-6.29) 
0.07 
 3 22 (46) 26 (54) 0.88 
(0.40-1.92) 
0.74 
 4 33 (66) 17 (34) 0.38 
(0.17-0.85) 
0.02 
 5-highest 42 (89) 5 (11) 0.09 
(0.03-0.26) 
<0.001 
 Maternal vitamin D 
supplementation in 
trimester 3         -no 
21 (50) 21 (50) 1 (ref)  
                             -yes 85 (65) 46 (35) 0.54 
(0.27-1.09) 
0.09 
6 months Ambient UVR 6 wk 
lag prior to 6 
month FBC 
-lowest quintile 
34 (57) 26 (43) 1 (ref)  
 2 31 (56) 24 (44) 1.01 
(0.48-2.12) 
0.912 
 3 30 (97) 1 (3) 0.04 
(0.01-0.34) 
0.003 
 4 41 (93) 3 (7) 0.09 
(0.03-0.34) 
<0.001 
 5-highest 36 (97) 1 (3) 0.04 
(0.004-0.28) 
0.002 
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Vitamin D ≥50nmol/L 
n (%) 
<50nmol/L 
n (%) 
OR 
(95% CI) 
P  
value 
 Infant feeding at 6 
months of age  
-breastfed 
56 (58) 41 (42) 1 (ref)  
 -formula fed 91 (99) 1 (1) 0.02 
(0.01-0.11) 
<0.001 
 -mixed 
(formula/breast) 
25 (66) 13 (34) 0.71 
(0.32-1.55) 
0.391 
 Number of siblings 
-none  
69 (85) 12 (15) 1 (ref)  
 -one 72 (77) 21 (23) 1.68 
(0.77-3.67) 
0.195 
 -two  25 (58) 18 (42) 4.14 
(1.75-9.80) 
0.001 
 -three or more 6 (60) 4 (40) 3.83 
(0.94-15.64) 
0.061 
 $Family history of 
allergy  -no 
22 (79) 6 (21) 1 (ref)  
               -yes 149 (76) 47 (24) 1.16 
(0.44-3.02) 
0.767 
12 
months 
Ambient UVR 6 wk 
lag prior to 12 
month FBC 
-lowest quintile 
31 (61) 20 (39) 1 (ref)  
 2 31 (72) 12 (28) 0.60 
(0.25-1.43) 
0.251 
 3 35 (90) 4 (10) 0.18 
(0.05-0.57) 
0.004 
 4 40 (91) 4 (9) 0.16 
(0.05-0.50) 
0.002 
 5-highest 48 (96) 2 (4) 0.06 
(0.01-0.29) 
<0.001 
 UVR exposure dose 
-lowest quintile 
38 (72) 15 (28) 1 (ref)  
 2 32 (89) 4 (11) 0.32 
(0.09-1.05) 
0.06 
 3 29 (76) 9 (24) 0.79 
(0.30-2.05) 
0.622 
 4 33 (75) 11 (25) 0.84 
(0.34-2.09) 
0.715 
 5-highest 52 (96) 2 (4) 0.10 
(0.02-0.45) 
0.002 
 Infant feeding at 12 
months  
 -breastfed 
41 (60) 27 (40) 1 (ref)  
  -formula fed 85 (92) 7 (8) 0.13 
(0.05-0.31) 
<0.001 
  -mixed  
(formula/breast) 
57 (89) 7 (11) 0.19 
(0.07-0.47) 
<0.001 
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Vitamin D ≥50nmol/L 
n (%) 
<50nmol/L 
n (%) 
OR 
(95% CI) 
P  
value 
 Caucasian ethnicity 
 -no 
48 (89) 6 (11) 1 (ref)  
  -yes 136 (79) 36 (21) 2.12  
(0.84-5.34) 
0.112 
 All Egg avoidance 
at 12 months     
 -no 
180 (82) 39 (18) 1 (ref)  
  -yes 2 (40) 3 (60) 6.92  
(1.12-42.83) 
0.04 
 $Family history of 
allergy    -no 
22 (85) 4 (15) 1 (ref)  
                 -yes 160 (81) 38 (19) 1.31  
(0.42-4.01) 
0.641 
 Number of siblings 
-none 
72 (96) 3 (4) 1 (ref)  
 -one 70 (73) 26 (27) 8.91  
(2.58-30.79) 
0.001 
 -two  35 (75) 12 (25) 8.23 
(2.18-31.05) 
0.002 
 -three or more 8 (89) 1 (11) 3.0 
(0.28-32.35) 
0.365 
$ History of asthma, eczema, hayfever or food allergy in a first degree relative. 
6.5.4 Food allergy and eczema prevalence 
The prevalence of clinically-proven food allergy among infants completing the one year review 
with valid outcome measures was 7.7% (95% CI, 6.0-9.8), with egg allergy the most common, 
6.5% (95% CI, 5.0-8.4) (Table 4.3).  
Eczema point prevalence rates in the cohort were: 0% at one month; 1.2% (12/973) at three 
months; 8.5% (78/923) at six months; 13.6% (120/880) at nine months; and 8% (71/884) at one 
year. The estimated eczema prevalence over the first year of life for the inception cohort was 
24.2% (95% CI, 21.2%-27.3%). The average SCORAD in infants with eczema at six months was 
9.9 (SD 11.4) with 69% (54/78) having a score consistent with mild disease (314). At one year 
the average SCORAD was 6.6 (SD 8.4) with 86% (61/71) having a score consistent with mild 
disease. 
6.5.5 Vitamin D status and IgE-mediated food allergy 
There was no evidence of an association between VDI at either birth (aRR 1.25, 95% CI 0.70-
2.22) or six months (aRR 0.93, 95% CI 0.41-2.14) and food allergy at one year of age (Figure 6.3). 
Analyses using deseasonalised 25(OH)D3 (Figure 6.4 & Table 6.3) showed similar patterns of 
associations to the primary analysis. The mean 25(OH)D3 level was similar at birth (Mean 
Chapter 6 
136 
Difference 2.10 nmol/L, 95% CI -3.70-7.91) and six months (Mean Difference -2.16 nmol/L, 95% 
CI -10.2-5.9) among infants with and without food allergy at one year of age (Table 6.3). There 
was no evidence of an association between 25(OH)D3 <25 nmol/L at birth and food allergy at 
one year of age (p=0.94). At each time point, there was some non-linearity between 25(OH)D3 
levels and food allergy risk (Figure 6.5 & Figure 6.6) but there was no evidence to support the 
use of a threshold other than 50 nmol/L. 
There was no evidence that change in 25(OH)D3 status from birth to six months of age was 
associated with food allergy at one year of age (aRR 0.99, 95% CI 0.96-1.02). Adjusting for C3-
epi-25(OH)D3 in maternal samples, at birth or six months by adding to the 25(OH)D3 level did 
not change the lack of association between 25(OH)D3 and food allergy (Table 6.4 & Table 6.5). A 
sensitivity analysis using 25(OH)D (i.e. the sum of 25(OH)D3 and 25(OH)D2, where available), 
rather than 25(OH)D3 alone as the exposure measure had negligible impact on the risk ratios 
(data not shown). 
There was no evidence that the lack of association between VDI during the first six months of 
infancy and food allergy at one year of age was modified by pet ownership status as a marker of 
microbial experience (p=0.96).  
There was also no association evident between maternal VDI and offspring food allergy at one 
year of age (aRR 0.87, 95% CI 0.27-2.77) (Table 6.3), and only a weak indication of a cross-
sectional association between VDI and food allergy at one year of age (aRR 1.89, 95% CI 0.86-
4.13) (Figure 6.3). 
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Figure 6.3: Association between VDI and clinically-proven food allergy at one year. Adjusted for family 
history of allergy, ethnicity, number of siblings, domestic pets, formula feeding at six and twelve 
months. Whiskers represent 95% CI for RR estimates.  
 
 
Figure 6.4: Association between deseasonalised VDI and clinically-proven food allergy at one year.  
Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets and, formula 
feeding at six and twelve months. Whiskers represent 95% CI for RR estimates.  
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Figure 6.5: The relationship between 25(OH)D3 quintiles at birth and risk of food allergy at one year. 
Lowest quintile is reference (aRR 1). Adjusted for family history of allergy, ethnicity, number of 
siblings and domestic pets. Whiskers represent 95% CI for RR estimates. 
 
 
Figure 6.6: The relationship between 25(OH)D3 quintiles at 6 months and risk of food allergy at one 
year. Lowest quintile is reference (aRR 1). Adjusted for family history of allergy, ethnicity, number of 
siblings, domestic pets and infant feeding. Whiskers represent 95% CI for RR estimates. 
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Table 6.3: Association between low VDS and clinically-proven food allergy at one year. 
 Non-deseasonalised Vitamin D3 Deseasonalised 
Vitamin D3 
Time point 25(OH)D3 
measured 
(%) 
25(OH)D3 
nmol/L, 
mean (SD) 
25(OH)D3     
Mean diff 
nmol/L,    
(95% CI) 
25(OH)D3 
<50 nmol/L 
(%) 
Relative 
Risk Ratio 
(95% CI) 
≠Adjusted 
Relative Risk 
Ratio  
(95% CI) 
Relative Risk 
Ratio  
(95% CI) 
≠Adjusted 
Relative   
Risk Ratio 
(95% CI) 
Maternal Cases 60/61 
(98%) 
82.7 
(23.1) 
4.87 
(-2.46-12.2) 
4/60 
(7%) 
0.78 
(0.27-2.26) 
0.87 
(0.27-2.77) 
0.31 
(0.04-2.32) 
0.35 
(0.04-2.98) 
Controls 225/227 
(99%) 
87.6 
(26.3) 
22/225 
(10%) 
Cord blood Cases 54/61 
(88%) 
52.0 
(17.1) 
2.10 
(-3.70-7.91) 
26/54 
(48%) 
1.21 
(0.69-2.12) 
1.25 
(0.70-2.22) 
1.16 
(0.66-2.04) 
1.29 
(0.71-2.23) 
Controls 193/227 
(85%) 
54.1 
(19.7) 
84/193 
(44%) 
6 months Cases 51/61 
(84%) 
71.4 
(23.9) 
-2.16 
(-10.2-5.9) 
11/51  
(22%) 
0.92 
(0.46-1.84) 
0.93 
(0.41-2.14) 
1.16 
(0.58-2.33) 
1.03 
(0.48-2.20) 
Controls 190/227 
(84%) 
69.2  
(26.6) 
46/190 
(24%) 
1 year Cases 50/61 
(82%) 
63.8  
(21.2) 
3.34  
(-2.99-9.68) 
13/50 
(26%) 
1.61  
(0.83-3.16) 
1.89 
(0.86-4.13) 
1.79 
 (0.86-3.73) 
1.79  
(0.76-4.21) 
Controls 195/227 
(86%) 
67.0 
(20.0) 
35/195 
(18%) 
(Controls = random subcohort of 274 minus 17 infants with FA and 30 infants with indeterminate food allergy status). ≠Adjusted for family history of allergy, 
ethnicity, number of siblings, maternal vitamin D supplementation, domestic pets and formula feeding at six and twelve months 
Chapter 6 
140 
 
Table 6.4: Sensitivity analysis incorporating C3-epi-25(OH)D3 at each time point for food allergy. 
Time point  Food allergy 
Relative 
Risk Ratio 
(95% CI) 
#Adjusted 
Relative  
Risk Ratio 
(95% CI) 
Maternal 0.91 
(0.31-2.63) 
0.98 
(0.30-3.18) 
Birth 1.06 
(0.59-1.91) 
1.04 
(0.57-1.92) 
6 months 0.79 
(0.40-1.56) 
0.70 
(0.28-1.70) 
1 year  1.85 
(0.94-3.62) 
2.32 
(0.97-5.51) 
#Adjusted for family history of allergy, ethnicity, number of siblings, maternal vitamin D 
supplementation, domestic pets and formula feeding at six and twelve months. 
 
 
Table 6.5: Sensitivity analysis incorporating C3-epi-25(OH)D3 at each time point for eczema. 
Time point Eczema 
Relative 
Risk Ratio 
(95% CI) 
#Adjusted Relative  
Risk Ratio 
(95% CI) 
Maternal Eczema in first 
year of life 
0.56 
(0.15-2.07) 
0.43 
(0.11-1.75) 
Cord 
blood 
Eczema onset up 
to 6 months 
1.16 
(0.50-2.67) 
1.16 
(0.51-2.65) 
Eczema in first 
year of life 
0.90 
(0.53-1.50) 
0.95 
(0.57-1.58) 
6 months Eczema between 
6 months and 1 
year* 
0.98 
(0.45-2.10) 
1.06 
(0.43-2.61) 
#Adjusted for family history of allergy, ethnicity, number of siblings, maternal vitamin D 
supplementation, domestic pets and formula feeding at six and twelve months. 
*Within the random subcohort (n=274), eczema identified between six and twelve months compared 
with infants who did not develop eczema. Infants with eczema identified at less than six months of age 
were excluded (n=19). 
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6.5.6 Vitamin D status and eczema 
Within the random subcohort there was no evidence of an association between VDI at either 
birth (aRR 0.88, 95% CI 0.54-1.43) or six months (aRR 0.84, 95% CI 0.33-2.14) and subsequent 
eczema (Figure 6.7 & Table 6.6). Adjustment for potential confounders made <10% difference 
to the estimated risk ratios. Analysis using deseasonalised 25(OH)D3 also indicated no 
association between VDI and eczema (Figure 6.8 & Table 6.6). 
 
 
Figure 6.7: Association between VDI and eczema.  ^Eczema identified during the first year of life in 
infants compared to infants without eczema in the random subcohort (n=274). 
* Eczema identified between six and twelve months compared with infants who did not develop 
eczema within the random subcohort (n=274). Infants with eczema identified at six months of age or 
earlier were excluded (n=19). 
Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets and formula feeding 
at six months. Whiskers represent 95% CI for RR estimates. 
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Figure 6.8: Association between deseasonalised VDI and eczema. ^Eczema identified during the first 
year of life in infants compared to infants without eczema in the random subcohort (n=274). 
* Within the random subcohort (n=274) Eczema identified between six and twelve months compared 
with infants who did not develop eczema. Infants with eczema identified at six months of age or 
earlier were excluded (n=19). 
Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets and, formula 
feeding at six and twelve months. Whiskers represent 95% CI for RR estimates. 
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Table 6.6: Association between low VDS and eczema. 
 Non-deseasonalised Vitamin D3 Deseasonalised  
Vitamin D3 
Time point 25(OH)D3 
measured 
(%) 
25(OH)D3 
nmol/L, 
mean (SD) 
25(OH)D3 
mean diff 
nmol/L 
(95% CI) 
25(OH)D3 
<50 nmol 
(%) 
Relative Risk 
Ratio 
(95% CI) 
¥Adjusted 
Relative Risk 
Ratio 
(95% CI) 
Relative Risk 
Ratio 
(95% CI) 
¥Adjusted 
Relative Risk 
Ratio 
(95% CI) 
Maternal Eczema onset up 
to 6 months 
21/21 
(100%) 
89.7 
(28.3) 
-2.41 
(-14.02-9.19) 
1/21 
(5%) 
0.49 
(0.07-3.54) 
0.45 
(0.06-3.47) 
0.61 
(0.09-4.32) 
0.53 
(0.06-4.39) 
Controls 234/236 
(99%) 
87.3 
(25.6) 
22/234 
(9%) 
Eczema in first 
year of life 
58/58 
(100%) 
87.5 
(26.5) 
0.46 
(-6.97-7.90) 
5/58 
(9%) 
0.49 
(0.13-1.83) 
0.41 
(0.10-1.64) 
0.38 
(0.06-2.50) 
0.32 
(0.04-2.25) 
Controls 214/216 
(86%) 
87.9 
(25.2) 
18/214 
(8%) 
Cord Blood Eczema onset up 
to 6 months 
21/21 
(100%) 
56.1 
(23.5) 
-2.16 
(-11.00-6.69) 
11/21 
(46%) 
1.39 
(0.62-3.14) 
1.35 
(0.61-2.99) 
1.91 
(0.82-4.42) 
1.95 
(0.86-4.45) 
Controls 196/236 
(83%) 
54.0 
(19.1) 
84/196 
(43%) 
Eczema in first 
year of life 
51/58 
(88%) 
54.8 
(20.9) 
-1.80 
(-7.90-4.31) 
21/51 
(42%) 
0.84 
(0.51-1.38) 
0.88 
(0.54-1.43) 
1.39 
(0.85-2.26) 
1.49 
(0.92-2.41)  
Controls 182/216 
(84%) 
53.0 
(19.2) 
84/182 
(46%) 
6 Months Eczema between 
6 months and 1 
year* 
33/37 
(89%) 
75.9 
(25.1) 
-7.18 
(-17.34-2.98) 
7/33 
(21%) 
0.82 
(0.38-1.78) 
0.84 
(0.33-2.14) 
0.73 
(0.30-1.78) 
0.74 
(0.27-2.02) 
Controls 167/201 
(83%) 
68.7 
(27.4) 
42/201 
(21%) 
*Within the random subcohort (n=274) eczema identified between six and twelve months compared with infants who did not develop eczema. Infants with 
eczema identified at less than six months of age were excluded (n=19). ¥Adjusted for family history of allergy, ethnicity, number of siblings, maternal vitamin D 
supplementation, domestic pets and formula feeding at six months. 
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6.5.7 Ambient UVR exposure dose and IgE-mediated food allergy 
In the full cohort analysis there was no evidence of a prospective association between UVR 
exposure dose at individual time points, and food allergy at one year of age (Figure 6.9 & Table 
6.7). Similarly, there was no evidence of a prospective association between maternal or infant 
UVR exposure dose and eczema in the first year of life (Figure 6.10 & Table 6.8). There was no 
evidence that the relationship between UVR exposure and food allergy was modified by any 
level of sunscreen use (p=0.32 for moderate UVR exposure, p=0.92 for high UVR exposure). 
 
 
Figure 6.9: Adjusted association between UVR exposure dose and clinically-proven food allergy at one 
year in the whole cohort. Y axis: UVR exposure divided into quintiles at Trimester 1, Trimester 2, 6 and 
12 months and lowest quintile used as baseline comparison group. 
^At 4 weeks 40% of infants were reported to have minimal or no exposure to direct sunlight so UVR 
exposure dose at 4 weeks is divided into quartiles and lowest quartile used as baseline comparison 
group. 
Adjusted for family history of allergy, ethnicity, number of siblings and domestic pets. Whiskers 
represent 95% CI for RR estimates.  
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Table 6.7: Association between UVR exposure dose and clinically-proven food allergy in the whole 
cohort. 
Ambient UVR 
exposure 
time point 
Whole cohort 
Cases/ 
cohort 
(n) 
Relative risk 
ratio 
(95% CI) 
×Adjusted 
relative risk 
ratio 
(95% CI) 
Trimester one-
lowest quintile 
12/137 1 (ref) 1 (ref) 
2 19/136 1.67 
(0.82-3.39) 
1.63 
(0.82-3.24) 
3 10/157 0.81 
(0.63-1.86) 
0.69 
(0.30-1.57) 
4 15/145 1.27 
(0.61-2.69) 
1.18 
(0.56-2.47) 
5-highest 4/141 0.38 
(0.12-1.16) 
0.34 
(0.11-1.03) 
Trimester two-
lowest quintile 
17/138 1 (ref) 1 (ref) 
2 13/140 0.82 
(0.41-1.64) 
0.83 
(0.42-1.63) 
3 9/141 0.58 
(0.27-1.27) 
0.56 
(0.26-1.20) 
4 9/151 0.55 
(0.25-1.20) 
0.54 
(0.25-1.15) 
5-highest 12/145 0.74 
(0.36-1.50) 
0.73 
(0.36-1.48) 
Four weeks-
lowest quartile 
21/286 1 (ref) 1 (ref) 
2 14/134 1.45 
(0.76-2.79) 
1.24 
(0.65-2.36) 
3 15/148 1.40 
(0.74-2.66) 
1.21 
(0.64-2.28) 
4-highest 11/130 1.20 
(0.59-2.44) 
1.27 
(0.63-2.57) 
Six months-
lowest quintile 
19/162 1 (ref) 1 (ref) 
2 5/107 0.45 
(0.17-1.17) 
0.51 
(0.20-1.34) 
3 12/143 0.78 
(0.39-1.57) 
0.79  
(0.40-1.55) 
4 12/142 0.80 
(0.40-1.60) 
0.85 
(0.43-1.69) 
5-highest 9/139 0.61 
(0.28-1.32) 
0.60 
(0.28-1.31) 
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Ambient UVR 
exposure 
time point 
Whole cohort 
Cases/ 
cohort 
(n) 
Relative risk 
ratio 
(95% CI) 
×Adjusted 
relative risk 
ratio 
(95% CI) 
Twelve 
months-lowest 
quintile 
11/144 1 (ref) 1 (ref)) 
2 14/139 1.31 
(0.62-2.80) 
1.49 
(0.71-3.13) 
3 13/139 1.15 
(0.53-2.54) 
1.23 
(0.57-2.67) 
4 14/147 1.27 
(0.60-2.72) 
1.29 
(0.61-2.76) 
5-highest 7/148 0.68 
(0.27-1.69) 
0.81 
(0.33-1.99) 
Cumulative 
postnatal UVR 
exposure-low 
12/134 1 (ref) 1 (ref) 
Cumulative 
postnatal UVR 
exposure-
moderate 
33/395 1.02 
(0.53-1.97) 
1.02 
(0.53-1.96) 
Cumulative 
postnatal UVR 
exposure-high 
10/136 0.90 
(0.40-2.06) 
0.92 
(0.41-2.06) 
Ambient UVR exposure was divided into quintiles at trimester one, two, six months and twelve months. 
At four weeks 40% of infants were reported to have minimal or no exposure to direct sunlight so UVR 
exposure dose at four weeks is divided into quartiles. Cumulative postnatal UVR exposure was a 
categorical variable based on the cumulative amount of UVR exposure at various time points in the first 
year of life. 
×Adjusted for family history of allergy, ethnicity, number of siblings and domestic pets.  
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Figure 6.10: Adjusted association between UVR exposure dose and eczema in the whole cohort. ^At 4 
weeks 40% of infants were reported to have minimal or no exposure to direct sunlight so UVR 
exposure dose at 4 weeks is divided into quartiles and lowest quartile used baseline comparison 
group. 
* Within the whole cohort, eczema identified between six and twelve months compared with infants 
who did not develop eczema. Infants with eczema identified at six months of age or earlier were 
excluded (n=70). 
Adjusted for family history of allergy, ethnicity, number of siblings and domestic pets. Whiskers 
represent 95% CI for RR estimates.  
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Table 6.8: Association between UVR exposure dose and eczema in the whole cohort. 
Time point  
ambient UVR 
exposure 
Whole cohort 
Case/controls (n)  Relative Risk 
Ratio  
(95% CI) 
πAdjusted 
Relative 
Risk Ratio 
(95% CI) 
Trimester one-lowest 
quintile 
38/120 1 (ref) 1 (ref) 
2 41/115 1.12 
(0.76-1.65) 
1.12 
(0.77-1.62) 
3 35/136 0.88 
(0.58-1.32) 
0.81 
(0.54-1.21) 
4 40/118 1.08 
(0.73-1.59) 
1.06 
(0.73-1.55) 
5-highest 36/114 1.03 
(0.69-1.54) 
0.99 
(0.67-1.46) 
Trimester two-lowest 
quintile 
45/110. 1 (ref) 1 (ref) 
2 34/121 0.77 
(0.52-1.13) 
0.78 
(0.54-1.13) 
3 31/133 0.67 
(0.45-1.00) 
0.65 
(0.44-0.97) 
4 40/113 0.92 
(0.64-1.32) 
0.89 
(0.63-1.27) 
5-highest 39/126 0.82 
(0.57-1.19) 
0.84 
(0.59-1.20) 
Four weeks 
-lowest quartile 
79/236 1 (ref) 1 (ref) 
2 36/118 0.94 
(0.67-1.33) 
0.91 
(0.65-1.28) 
3 37/123 0.92 
(0.66-1.30) 
0.91 
(0.65-1.26) 
4-highest 33/114 0.91 
(0.64-1.30) 
0.92 
(0.65-1.31) 
Six months-lowest 
quintile 
29/143* 1 (ref)  1 (ref) 
2 11/94 0.62 
(0.32-1.19) 
0.65 
(0.34-1.25) 
3 21/124 0.87 
(0.52-1.45) 
0.85 
(0.51-1.41) 
4 24/127 0.97 
(0.60-1.59) 
1.01 
(0.63-1.65) 
5-highest 15/129 0.62 
(0.35-1.11) 
0.60 
(0.34-1.07) 
Ambient UVR exposure was divided into quintiles at trimester one, two and six months. At four weeks 
40% of infants were reported to have minimal or no exposure to direct sunlight so UVR exposure dose at 
four weeks is divided into quartiles.*Eczema identified between six and twelve months compared with 
infants who did not develop eczema. Infants with eczema identified at less than six months of age were 
excluded.π Adjusted for family history of allergy, ethnicity, number of siblings and domestic pets. 
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6.5.8 Vitamin D status and food sensitisation 
Food sensitisation at year 1 defined as a SPT wheal size 3 mm or greater than the negative 
control: There was no evidence that VDI at any time point was associated with food 
sensitisation (Table 6.9). Food sensitisation at year 1 defined as a SPT wheal size 2 mm or 
greater than the negative control: There was no evidence of an association between VDI during 
pregnancy or at birth and food sensitisation. There was however weak evidence of associations 
between VDI at six (p=0.04) and twelve months (p=0.04) and food sensitisation defined using 
this more inclusive threshold (≥2 mm) (Table 6.10). 
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Table 6.9: Association between low VDS and food sensitisation (≥3 mm SPT). 
 Non-deseasonalised Vitamin D3 Deseasonalised  
Vitamin D3 
Time point 25(OH)D3 
measured 
(%) 
25(OH)D3 
nmol/L, 
mean (SD) 
25(OH)D3     
Mean diff 
nmol/L,    
(95% CI) 
25(OH)D3 
<50nmol/L 
(%) 
Relative Risk 
Ratio 
(95% CI) 
≠Adjusted 
Relative Risk 
Ratio  
(95% CI) 
Relative Risk 
Ratio 
(95% CI) 
≠Adjusted 
Relative   
Risk Ratio 
(95% CI) 
Maternal Cases 60/62 
(97%) 
80.6 
(24.3) 
7.1 
(-0.3-14.4) 
5/60 
(8%) 
0.88 
(0.31-2.51) 
1.01 
(0.36-2.83) 
1.39 
(0.43-4.46) 
1.56 
(0.50-4.83) 
Controls 220/222 
(99%) 
87.6 
(26.0) 
21/222 
(9%) 
Cord blood Cases 53/62 
(85%) 
50.7 
(19.4) 
3.2 
(-2.7-9.2) 
26/53 
(49%) 
1.54 
(0.83-2.85) 
1.65 
(0.89-3.08) 
1.17 
(0.63-2.18) 
1.33 
(0.71-2.51) 
Controls 188/222 
(85%) 
53.9 
(19.5) 
84/188 
(45%) 
6 months Cases 52/62 
(84%) 
74.5 
(22.4 ) 
-5.6 
(-13.6-2.4) 
8/52 
(15%) 
0.38 
(0.17-0.84) 
0.43 
(0.15-1.21) 
0.65 
(0.27-1.54) 
0.76 
(0.25-2.36) 
Controls 189/222 
(85%) 
68.9 
(26.9) 
47/189 
(25%) 
1 year Cases 46/62 
(75%) 
65.9 
(19.9) 
1.6 
(-4.9-8.1) 
11/46 
(24%) 
2.09 
(0.98-4.48) 
4.64 
(0.73-29.67) 
1.10 
(0.43-2.80) 
1.24 
(0.42-3.65) 
Controls 192/222 
(86%) 
67.5 
(20.0) 
31/192 
(16%) 
≠Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets, formula feeding at six and twelve months and maternal vitamin D 
supplementation. 
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Table 6.10: Association between low VDS and food sensitisation (≥2 mm SPT). 
 Non-deseasonalised Vitamin D3 Deseasonalised  
Vitamin D3 
Time point 25(OH)D3 
measured 
(%) 
25(OH)D3 
nmol/L, 
mean (SD) 
25(OH)D3 
Mean diff 
nmol/L, 
(95% CI) 
25(OH)D3 
<50nmol/L 
(%) 
Relative Risk 
Ratio  
(95% CI) 
≠Adjusted 
Relative Risk 
Ratio  
(95% CI) 
Relative Risk 
Ratio  
(95% CI) 
≠Adjusted 
Relative   
Risk Ratio 
(95% CI) 
Maternal Cases 91/93 
(98%) 
86.1 
(26.6) 
0.9 
(-5.4-7.2) 
6/91 
(7%) 
0.54 
(0.19-1.50) 
0.61 
(0.22-1.68) 
0.85 
(0.27-2.66) 
0.93 
(0.30-2.87) 
Controls 217/219 
(99%) 
86.9 
(25.2) 
21/217 
(9%) 
Cord blood Cases 81/93 
(87%) 
54.5 
(20.2) 
-0.9 
(-6.0-4.1) 
35/81 
(43%) 
0.94 
(0.59-1.50) 
0.98 
(0.61-1.58) 
0.71 
(0.44-1.15) 
0.74 
(0.44-1.24) 
Controls 185/219 
(85%) 
53.5 
(18.8) 
83/185 
(45%) 
6 months Cases 78/93 
(84%) 
73.3 
(21.6) 
-4.5 
(-11.3-2.3) 
12/78 
(15%) 
0.45 
(0.17-0.84) 
0.42 
(0.18-0.97) 
0.69 
(0.36-1.35) 
0.70 
(0.32-1.50) 
Controls 186/219 
(85%) 
68.8 
(27.1) 
47/186 
(25%) 
1 year Cases 75/93 
(81%) 
63.3 
(19.8) 
4.35 
(-1.0-9.7) 
19/75 
(25%) 
1.56 
(0.90-2.71) 
2.46 
(1.02-5.91) 
1.24 
(0.65-2.36) 
1.39 
(0.65-2.99) 
Controls 189/219 
(86%) 
67.7 
(20.0) 
30/189 
(16%) 
≠Adjusted for family history of allergy, ethnicity, number of siblings, domestic pets, formula feeding at six and twelve months and maternal vitamin D 
supplementation.
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6.6 Discussion 
This is the first study to investigate 25(OH)D3 measured during the first six months of infancy in 
relation to clinically-proven food allergy at one year of age. In a predominantly Caucasian 
cohort, among whom raw egg was the most common food allergy, there was no evidence of an 
association between infant VDI during the first six months of infancy and IgE-mediated food 
allergy at one year of age or eczema. There was also no evidence of a positive association 
between estimated UVR exposure dose and either food allergy or eczema.  
VDI was present in almost half of the infants at birth and a quarter of infants at six months of 
age. Egg avoidance, the absence of formula feeding and a greater number of siblings were each 
associated with increased risk of VDI during infancy. However, a large proportion of the 
variation in VDS remained unexplained and unmeasured genetic factors are likely to be 
important (370). Food allergy prevalence, although less common than observed in the 
Australian HealthNuts study (3), was still substantially higher than recent reports from Europe 
with similar outcomes (92, 333). 
Over the last decade there has been intense interest in the potential relationship between VDI 
and food allergy, given a range of ecological findings and a wealth of mechanistic studies 
regarding the influence of 25(OH)D3 on gut epithelial integrity (39, 374, 375) and immune 
function (38). However, the data from studies relating directly measured 25(OH)D or 25(OH)D3 
during early infancy to various markers of allergic disease are conflicting. Early papers reported 
positive associations between low cord blood 25(OH)D and subsequent allergic sensitisation 
(47, 48) and eczema (50). Another study using cord blood 25(OH)D3 also reported similar 
associations with eczema (44). More recent studies have been unable to replicate these 
positive associations using either 25(OH)D (49, 51) or 25(OH)D3 (42) as the exposure. The 
current study extends the body of evidence against a prospective association between VDI and 
allergy by measuring 25(OH)D3 at two time points during early infancy and including the more 
robust and clinically relevant measure of clinically-proven food allergy status. 
Birth 25(OH)D3 was generally around sixty percent of the maternal level, consistent with 
previous studies (376). Thus relatively lower 25(OH)D3 levels in cord blood may be 
physiological, and it is uncertain whether a cut-off of 50 nmol/L to define VDI in cord blood is 
appropriate, particularly as this threshold is based predominantly on markers of bone health in 
adults (156) and an appropriate immune related level remains uncertain. Accordingly, the 
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current study explored a range of threshold levels including 25(OH)D3 <25 nmol/L as well as 
25(OH)D3 quintiles, but remained unable to identify a relationship between cord 25(OH)D3 and 
food allergy at one year of age. 
It has been proposed that 25(OH)D3 status may be particularly important during the period of 
introduction of dietary solids (12, 323). A small study has previously suggested 25(OH)D3 may 
promote immune tolerance during initial exposure to solids (377), but the current study is the 
first to relate 25(OH)D3 around the time of weaning to the clinically relevant outcome of 
clinically-proven food allergy. There was no evidence of an association between VDI at six 
months and food allergy at one year of age. 
The lack of association between VDI and food allergy at each timepoint with the summation of 
C3-epi-25(OH)D3 and 25(OH)D3 is notable. C3-epi-25(OH)D3 levels are highest in the infant 
population and decrease over the first year of life (378). C3-epi-25(OH)D3 has effects on 
parathyroid hormone secretion, but it is unknown whether it possesses other physiological 
functions of  25(OH)D3 (379), and further work is required to delineate the potential relevance 
of C3-epi-25(OH)D3 to clinical outcomes. 
Whilst there is consistent evidence of an association between latitudes further from the 
equator and various proxy markers of food allergy prevalence (36, 41, 164, 178), the current 
study was unable to demonstrate an association between UVR exposure measured at the 
individual level and allergic outcomes. The UVR exposure dose measure, which combined 
ambient UVR and parent-reported time in the sun (370) was associated with 25(OH)D3 at each 
time point, and is likely to provide a more accurate estimate than latitude alone, which may be 
a proxy for a wide range of factors including ethnicity, genetics and microbial environment. The 
findings, therefore suggest that the relationship between latitude and allergic disease may 
relate to factors other than 25(OH)D3  status. 
The strengths of the current study include the use of a population-derived cohort with 
adequate retention rates; measurement of infant 25(OH)D3 at both birth and during the 
introduction of solids; delineation of food allergy status by formal food challenge; and detailed 
measurement of relevant covariates, including UVR exposure at the individual level. The 
current study was also able to conduct relevant sensitivity analyses and tests of effect 
modification, and show that these did not substantially alter the findings. The predominantly 
Caucasian cohort limits the generalisability of the findings, and this may be important in the 
context of growing evidence that the relationship between either 25(OH)D (196) or 25(OH)D3 
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(184) and food allergy may be modified by genetic factors. On the other hand, the relative 
homogeneity of the BIS cohort assists internal validity. Twins were included in the cohort, 
which may be regarded as a potential limitation. Sensitivity analyses conducted excluding twins 
(data not shown) had negligible impact on the risk ratios. The current study did not measure 
free 25(OH)D and vitamin D binding protein which limited the ability to investigate the role of 
bioavailable 25(OH)D. The statistical power was limited by the number of food allergy cases, 
and it is important to recognise that the 95% confidence intervals around the point estimates 
did not exclude potential effects of a relative risk up to about two-fold. It is also noteworthy 
that there were only 12 cases of peanut allergy; and the aRR regarding a cross-sectional 
association between VDI and food allergy at one year is consistent with the positive association 
observed among infants of Australian parents in the HealthNuts study (21). The current study 
was unable to conduct a meaningful analysis of the relationship between 25(OH)D3 status and 
severe eczema, as there were very few children with severe eczema in the current study.  
In conclusion, in a predominantly Caucasian cohort in which egg was the commonest food 
allergy, there was no evidence of a longitudinal association between either VDI during the first 
six months of infancy, or UVR exposure and clinically-proven food allergy at one year of age or 
eczema. The findings require replication in larger observational studies and/or clinical trials, 
including a sufficient number of children with peanut allergy, and relating directly measured 
25(OH)D3 to robust measures of clinically relevant food allergy status. A current example is the 
VITALITY randomised control trial (NCT02112734) in Australia examining infant 25 (OH)D3 
supplementation in relation to challenge-proven food allergy at one year (380).  Until such 
studies are completed, the balance of current evidence does not support the widespread 
implementation of routine vitamin D supplementation during early infancy for the purpose of 
preventing allergic outcomes.  
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CHAPTER 7 STUDY 4: MICROBIAL EXPOSURE AND RISK OF IGE-
MEDIATED FOOD ALLERGY IN INFANCY. 
7.1 Introductory Statement  
This Chapter describes Study 4, the aim of which was to investigate the potential relationship 
between antenatal and early life microbial exposures and risk of IgE-mediated food allergy at 
one year of age. The hypothesis tested within this chapter was that early life microbial 
exposures are associated with a reduced risk of IgE-mediated food allergy in the first year of 
life. 
7.2 Introduction 
The hygiene hypothesis, which has stimulated a substantial proportion of research into the 
allergic disease epidemic over recent decades, proposes that insufficient early life exposure to 
environmental microbes leads to the development of a naïve immune system primed for hyper-
responsiveness (57, 67). In the case of childhood food allergy this has resulted in increased 
numbers of food related anaphylaxis admissions, particularly among children less than five 
years old (4, 5).  
The original ‘hygiene hypothesis’ was published by Strachan in 1989 (57). He demonstrated an 
association between larger family size and decreased allergic rhinitis prevalence among 
younger siblings, and he hypothesised that this was due to a greater exposure to childhood 
infections in early life (57). Subsequently, an increased number of older siblings have been 
associated with a reduced risk of egg allergy (20), asthma (56), atopy (58) and eczema (59).  
The mechanism underlying the hygiene hypothesis has been revised over the last twenty years 
with the emphasis changing from early life multiple infection exposure to the composition 
of/presence of non-pathogenic commensal flora (67). In particular changes in the human gut 
microbiome during early life (232, 381) may influence the development of the foetal/ infant 
immune system and subsequent hyper-responsiveness (67). It is unknown whether this 
influence is an in utero microbiome immune programming process, a perinatal maternal 
vaginal-enteric microbiome process or a postnatal event (382).  
Proxy markers of early life microbial exposures, such as domestic pet ownership and siblings 
(69), farming and livestock exposure (63, 264) and Caesarean section delivery (247, 248), have 
been associated with alterations in the infant gut microbiota profile. In turn, dog ownership 
(20, 60), siblings (20) and farming exposure (62, 295, 297) have been associated with a reduced 
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risk of infant allergy, while there is conflicting evidence regarding Caesarean section delivery 
and infant food allergy risk (383). The theoretical background and evidence for these factors are 
detailed in the Literature Review, Chapter 2, section 2.12.  
The evidence regarding the potential influence of maternal GBS colonisation in pregnancy on 
both the composition of the gut microbiome and risk of food allergy among the offspring is 
conflicted and is summarised in the Literature Review, Chapter 2, section 2.12.3. Maternal GBS 
status in pregnancy and intrapartum antibiotics are correlated (384), as intrapartum antibiotics 
are routinely administered to GBS colonised mothers in labour to minimise GBS transmission to 
the neonate (279). This perinatal antibiotic use is associated with lower counts of bacteria in 
the infant gut, including Bifidobacteria (258), and antibiotic exposure has been associated with 
an increased risk of subsequent allergy in infancy (281, 385). Maternal GBS colonisation as a 
measure of microbial exposure may simply be a proxy marker for the effect of intrapartum 
antibiotics on the maternal and infant microbiome (258, 386). Alternatively, the presence of 
GBS may represent a general maternal vaginal-enteric microbiome profile, compared to GBS 
negative women (280).  
Previous studies regarding the relationship between early life microbial exposures and 
subsequent IgE-mediated food allergy have been limited by a scarcity of longitudinally 
assembled data (325), including biospecimens in combination with a robust assessment of 
clinically relevant food allergy status. The BIS cohort provides the ideal setting to examine this 
relationship. The aim of this Chapter is to investigate the role of microbial exposures through 
putative early life proxy markers in pregnancy and in infancy, in relation to IgE-mediated food 
allergy at one year of age. 
7.3 Methods  
This study investigated the relationship between proxy markers of microbial exposure and 
clinically-proven IgE-mediated food allergy within BIS. An overview of BIS and general methods 
has been provided earlier in the thesis in Chapter 3. 
7.4 Exposures 
The exposures used in the Chapter analyses, pet ownership, number of siblings, mode of 
delivery, maternal GBS status and antibiotics in labour were determined from hospital medical 
records and questionnaire data compiled through regular BIS participant reviews prenatally and 
in the first year of life and are defined in Chapter 3, section 3.4.4. As pet species and location 
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may confer differing changes in the microbiome and variable risks to food allergy development, 
individual pet species were analysed in relation to food allergy (387). 
7.5 Outcome 
The outcome of clinically-proven IgE-mediated food allergy was determined at one year, 
through initial skin prick testing and subsequent formal open oral food challenge, which is 
described in detail in Chapter 3, section 3.4.2. 
7.6 Statistical analysis  
Multiple logistic regression models were fitted to estimate odds ratios for associations between 
environmental microbial factors and subsequent clinically-proven food allergy or eczema (355). 
Family history of allergy, ethnicity and SES were considered a priori to be included as covariates 
in the model as potential confounders, given (a) they have each been previously related to both 
environmental microbial risk factors and allergic disease, and (b) it is relatively unlikely that the 
relationship between each of these variables and the allergic outcomes is mediated by 
microbial factors. Maternal age, other pets, number of siblings or antibiotics in labour were 
retained in the model if they made a greater than 10% change to the odds ratio point estimate. 
Analyses were performed using Stata (version 14.1, College Station, Texas). Missing data were 
not imputed in the analysis. 
7.7 Results 
7.7.1 Pet ownership in pregnancy and risk of food allergy among the offspring 
In BIS 74% (789/1069) of the inception cohort owned a pet during pregnancy: fifty five percent 
(595/1069) had a dog and 25% (267/1068) had a cat. Among those with a dog, 68% (402/589) 
were kept indoors some of the time (Table 7.1). 
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Table 7.1: Baseline participant characteristics for the BIS microbial exposures and food allergy study. 
Characteristics Inception birth cohort  
(n=1074) 
Food allergic  
(n=61) 
Sex of child 
male 
female 
 
557 (51.9%) 
517 (48.1%) 
 
34 (55.7%) 
27 (44.3%) 
Twins 20 (1.9%) 2 (3%) 
Maternal country of birth 
Australia 
other 
unknown 
 
946 (88%)  
107 (10%) 
21   (2%) 
 
56 (91.8%) 
5 (8.2%) 
0 (0.0%) 
Paternal country of birth 
Australia 
other  
unknown 
 
923 (85.9%) 
109 (10.2%) 
42   (3.9%) 
 
49 (80.3%) 
8 (13.1%) 
4 (6.6%) 
Participant Caucasian ethnicity 
yes 
no 
unknown 
 
772 (71.9%) 
299 (27.8%) 
3 (0.3%) 
 
43 (70.5%) 
17 (27.9%) 
1 (1.6%) 
Number of siblings 
0 
1 
2 
3 or more 
 
453 (42.2%) 
383 (35.7%) 
183 (17.0%) 
55 (5.1%) 
 
22 (36.07%) 
28 (45.9%) 
10 (16.3%) 
1 (1.6%) 
Family history in a first degree 
relative of 
asthma 
hay fever 
eczema 
food allergy 
 
 
542 (50.5%) 
674 (62.8%) 
480 (44.7%) 
265 (24.7%) 
 
 
43 (70.5%) 
47 (77.1%) 
40 (65.6%) 
16 (26.2%) 
Livestock ownership 
yes 
no 
unknown 
 
73 (6.8%) 
985 (91.7%) 
16 (1.5%) 
 
1 (1.6%) 
59 (96.7%) 
1 (1.6%) 
Pet ownership in pregnancy  
yes 
no 
unknown 
 
789 (73.5%) 
280 (26.1%) 
5     (0.5%) 
 
34 (55.7%) 
27 (44.3%) 
0   (0.0%) 
Pet ownership in infancy 
yes 
No 
unknown 
 
606 (56.4%) 
257 (23.9%) 
211 (19.7%) 
 
27 (44.3%) 
32 (52.5%) 
2   (3.3%) 
Dog ownership in pregnancy  
yes 
no 
unknown 
 
595 (55.4%) 
474 (44.1%) 
5     (0.5%) 
 
21 (34.4%) 
40 (65.6%) 
0   (0.0%) 
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Characteristics Inception birth cohort  
(n=1074) 
Food allergic  
(n=61) 
Dogs location in pregnancy 
outdoor 
indoor  
both  
unknown 
 
187 (31.4%) 
80   (13.5%) 
322 (54.1%) 
6     (1.0%) 
 
10 (47.6%) 
0   (0.0%) 
10 (47.6%) 
1   (4.8%) 
Dog ownership in infancy  
yes 
no 
unknown 
 
470 (43.8%) 
393 (36.6%) 
211 (19.6%) 
 
19 (31.1%) 
40 (65.6%) 
2   (3.3%) 
Dogs location in infancy 
outdoor 
indoor  
both  
unknown 
 
162 (34.5%) 
34   (7.2%) 
271 (57.7%) 
3     (0.6%) 
 
8 (42.1%) 
1 (5.3%) 
10 (52.6%) 
0   (0.0%) 
Cat ownership in pregnancy  
yes 
no 
unknown 
 
267 (24.9%) 
801 (74.6%) 
6 (0.5%) 
 
12 (19.7%) 
49 (80.3%) 
0   (0.0%) 
Cats location in pregnancy 
outdoor 
indoor  
both  
unknown 
 
49 (18.3%) 
52 (19.5%) 
165 (61.8%) 
1     (0.4%) 
 
2 (16.7%) 
2 (16.7%) 
8 (66.6%) 
0 (0.0%) 
Cat ownership in infancy  
yes 
no 
unknown 
 
203 (18.9%) 
660 (61.5%) 
211 (19.6%) 
 
9   (82.0%) 
50 (14.7%) 
2   (3.3%) 
Cats location in infancy 
outdoor 
indoor  
both  
unknown 
 
33 (16.3%) 
24 (11.8%) 
144 (70.9%) 
2 (1.0%) 
 
2 (22.2%) 
1 (11.1%) 
6 (66.7%) 
0 (0.0%) 
GBS positive in pregnancy 
yes 
no 
unknown 
 
212 (19.7%) 
795 (74.0%) 
67   (6.2%) 
 
5 (8.2%) 
56 (91.8%) 
0 (0.0%) 
Antibiotics in labour 
yes 
no 
unknown 
 
501 (46.6%) 
566 (52.7%) 
7     (0.7%) 
 
25 (41.0%) 
36 (59.0%) 
0   (0.0%) 
Mode of delivery 
vaginal  
emergency Caesarean 
elective Caesarean 
unknown 
 
739 (68.8%) 
154 (14.3%) 
178 (16.6%) 
3   (0.3%) 
 
41 (67.2%) 
10 (16.4%) 
10 (16.4%) 
0 (0.0%) 
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Figure 7.1: Summary of pet ownership among pregnant women in BIS represented by a Venn diagram.  
 
 
Figure 7.2: Summary of pet ownership in infancy in BIS represented by a Venn diagram.  
 
Pet ownership in pregnancy was associated with decreased offspring food allergy (aOR 0.44, 
95% CI 0.25-0.77, p=0.004). Using no dogs as the reference group, there was strong evidence of 
association between pet dog ownership in pregnancy and decreased offspring allergy (aOR 
0.40, 95 %CI 0.23-0.71, p=0.002) (Table 7.2). To investigate a dose effect, dogs were stratified 
by indoor or outdoor location. An indoor dog was associated with a greater decrease in 
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offspring food allergy (aOR 0.26, 95% CI 0.12-0.56, p=<0.001) than an outdoor dog (aOR 0.65, 
95% CI 0.31-1.36, p=0.25) (Table 7.2 & Figure 7.3). 
 
Table 7.2: Associations between pet exposures in pregnancy and IgE-mediated food allergy among the 
offspring. 
 Clinically-proven food allergy at one year 
Exposure  
variable 
 Unadjusted Adjusted 
 N OR      95% CI P value aOR      95% CI P value 
No pets 203/759 1 (ref)  1 (ref)  
Pets  416/759 0.42 (0.24-0.72) 0.002 0.44 (0.25-0.77) 0.004 
      
Dogs vs no dogs      
No dog 342/758 1 (ref)  1 (ref)  
Pet dog 416/758 0.40 (0.23-0.71) 0.002 0.40 (0.23-0.71) 0.002 
      
Indoor/outdoor dog 
vs no dogs 
     
No dogs 342/755 1 (ref)  1 (ref)  
Pet dog (outdoor) 133/755 0.65 (0.31-1.35) 0.25 0.65 (0.31-1.36) 0.25 
Pet dog (indoor) 280/755 0.27 (0.13-0.56) <0.001 0.26 (0.12-0.56) <0.001 
      
Cats vs no cats      
No cat 573/758 1 (ref)  1 (ref)  
Pet cat  185/758 0.63 (0.31-1.26) 0.19 0.61 (0.30-1.25) 0.18 
      
Indoor/outdoor Cat 
vs no cats 
     
No cats 573/758 1 (ref)  1 (ref)  
Pet cat (outdoors) 34/758 0.68 (0.16-2.94) 0.61 0.81 (0.18-3.58) 0.78 
Pet cat (indoors) 151/758 0.61 (0.28-1.32) 0.21 0.58 (0.26-1.26) 0.17 
Adjusted for family history of allergy, ethnicity, number of siblings and SES. For the model including dog 
ownership as an exposure, cat ownership was included as a potential confounder. 
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Figure 7.3: Maternal dog ownership and IgE-mediated food allergy. Adjusted for family history of 
allergy, ethnicity, number of siblings, SES and cat ownership. Whiskers represent 95% CI for OR 
estimates. 
 
There was no evidence of an association between a pet cat in pregnancy and decreased food 
allergy among offspring (aOR 0.61, 95 %CI 0.30-1.25, p=0.18). Stratifying cat ownership by 
location did not demonstrate a significant dose effect (Table 7.2).  
7.7.2 Pet ownership in infancy and risk of food allergy 
In infancy, 70% (606/863) of the participants at 12 months owned a pet: fifty-four percent 
(470/863) had a dog and 24% (203/863) had a cat. Among those with a dog in infancy, 65% 
(305/467) kept the dog indoors some of the time (Table 7.1).  
With no pets as the reference group, pet ownership in infancy was associated with decreased 
infant food allergy at one year (aOR 0.32, 95% CI 0.18-0.56, p=<0.001) (Table 7.3). There was 
evidence of an association between dog ownership in infancy and decreased infant food allergy 
compared to no dogs (aOR 0.38, 95% CI 0.21-0.68, p=0.001). Stratifying dog ownership in 
infancy into indoor and outdoor dogs demonstrated evidence of a dose effect and a strong 
effect for indoor dogs on decreased infant food allergy. (aOR 0.34, 95% CI 0.16-0.70, p=0.003) 
(Table 7.3 & Figure 7.4). There was weak evidence for cat ownership in infancy and decreased 
infant food allergy (aOR 0.44, 95% CI 0.19-1.00, p=0.05) (Table 7.3). Stratifying cat ownership in 
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infancy into indoor and outdoor cats demonstrated a dose effect with weak evidence for indoor 
cat ownership (aOR 0.36, 95% CI 0.14-0.94, p=0.04) (Table 7.3). Neither a pet bird nor a pet 
fish/reptile in infancy was associated with decreased infant food allergy (data not shown). 
 
Table 7.3: Associations between pet exposures in infancy and subsequent IgE-mediated food allergy. 
 Clinically-proven food allergy at one year 
Exposure 
variable 
 Unadjusted Adjusted 
 N OR      95% CI P value aOR      95% CI P value 
Pets vs no pets      
No pets 223/740 1 (ref)  1 (ref)  
Pets 517/740 0.31 (0.18-0.55) <0.001 0.32 (0.18-0.56) <0.001 
      
Dogs vs no dogs      
No dogs 347/753 1 (ref)  1 (ref)  
Pet dog 406/753 0.38 (0.21-0.68) 0.001 0.38 (0.21-0.68) 0.001 
Indoor/Outdoor Dog 
vs no dogs 
     
No dogs  342/737 1 (ref)  1 (ref)  
Pet dog outdoors 138/737 0.49 (0.22-1.08) 0.08 0.45 (0.20-1.00) 0.05 
Pet dog indoors 257/737 0.32 (0.16-0.66) 0.002 0.34 (0.16-0.70) 0.003 
      
Cats vs no cats      
No cats 565/740 1 (ref)  1 (ref)  
Pet cat 175/740 0.44 (0.20-0.99) 0.05 0.44 (0.19-1.00) 0.05 
      
Indoor/outdoor Cats 
vs no cats 
     
No cats  565/738 1 (ref)  1 (ref)  
Pet cat outdoors 26/738 0.88 (0.20-3.82) 0.86 1.10 (0.24-5.10) 0.90 
Pet cat indoors 147/738 0.37 (0.15-0.95) 0.04 0.36 (0.14-0.94) 0.04 
Adjusted for family history of allergy, ethnicity, number of siblings and SES. For the model including dog 
ownership as an exposure, cat ownership was included as a potential confounder. 
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Figure 7.4: Dog ownership in infancy and IgE-mediated food allergy. Adjusted for family history of 
allergy, ethnicity, number of siblings, SES and cat ownership. Whiskers represent 95% CI for OR 
estimates. 
 
7.7.3 Pet ownership in pregnancy and infancy and timing of exposure effect 
Only six percent (49/854) of families that were retained in the study at one year and responded 
to both questionnaires in pregnancy and at twelve months had a pet in pregnancy only. Three 
percent (25/854) had a pet in infancy only. 
These very small groups with either pets only in pregnancy or in infancy meant there was 
insufficient numbers to deduce whether the protective effect of pet ownership with regards to 
food allergy in infancy related to the prenatal period, the postnatal period or both. 
7.7.4 Livestock exposure and food allergy  
Seven percent (73/1074) of the participants were resident on a farm. There was some 
indication of an association between livestock exposure alone against decreased risk of food 
allergy in infancy. When using no pets/livestock as the reference group, the category of pet or 
livestock ownership in pregnancy was associated with decreased food allergy (aOR 0.42, 95% CI 
0.24-0.74) among the offspring (Table 7.4). There was strong evidence of an association 
between the category of livestock exposure antenatally or pet ownership in infancy and 
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decreased food allergy (aOR 0.31, 95% CI 0.17-0.54, p=<0.001) at one year of age (Table 7.4). 
Using no pets as the reference group, there was evidence of a dose effect for pet ownership 
only (aOR 0.33, 95% CI 0.19-0.58) and the category of combined pet and livestock ownership in 
infancy (aOR 0.13, 95% CI 0.02-0.98) in relation to decreased food allergy at one year of age 
(Table 7.4 & Figure 7.5). 
Table 7.4: Associations between pet/livestock exposure and IgE-mediated food allergy in infancy. 
 Clinically-proven food allergy at one year 
Exposure  
variable 
 Unadjusted Adjusted 
 N OR      95% CI P value aOR      95% CI P value 
Pet/Livestock 
exposure in 
early/mid pregnancy 
     
Livestock/pets vs no 
pets 
     
No pets/livestock  195/778 1 (ref)  1 (ref)  
Pets or livestock 583/778 0.40 (0.24-0.69) 0.001 0.42 (0.24-0.74) 0.003 
Livestock and pets vs 
no pets 
     
No pets/livestock  195/771 1 (ref)  1 (ref)  
Pets only 524/771 0.43 (0.25-0.76) 0.003 0.46 (0.26-0.80)  0.006 
Pets and livestock 52/771 0.14 (0.02-1.05) 0.06 0.15 (0.02-1.13) 0.07 
Livestock vs no 
livestock 
     
No livestock 697/752 1 (ref)  1 (ref)  
Livestock  55/752 0.21 (0.03-1.56) 0.13 0.25 (0.03-1.84) 0.17 
      
Livestock/Pet 
exposure in infancy 
     
Livestock or pets vs 
no pets 
     
No pets/livestock  214/760 1 (ref)  1 (ref)  
Pets or livestock 546/760 0.30 (0.17-0.52) <0.001 0.31 (0.17-0.54) <0.001 
Livestock and pets vs 
no pets 
     
No pets/livestock  214/749 1 (ref)  1 (ref)  
Pets only 486/749 0.32 (0.18-0.57) <0.001 0.33 (0.19-0.58) <0.001 
Pets and livestock 49/749 0.13 (0.03-0.98) 0.05 0.13 (0.02-0.98) 0.05 
Adjusted for family history of allergy, ethnicity, number of siblings, SES. 
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Figure 7.5: Associations between Pets only in infancy/Pets in infancy and livestock exposure and 
infant IgE-mediated food allergy. Adjusted for family history of allergy, ethnicity, number of siblings, 
SES. Whiskers represent 95% CI for OR estimates. 
 
7.7.5 Number of siblings and food allergy 
Fifty-eight per cent (622/1074) of infants had at least one older sibling. Of those with siblings, 
63% (383/622) had one sibling, 29% (183/622) had two siblings and 9% (55/622) had three or 
more siblings (Table 7.5). Using no siblings as the reference group, there was no evidence of an 
association between either one sibling (aOR 1.27, 95% CI 0.69-2.32) or two siblings (aOR 0.94, 
95% CI 0.43-2.06) and decreased infant food allergy (Table 7.5). There was an indication of a 
protective effect for three or more siblings (aOR 0.40, 95% CI 0.05-3.07) against infant food 
allergy development (Table 7.5), but there was no evidence of a trend for increasing number of 
siblings and decreased infant food allergy (p=0.35).  
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Table 7.5: Association between number of siblings and infant IgE-mediated food allergy. 
  Clinically-proven food allergy at one year 
Exposure 
variable 
 Unadjusted Adjusted 
 N OR      95% CI P value aOR      95% CI P value 
Number of 
siblings-none 
312/759 1 (ref)  1 (ref)  
1 sibling 265/759 1.38  (0.76-2.51) 0.29 1.27  (0.69-2.32) 0.44 
2 siblings 144/759 0.99  (0.46-2.15) 0.98 0.94  (0.43-2.06) 0.88 
3 or more 
siblings 
38/759 0.36  (0.05-2.74) 0.32 0.40  (0.05-3.07) 0.38 
Adjusted for family history of allergy, ethnicity, SES and pets in pregnancy. 
7.7.6 Mode of delivery and food allergy 
Sixteen percent (178/1074) of participants had an elective Caesarean section delivery and 14% 
(154/1074) had an emergency Caesarean section delivery (Table 7.1). Using vaginal delivery as 
the reference group, there was no evidence of an association between Caesarean section 
delivery and decreased offspring food allergy (aOR 1.05, 95% CI 0.59-1.87). Stratifying 
Caesarean section delivery into elective and emergency categories did not demonstrate any 
association with offspring food allergy (for elective Caesarean section delivery, aOR 0.88, 95% 
CI 0.41-1.87, for emergency Caesarean section delivery, aOR 1.29, 95% CI 0.60-2.76) (Table 7.6). 
The model included adjustment for family history of allergy, siblings, ethnicity, SES and 
maternal GBS status. 
 
Table 7.6: Associations between mode of delivery and infant IgE-mediated food allergy. 
  Clinically-proven food allergy at one year 
Exposure 
variable 
 Unadjusted Adjusted 
 N OR      95% CI P value aOR      95% CI P value 
Mode of 
delivery 
     
Vaginal  490/714 1 (ref)  1 (ref)  
Caesarean 
section 
224/714 1.17  (0.66-2.05) 0.60 1.05  (0.59-1.87) 0.87 
Vaginal 509/760 1 (ref)  1 (ref)  
Elective 
Caesarean 
section 
140/760 1.03  (0.50-2.14) 0.93 0.88  (0.41-1.87) 0.74 
Emergency 
Caesarean 
section 
111/760 1.34  (0.64-2.78) 0.44 1.29  (0.60-2.76) 0.51 
Adjusted for family history of allergy, ethnicity, number of siblings, SES and maternal GBS status. 
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7.7.7 Maternal GBS status in pregnancy, antibiotics in labour and food allergy 
Twenty percent (212/1007) of participants’ mothers were vaginally colonised with GBS during 
the third trimester (Table 7.1). Forty seven percent (501/1067) of mothers received antibiotics 
during labour and 89% (188/212) of mothers who were GBS colonised received antibiotics in 
labour. Maternal GBS colonisation in pregnancy was associated with decreased offspring food 
allergy (aOR 0.33, 95% CI 0.13-0.87) (Table 7.7).  
Mode of delivery may influence the infant’s exposure to the maternal vaginal-enteric 
microbiome. To further explore whether the association between maternal GBS and offspring 
food allergy relates to intrapartum inoculation with the vaginal-enteric microbiome, infants 
were classified according to mode of delivery and GBS status with Caesarean section delivery 
and negative GBS status (minimal exposure to GBS) as the reference group. No infant who had 
a Caesarean section delivery and a GBS colonised mother subsequently developed food allergy 
at one year meaning only 3 of the 4 groups could be analysed (Table 7.7). There was some 
evidence of an association between vaginal delivery in a GBS positive mother and decreased 
offspring food allergy (aOR 0.39, 95% CI 0.14-1.08) with a dose effect across the three groups 
(Table 7.7 & Figure 7.6). Among infants undergoing labour (vaginal delivery and emergency 
Caesarean section) there was evidence of an association between maternal GBS status in 
pregnancy and decreased offspring allergy (aOR 0.31, 95% CI 0.11-0.91).  
There was no evidence of an association between antibiotics in labour and decreased offspring 
food allergy (aOR 1.19, 95% CI 0.32-4.40) (Table 7.7).  
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Table 7.7: Associations between maternal GBS colonisation in pregnancy and IgE-mediated food 
allergy in infancy. 
 Clinically-proven food allergy at one year 
Exposure 
variable 
 Unadjusted Adjusted 
 N OR        95% CI P value aOR        95% CI P value 
GBS status in 
pregnancy 
     
Maternal 
GBS negative 
567/714 1 (ref)  1 (ref)  
Maternal 
GBS positive 
147/714 0.34  (0.13-0.87) 0.024 0.33  (0.13-0.87) 0.024 
      
GBS status with 
intrapartum 
antibiotics in 
model 
147/713 0.34  (0.13-0.87) 0.024 0.30  (0.09-1.07) 0.06 
      
Antibiotics in 
labour 
339/713 0.82  (0.48-1.41) 0.48 1.19  (0.32-4.40) 0.79 
GBS stratified 
by mode of 
delivery 
     
Vaginal  121/489 0.43  (0.17-1.15) 0.09 0.54  (0.12-2.40) 0.42 
Caesarean 26/224 0 N/A 0 N/A 
 
*C/section + 
GBS negative 
198/713 1 (ref)  1 (ref)  
Vaginal delivery 
+ GBS negative 
369/713 0.87  (0.49-1.57) 0.65 0.85  (0.47-1.54) 0.60 
Vaginal delivery 
+ GBS positive 
121/713 0.38  (0.14-1.10) 0.06 0.39  (0.14-1.08) 0.07 
C/section 
+ GBS positive 
26/713 0 N/A 0 N/A 
*Adjusted for family history of allergy, ethnicity, siblings, SES and antibiotics in labour. 
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Figure 7.6: Association between mode of delivery, maternal GBS colonisation and IgE-mediated food 
allergy in infancy. Adjusted for family history of allergy, ethnicity, siblings, SES and antibiotics in 
labour. Whiskers represent 95% CI for OR estimates. 
 
7.8 Discussion 
This study examined proxy markers for antenatal and postnatal microbial exposure and 
associations with IgE-mediated food allergy at one year of age. The study demonstrated 
evidence of a longitudinal association between pet ownership in pregnancy and decreased 
infant food allergy at one year, and confirmed a cross-sectional association between pet 
ownership in infancy and decreased infant food allergy at one year. There was also an 
association between the category of livestock exposure or pet ownership in infancy and 
decreased infant food allergy. In BIS there was no clear evidence of an association between a 
greater number of siblings and decreased infant food allergy, but there was some indication of 
a protective effect for three or more siblings. There was no evidence of an association between 
Caesarean section delivery and decreased infant food allergy. The study provides the first 
report of an association between maternal GBS colonisation in pregnancy and decreased food 
allergy among offspring. There was some evidence of an association between infants delivered 
vaginally in GBS positive mothers and decreased food allergy at one year of age compared to 
infants delivered by Caesarean section in GBS negative mothers, but it was not possible to 
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determine whether the relationship between maternal GBS status and food allergy among 
offspring was modified by mode of delivery. Thus the study was unable to definitively indicate 
whether the GBS protective effect was due to intrapartum inoculation. 
7.8.1 Significance of findings 
7.8.1.1 Pet ownership and food allergy 
This study has extended existing cross-sectional evidence for a protective effect of pet 
ownership against clinically-proven IgE-mediated food allergy in infancy (20) by demonstrating 
a novel longitudinal prenatal association. The protective effect of pet ownership in each time 
period appeared to be driven primarily by dog ownership, as there was evidence for association 
between dog ownership and decreased infant food allergy even after adjusting for cat 
ownership. There was a dose effect for indoor and outdoor dog location in both pregnancy and 
infancy and decreased infant food allergy (20). There was also evidence of a cross-sectional 
association between indoor cat ownership in infancy and decreased infant food allergy. 
The majority of previous pet exposure and allergy studies have used the weaker outcomes of 
cord blood IgE and infant/child allergic sensitisation rather than clinically-proven IgE-mediated 
food allergy. In a Dutch study of 1027 children, dog ownership in pregnancy was associated 
with lower total IgE at birth, but dogs were not subsequently associated with reduced allergic 
sensitisation at 12 months or four years (388). In the same study, cat ownership in pregnancy 
was associated with reduced offspring allergic sensitisation at 12 months but the authors could 
not exclude avoidance of cats among families with a history of allergy influencing this finding 
(388). This study was also limited by the use of more general markers, total IgE and allergic 
sensitisation, as outcomes. Within the WHEALS cohort from the USA, indoor prenatal pet 
ownership was associated with lower cord blood IgE in 1049 infants (389). Subsequent 
measurement of infant IgE at regular intervals until two years of age led to a positive 
association of indoor prenatal pet exposure and a lower total IgE trajectory over infancy. The 
pet effect was stronger in infants delivered by Caesarean section and it was suggested such 
infants may benefit more from pet-related microbial exposure than infants who were exposed 
to the maternal vaginal-enteric microbiome during birth (390). In the same group, dog 
ownership in infancy was associated with reduced risk of allergic sensitisation at two years, 
particularly among those delivered by Caesarean section (60). However this finding was also 
limited by use of the general marker of total IgE as an outcome. The HealthNuts study 
demonstrated an association between pet ownership in infancy and reduced egg allergy in 
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infants with eczema (20) and subsequently demonstrated similar findings for multiple food 
allergies (391).  
The small numbers of families with pets in one time period only (pregnancy or infancy) meant 
the current study was underpowered to disentangle whether the pet protective effect was in 
pregnancy or infancy respectively, or represented a continuous effect. The WHEALS cohort 
attempted to analyse pre-natal (n=55) versus a postnatal (n=83) pet ownership effect with no 
difference demonstrated (390). 
Previously the protective effect of pet ownership was hypothesised to be due to increased 
exposure to microbial products such as endotoxin, a biological product of the bacterial cell wall 
(392). An older study examined cytokines stimulated by endotoxin exposure such as IL-10 in 
relation to atopic outcomes in homes with pet exposure. While they found a reduced risk of 
allergic sensitisation with dog ownership (p=0.02), they were unable to find an association 
between dog or cat ownership and food allergy (defined as a convincing history and positive 
specific IgE) (393). IL-10 levels were increased in those infants exposed to dogs suggesting a 
potential role for endotoxin in the pet effect. It was subsequently demonstrated in another 
study that the pet protective effect was independent of endotoxin exposure (55). Recent work 
suggests that endotoxin exposure may be an important factor in reducing the risk of childhood 
asthma. Higher endotoxin levels were recorded in the homes of traditional farming families, 
which experienced lower rates of asthma and allergic sensitisation compared to modern 
farming families of similar genetic background (63). The results were limited by a relatively 
small number of older children as cases thus missing potentially critical periods of immune 
development.  
More recent evidence suggests the pet protective effect may actually be mediated through 
sharing of commensal microbes (95). It has been demonstrated that skin microbiota are shared 
among cohabiting family members and domestic dogs (394). Common gut bacteria have been 
identified between infants and furry pets in regular contact (73). In a descriptive Canadian 
study, albeit with a very small sample size (n=24), the gut microbiota of infants in contact with 
pets was more rich and diverse than the gut microbiota of infants without pet contact (69). It 
may be that microbes carried by pets such as dogs colonise the human microbiome at critical 
developmental time points and promote a more tolerant immune profile in infants. The cross 
sectional association for dog ownership demonstrated in this Chapter and HealthNuts (20) 
suggest the postnatal period is also influential but it is unknown whether the pre or postnatal 
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effect is more important. 
7.8.1.2 Livestock exposure and food allergy 
There is already extensive evidence for the protective effect of a farming lifestyle both in 
pregnancy (61) and infancy (58, 62, 295) on infant and childhood allergy. There is limited and 
conflicting evidence for a farming lifestyle and food sensitisation (395), but no study examining 
clinically-proven food allergy as an outcome. 
Residence on a farm was relatively uncommon among participants in BIS. There was a 
suggestion of a protective effect for livestock exposure alone on risk of infant food allergy, but 
with wide confidence intervals that reflected the small sample size. There was, however, 
evidence of an association between the categories of pet or livestock ownership in both 
pregnancy and infancy and decreased infant food allergy. When using no pets/livestock as the 
reference group, there was a dose effect across the categories of pets only and combined pet 
and livestock ownership in infancy in relation to decreased infant food allergy. The dose effect 
suggests the association between animal contact as a proxy marker of microbial exposure and 
decreased infant food allergy may be statistically robust and require further investigation (396).  
Modern farming methods tend to be intensive and industrialised (397), which may minimise 
contact between farm residents, livestock and fodder (63), and thus reduce microbial exposure 
experienced by farming families. In previous positive studies on farm exposure and allergy 
outcomes, the participants engaged in more traditional farming methods where pregnant 
mothers worked in barns and stables (61) and infants had regular exposure to farm life in the 
first months of life (398). In a recent study of farming communities with similar genetic 
backgrounds, child asthma rates were lower among the communities that practiced traditional 
farming methods compared directly to the communities with industrialised farming (63). 
In BIS, the majority of pet dogs in farming families spent time both indoors and outdoors. It is 
possible therefore, the dog may act as a conduit for bacteria sharing between family members 
and livestock, as pathogen sharing occurs between farming dogs and livestock (399). This may 
explain the dose effect for pets/livestock demonstrated in BIS.  
7.8.1.3 Number of siblings and food allergy 
The findings are not consistent with the findings of the HealthNuts study (n=5302) in 
Melbourne, where a greater number of siblings were protective against egg allergy (aOR 0.72, 
95% CI 0.62-0.83) (20). A cross sectional study in the USA (n=1359) demonstrated a positive 
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association between number of siblings and decreased prevalence of parent reported food 
allergy (RR 0.79, 95% CI 0.75-0.84) (56). These findings are limited by the sub-optimal outcome 
measure and the cohort composition of mainly Caucasian upper income families limiting 
generalisation. A Finnish study (n=16,237) found that an increasing number of siblings were 
associated with a reduced risk of cows milk allergy (p<0.01) but the effect was only present in 
families with four or more children (252). In the current study, although the trend did not reach 
significance, the risk ratio decreased as the number of siblings increased. Only 5% of 
participants in the BIS cohort had three or more siblings. However, there was some evidence in 
this group of decreased infant food allergy, with the wide confidence intervals probably 
reflecting the low numbers in the group. 
In line with the other exposures discussed in this Chapter, the putative protective sibling effect 
may be mediated by changes in the maternal or infant gut microbiome (68, 400). In a Canadian 
study with a small sample size (n=24) there was no evidence of an association between gut 
microbiota diversity in infants at three to four months of age and number of siblings (69). In a 
larger Danish study (n=114) the presence of more siblings was associated with increased 
microbiota diversity in infants at 18 months of age, but not at nine months of age (401). These 
findings suggest the sibling effect may be more important in later infancy. A Dutch study 
(n=571) identified a positive association between a greater number of siblings and colonisation 
of the gut microbiota with Lactobacilli sp.(p< 0.001) and Bacteroides sp. (p=0.02) at five weeks 
of age and a lower colonisation rate with Clostridia sp. (68). The prevalence of increased 
Lactobacilli sp. and Bacteroides sp. persisted until seven months of age in infants with more 
siblings (402). There is limited evidence that the microbes previously associated with increased 
sibling numbers are in turn associated with decreased food allergy. Lactobacilli used as a 
bacterial adjuvant in peanut oral immunotherapy has been associated with sustained 
unresponsiveness to peanut in a human trial (403), but the overall evidence for Lactobacilli sp. 
and probiotics in relation to allergy is conflicting (404). Similarly, the evidence to date regarding 
Clostridia species and allergic outcomes is conflicting (69, 237, 402, 405).  
7.8.1.4 Mode of delivery and food allergy 
There was no evidence of a positive association between mode of delivery and food allergy, 
which is consistent with the findings of the HealthNuts study (20). Evidence regarding 
Caesarean section delivery and subsequent food allergy in infancy is conflicting. Eggsebo et al 
found an association between Caesarean section delivery and food allergy particularly in those 
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with a maternal history of allergy (251). A German study suggested that Caesarean section 
delivery was associated with food sensitisation up to two years of age (aOR 1.64, 95% CI 1.03-
2.63) (406) and a Finnish study demonstrated an association between Caesarean section 
delivery and cow’s milk allergy (aOR 1.18, 95% CI 1.10-1.27) (252). By contrast two 
retrospective studies of medical records (n=291 and n=8953 respectively) found no association 
between Caesarean section delivery and food allergy development (256, 407). A large Finnish 
study (n=3181) found no association between Caesarean section delivery and subsequent 
allergic sensitisation and physician diagnosed food allergy up to four years of age (257). 
The reasons for the conflicted evidence of Caesarean section delivery and infant food allergy 
are unknown. Caesarean section delivery is associated with alterations in the infant gut 
microbiota (247, 248) that can persist into middle childhood (249). This suggests that lack of a 
particular microbial exposure, for example to a GBS colonised vaginal-enteric microbiome may 
be a factor in increased risk of infant food allergy. The impact of a Caesarean section delivery 
on lack of neonatal microbial exposure may be varied, however, as infants undergoing an 
emergency Caesarean section may have had some vaginal microbial exposure through ruptured 
membranes (408). Another factor may be that other microbial exposures such as dog exposure 
may have a greater effect antenatally than Caesarean section delivery on infant food allergy risk 
(390). A third possible contributing factor is that Caesarean section delivery may bypass the 
immune stimulation labour provides contributing to an altered infant immune profile 
favourable to hyper-responsiveness (409). 
7.8.1.5 Maternal GBS status in pregnancy and food allergy 
The current study’s findings are the first evidence of a positive association between maternal 
GBS status in pregnancy and decreased offspring food allergy. Previous evidence regarding 
maternal GBS status in pregnancy and food allergy among the offspring is limited. Maternal GBS 
status was not associated with an increased risk of offspring food allergy (OR 1.14, 95% CI 0.56-
2.35) in a USA based retrospective study (n=281) of medical records (256). GBS status however 
was determined in only 50% of women limiting the sample size (256).  
Maternal GBS status in pregnancy is potentially a marker of the general maternal vaginal-
enteric microbiome, which in turn may influence the composition of the infant microbiome 
(261). Maternal GBS may also be a proxy marker of other exposures in the birthing process as it 
is highly correlated with receiving intrapartum antibiotics (410) and Caesarean section delivery, 
both of which reduce the probability of exposure to the maternal vaginal-enteric microbiome 
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during delivery (248). When stratified by mode of delivery and GBS status, there was an 
indication of a protective effect for vaginally delivered infants in GBS positive mothers even 
after adjustment for intrapartum antibiotics. It is possible that intrapartum inoculation by a GBS 
colonised maternal vaginal-enteric microbiome may be a mechanism that reduces risk of infant 
food allergy. However, the high correlation of maternal GBS status and intrapartum antibiotics 
meant the current study was unable to differentiate between the potential effects of the two 
exposures. It is noteworthy in this context, that there was no evidence of an association 
between intrapartum antibiotics and infant food allergy.  
7.9 Strengths and limitations 
The strengths of this study include the use of a population based birth cohort with extensive 
epidemiological data at critical developmental time points and longitudinal objectively defined 
robust outcomes, particularly clinically-proven IgE-mediated food allergy. 
Family history of allergy has been traditionally regarded as a limitation in allergy research 
studies because it can alter health-related behaviour. Families with a history of allergy tended 
to avoid pet ownership due to pets being perceived as a trigger for new or existing allergies 
(411). Consequently, previous evidence for a protective effect of dog ownership tended to be 
among those without a family history of allergy (412). Adjustment in the analysis for the high 
prevalence of a family history of allergy in the BIS cohort did not alter the association between 
pet ownership and decreased offspring food allergy further strengthening confidence in the 
conclusions. It should be noted that a family history of allergy in BIS was defined by parental 
report of a doctor diagnosis which may inflate the estimation of family history of allergy in the 
cohort. 
The relatively small number of food allergic cases and the small number of families with three 
or more siblings in BIS meant this study was underpowered to examine some key relationships. 
In particular, the small numbers of participants with an exposure only in the pre or postnatal 
period prevented meaningful analysis of the importance of the timing of microbial exposures. It 
is possible that all exposures examined in this study may have an effect solely in pregnancy or 
infancy, or in contrast have a continuous early life effect. Recent molecular data published on 
immune markers in food allergic infants in BIS at birth (136) may provide an opportunity to 
further investigate timing of microbial exposures on infant allergic disease.  
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7.10  Implications for future studies and conclusions 
The findings in this Chapter provide further evidence to support the ‘hygiene hypothesis’ that 
insufficient microbial exposure in early life may be a risk factor for food allergy development in 
infancy. Dog ownership (with a dose effect for indoor/outdoor location), combined 
pet/livestock exposure and maternal GBS colonisation are associated with a strong statistical 
reduction in the risk of infant food allergy in this study. The challenge for future studies is to 
determine whether microbial exposure prenatally, postnatally or as a continuous exposure is 
more effective in reducing risk of infant allergy. Future work planned in BIS includes 
examination of the relationship between the maternal gut microbiome in late pregnancy, the 
infant gut microbiome at four weeks of age and food allergy at one year. 
The strong statistical association for maternal GBS colonisation and decreased infant food 
allergy coupled with the lack of effect of intrapartum exposures such as Caesarean section 
delivery and intrapartum antibiotics support the potential role of the maternal microbiome in 
foetal immune programming. Recent evidence suggests the in-utero environment may not be 
sterile (204, 413), so bacterial exposure during pregnancy may induce a foetal immune profile 
that promotes tolerance. Future studies may need to focus on changes in the maternal 
microbiome during pregnancy as a proxy marker for foetal immune programming and allergic 
outcomes in infancy. Regular sampling of the vaginal-enteric microbiota throughout pregnancy 
may be required to effectively monitor changes in the vaginal-enteric microbiome.  
This study was insufficiently powered to definitively determine whether intrapartum 
inoculation with maternal GBS was a mechanism to reduce infant allergy risk, but the same 
process has been associated with altering early life precursors of other non-communicable 
diseases such as cardiovascular disease (384). Larger observational studies focusing on the 
intrapartum period in relation to allergic outcomes in infancy may be useful in determining 
whether GBS inoculation of the neonate during birth is a factor in the development of infant 
food allergy. 
Positive findings for livestock exposure and pets in infancy with a dose effect suggest that 
microbial exposure in infancy may still play a role in decreasing infant food allergy risk. To 
progress previous findings, larger cohort studies are required that examine gut microbiota in 
both domestic pets and farm animals at regular intervals in relation to gut microbiota and 
robust allergic outcomes in infants.  
In conclusion, this study extended existing evidence for an association between proxy markers 
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of microbial exposure and clinically-proven infant food allergy at one year of age. These findings 
support further research into foetal immune programming and maternal and infant 
microbiome changes in relation to infant food allergy development. Subsequent findings may 
inform allergy prevention strategies.  
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CHAPTER 8 CONCLUDING DISCUSSION AND FUTURE DIRECTIONS 
8.1 Introduction 
The overall aim of this thesis was to examine the potential role of maternal and infant 
micronutrient status and environmental and early life microbial factors as risk factors for the 
development of IgE-meditated food allergy in infancy in Australia.  
The primary exposures investigated were maternal antenatal folate status, VDS at birth and six 
months, and the environmental and early life microbial factors of maternal GBS status in 
pregnancy, Caesarean section delivery, pet ownership, farm environments and family size. The 
outcome was clinically-proven IgE-mediated infant food allergy at one year of age.  
In this Chapter the key findings of the thesis are summarised below (figure 8.1). The 
implications for future clinical practice and future research are then discussed. 
8.2 Key findings 
8.2.1 Infant food allergy prevalence differences in harmonised cohorts and contributing 
factors 
The food allergy prevalence in one year old infants in BIS was lower than in the HealthNuts 
study in Melbourne, particularly following adjustment for the higher rate of family history of 
allergy among the BIS cohort relative to the HealthNuts cohort. The lower food allergy 
prevalence in BIS may be largely statistically accounted for by earlier introduction of allergenic 
solids, increased rates of dog ownership and lower proportion of participants with parental 
Asian ethnicity. Lower rates of early onset eczema in the BIS population may also have been a 
factor. 
8.2.2 Maternal folate status in pregnancy and offspring food allergy  
There was no evidence of an association between elevated maternal folate status in pregnancy 
and an increased risk of food allergy or eczema among the offspring. There was weak evidence 
of a positive association between elevated maternal folate status and food sensitisation among 
the offspring. There was also no evidence of an association between folic acid supplementation 
in early to middle pregnancy and increased risk of food allergy among the offspring.  
8.2.3 Vitamin D status during the first six months of infancy and food allergy. 
There was no evidence of an association between VDS at birth or six months and IgE-mediated 
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food allergy at one year of age. There was no evidence of an association between maternal VDS 
and IgE-mediated food allergy at one year of age. There was weak evidence of a positive cross-
sectional association between VDI at 12 months of age and IgE-mediated food allergy. There 
was no evidence of a positive association between VDS at any time point and infant eczema 
during the first year of life. There was also no evidence of a positive association between UVR 
exposure dose at any time point and IgE-mediated food allergy or eczema. 
8.2.4 Environmental and early life microbial factors and food allergy  
Pet ownership in pregnancy and infancy (in particular dog ownership) were associated with a 
reduced risk of food allergy at one year. Infants exposed to pets or livestock compared to 
infants with pets only had a lower risk of food allergy at one year of age. Maternal GBS 
colonisation in pregnancy was also associated with a reduced risk of food allergy among 
offspring at one year of age. It was not possible to determine whether these exposures were 
effective during the prenatal period, the postnatal period or both. In this study neither a 
greater number of siblings nor Caesarean section delivery were associated with food allergy at 
one year of age.  
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Figure 8.1: Diagram illustrating the findings of this thesis at each early life stage.  Positive associations 
are in red text and negative associations in black text. 
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Table 8.1: Summary of hypotheses in the thesis and responses based on thesis findings. 
Study Hypothesis Response based on findings Chapter 
(1a) The prevalence of IgE-mediated 
food allergy among one year old 
infants in the Barwon region of 
Australia. 
That the prevalence of IgE-mediated food allergy in 
the Barwon region is the same as previously 
reported for Melbourne. 
The prevalence of infant IgE-mediated food allergy 
in the Barwon region is lower than the proximal 
urban centre of Melbourne. The regional IgE-
mediated food allergy prevalence is higher than 
comparable international estimates. 
4 
(1b) The contribution of 
environmental and early life risk 
factors to differences in food allergy 
prevalence between two proximal 
harmonised cohorts. 
Putative environmental and early life risk factors 
contribute to food allergy prevalence differences 
between urban and mixed regions. 
The difference in food allergy prevalence’s between 
regional and urban cohorts could be largely 
statistically accounted for by lower rates of early 
onset eczema, earlier introduction of allergenic 
solids and increased rates of dog ownership in the 
regional cohort. 
4 
(2) Maternal prenatal folate levels and 
risk of IgE-mediated food allergy and 
eczema among the offspring. 
That elevated maternal folate status is associated 
with an increased risk of IgE-mediated food allergy 
and/or eczema among the offspring. 
Maternal RBC folate examined as a continuous 
measure or at a defined high threshold was not 
associated with an increased risk of IgE-mediated 
food allergy or eczema among the offspring. 
5 
(3) Vitamin D status in the first six 
months of infancy and subsequent 
clinically-proven IgE-mediated food 
allergy. 
That low VDS in the first six months of infancy is 
associated with increased risk of IgE-mediated food 
allergy and/or eczema in the first year of life. 
Low VDS at birth or six months was not associated 
with IgE-mediated food allergy at one year of age 
or eczema during the first year of life. 
6 
(4) Early life microbial exposure and 
risk of subsequent IgE-mediated food 
allergy. 
That early life microbial exposures are associated 
with a reduced risk of IgE-mediated food allergy in 
the first year of life. 
Pet ownership in pregnancy and infancy, pet or 
livestock exposure and maternal GBS colonisation 
during pregnancy were associated with decreased 
IgE-mediated food allergy in infancy. 
7 
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8.3 Implications for future clinical practice 
This thesis draws on a large-scale prospective birth cohort study with antenatal recruitment to 
investigate the early life origins of clinically proven food allergy. The relevance of the findings to 
clinical practice are discussed below. 
8.3.1 Study 1 
This thesis detailed the high prevalence of IgE-mediated food allergy at one year of age in BIS in 
comparison to international estimates (92, 333) (Table 8.1). Childhood food allergy 
management currently places a substantial burden on paediatric healthcare services within 
Australia (414) and the findings of this study further support the need for continued investment 
in primary prevention strategies and childhood food allergy services.  
Modifiable lifestyle factors have been associated with decreased infant food allergy prevalence 
in this study. Public health strategies recommending early introduction of allergenic foods in 
infancy, promoting the benefits of contact with domestic pets and optimising early life skin 
health may influence families’ health related behaviours and reduce the prevalence of infant 
food allergy, thereby decreasing the food allergy burden on healthcare services.  
8.3.2 Study 2 
This thesis presented evidence that elevated maternal folate levels in mid to late pregnancy 
were not associated with an increased risk of IgE-mediated food allergy at one year of age or 
eczema among the offspring (Table 8.1 & Figure 8.1). 
The findings suggest the primary purpose of mandatory folic acid fortification of wheat flour 
and folic acid supplementation as a strategy to prevent NTDS (29) has been highly successful, 
and there is no clear evidence of adverse allergic outcomes among the offspring. It further 
suggests that the combination of folic acid fortification of commonly available foodstuffs and 
folic acid supplementation may result in an excessively elevated maternal folate status in 
pregnancy. While the definition and effect of an elevated maternal folate status in relation to 
infant health outcomes remains uncertain, it may be prudent to emphasise that 
periconceptional folic acid supplementation doses correspond to, rather than exceed, national 
recommendations (353, 359). 
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8.3.3 Study 3 
This thesis presented evidence that low VDS at birth and six months was not associated with an 
increased risk of IgE-mediated food allergy at one year of age or eczema (Table 8.1 & Figure 
8.1). 
The findings indicate that the role of early life vitamin D supplementation to maintain vitamin D 
sufficiency in the prevention of food allergy or eczema remains uncertain and currently, there is 
insufficient evidence to implement routine vitamin D supplementation in the infant population. 
The weak evidence for an association between VDI at 12 months and IgE-mediated food allergy 
at one year suggests there may yet be a role for vitamin D supplementation in relation to 
allergy prevention in later infancy, possibly in infants identified as “high-risk” for food allergy 
development. This association may also be non-causal however, and randomised trials of 
vitamin D supplementation are required before any change to clinical practice could be widely 
recommended. 
8.3.4 Study 4 
This thesis added to the evidence that environmental markers of early life microbial exposures 
are associated with reduced risk of Infant IgE-mediated food allergy at one year of age (Table 
8.1 & Figure 8.1). 
The findings further inform clinical advice regarding primary allergy prevention strategies such 
as promoting the benefits of domestic pet ownership and introduction of allergenic solids. 
Given the neonatal morbidity associated with maternal GBS colonisation in pregnancy, it is 
unlikely that the findings in this thesis will instigate any change in current clinical practice 
regarding prevention of perinatal GBS disease (279, 415). However, the findings provide good 
evidence for further investigations into the role of the vaginal-enteric microbiome in 
pregnancy. If maternal GBS colonisation is a proxy for another perinatal factor, such as 
administration of antibiotics, the findings may yet prove relevant to obstetric practice. 
8.4 Implications for future research  
The work in this thesis forms part of BIS; a multi-faceted cohort investigating early life origins of 
non-communicable diseases. The establishment of IgE–mediated food allergy prevalence at one 
year now provides the platform to monitor the evolution of childhood food allergy prevalence 
and any effects putative protective factors identified in this thesis may have on later childhood 
food allergy prevalence. Recently, there have been successful randomised trials demonstrating 
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the success of early introduction of allergenic solids, for example early introduction of peanut in 
reducing the risk of peanut allergy in the LEAP study (318). There are also ongoing trials to 
optimise early life skin health to delay onset of eczema. These trials have tended to be 
conducted in selected well motivated circumscribed populations with intensive supervised 
treatment regimes. Future studies will need to assess the implementation of clinical 
recommendations derived from these trial results on a multi-ethnic population basis to 
evaluate the long term effect on child food allergy prevalence and whether such an approach is 
cost effective. The predominantly Caucasian ethnicity in the BIS cohort and its regional location 
may provide opportunities to conduct collaborative research studies examining the effect of 
clinical childhood allergy prevention recommendations with other ethnically distinct cohorts.  
Following the identification of modifiable environmental risk factors for food allergy 
development, the next stage is to investigate the mechanisms underlying the effect of these 
risk factors. The longitudinal structure of BIS and related biospecimens repository enables 
further investigation of immunological mechanisms promoting the development of oral 
tolerance post food allergy development in infancy, for example, resolution of egg allergy. 
The results in this thesis identify the urgent need to establish the range of an elevated maternal 
folate status in relation to a number of offspring health outcomes including food allergy. Future 
studies need ideally to be randomised control trials of folic acid supplementation in women of 
childbearing age. There would be ethical issues involved, however, due to the potential 
morbidity of periconceptional folate insufficiency in any trial. A less robust alternative would be 
a larger prospective observational study with larger outcome numbers and meticulous 
recording of folic acid intake and regular measurement of maternal folate status. The 
generalisation of the study results may be improved by advising participants to adhere to 
national folic acid supplementation guidelines. This approach, however, may not overcome 
limitations such as changes in participants’ health behaviours after recruitment into a study. 
There has been extensive recent research that suggests genetic factors and bioavailability of 
vitamin D are important modifiers in the relationship between VDS and food allergy (184, 196). 
In the context of the findings of this thesis, future research may need to focus on VDS in later 
infancy post introduction of solids within a multi-ethnic cohort to delineate the influence of 
genetic factors on infant VDS and risk of food allergy. While this study was unable to identify 
epidemiological evidence of an association between maternal or infant UVR exposure and food 
allergy in infancy, further research may need to be conducted on potential direct immune 
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effects of UVR exposure independent of VDS. Despite the conflicted evidence regarding VDS 
and food allergy the positive latitude gradient for proxy markers of food allergy prevalence (36, 
37, 178) suggests UVR exposure may have effects on immune function independent of vitamin 
D (366). 
In Study 1 and 4, this thesis demonstrated proxy markers of microbial exposure are associated 
with decreased food allergy in infancy. These microbial exposures may influence the maternal 
and infant microbiome, in particular the gut microbiome. The findings suggest that future 
research should focus on changes in the maternal and infant gut microbiome in the antenatal 
and postnatal time periods in relation to robust allergic outcomes. It is hypothesised that there 
is an early life time period in which the gut microbiome may influence development of the 
infant immune system (227, 381). BIS is well positioned to conduct research into early life 
immune development. A major difficulty in this type of longitudinal study is to disentangle 
whether the microbial exposure effect occurs in the antenatal or postnatal period or is a 
continuous effect. Future studies may need to attempt to randomise particular microbial 
exposures (for example pet ownership) to antenatal or postnatal time periods with sufficient 
numbers in each group to detect a difference. This approach may not be feasible, however, as 
many microbial exposures are life experiences (for example, birth factors) that may not be 
appropriate to randomise in a trial. Hence, a larger longitudinal observational study may be 
required. 
In the event of a positive association between gut microbiota and food allergy, the next stage 
would be trials of intervention. Experimental works in mouse models of allergy have 
demonstrated development of oral tolerance after faecal transplantation with particular 
targeted bacterial species such as Clostridia (237). Faecal transplantation has been used in 
humans in treatment of non-communicable diseases and chronic infection with variable results 
(416). Other options for future trials to alter the gut microbiota may include dietary 
manipulation, direct supplementation with specific microbiota metabolic products such as 
butyrate or acetate or modification of determinants of microbiota composition (e.g. perinatal 
antibiotics for Group B Streptococcus prophylaxis). 
8.5 Conclusion 
This thesis has examined the potential role of the micronutrients folic acid in pregnancy and 
vitamin D in pregnancy and infancy, environmental and microbial risk factors in relation to 
development of IgE-mediated food allergy at one year of age. The project established the 
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prevalence of IgE-mediated food allergy at one year of age in BIS and provided the platform for 
future research on the natural history of food allergy in childhood and the early life origins of 
allergic disease. This project has demonstrated the need to establish a threshold for an 
elevated maternal folate status while also providing some reassurance that there is currently 
no consistent or compelling evidence that elevated maternal folate status in pregnancy is a risk 
factor for offspring IgE-mediated food allergy.  
This thesis conducted the first study to relate directly measured early life VDS during infancy to 
subsequent clinically-proven IgE-mediated food allergy at one year – the findings of which draw 
into question current moves toward widespread vitamin D supplementation for the prevention 
of food allergy and highlight the need for well conducted clinical trials to inform the merit of 
such strategies. 
In addition, this research has provided novel evidence for the potential protective effect of 
maternal GBS colonisation in pregnancy in relation to food allergy among offspring at one year. 
This finding is compatible with the importance of the maternal vaginal-enteric microbiome 
during pregnancy with offspring immune development and risk of allergy. 
This thesis has extended existing evidence for microbial exposures and decreased risk of infant 
food allergy by demonstrating longitudinal evidence for pet ownership in pregnancy or 
livestock exposure and decreased clinically relevant infant food allergy. The evidence of dose-
responses adds to the likelihood that this association is causal rather than an epidemiological 
phenomenon. 
In summary, the findings in this thesis provide insights into food allergy development that can 
guide future research into early life origins of allergic disease and contribute to public health 
strategies. BIS and other modern cohorts with extensive collection of biological samples, 
provide valuable opportunities to extend these epidemiological findings by exploring the 
underlying mechanistic pathways of early life allergic disease. Ultimately, such studies may 
inform the prevention of early life allergy, which now affects a large proportion of children in 
the modern environment.
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agreement between the new study investigator(s) and the BIS team for the conduct of any 
future studies/publications using the BIS Databank.  
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